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SUMMARY
The main objective of this research was to assess the 
defensive roles of both the humoral and cellular 
defences of the pig against Actinobacillus 
pleuropneumoniae (A, pleuropneumoniae) in vitro. The 
aims were firstly to establish the effects of complement 
on the survival of A. pleuropneumoniae and secondly, to 
study the ability of alveolar macrophages to phagocytose 
A. pleuropneumoniae.
In Chapter 3 the effect of complement on the survival of
A. pleuropneumoniae was examined. All strains of A. 
pleuropneumoniae tested were found to be resistant to 
pig complement. The strains were also found to be 
resistant to both immune pig serum and hyperimmune 
rabbit serum containing specific antibodies against A. 
pleuropneumoniae. Three of the four strains were found 
however to have a delayed sensitivity to normal human 
serum.
The mode of complement resistance in A. pleuropneumoniae 
was compared to a known serum resistant Escherichia coli 
strain using the outer membrane disorganising chemical 
polymyxin B. All A. pleuropneumoniae strains tested 
could not be sensitised to complement bactericidal 
activity by this method. This was in contrast to the 
serum resistant E. coli which was sensitised to the 
effects of complement following treatment with polymyxin
B.
In Chapter 4 the method by which A. pleuropneumoniae 
avoided complement-mediated damage was investigated. A. 
pleuropneumoniae was found to consume large amounts of 
complement activity via the classical and alternative 
pathways from both pig and human serum. Activation of 
the complement component C3 also occurred in both pig 
and human serum. Activation of factor B, which occurs
XXI
via the alternative pathway only, was also demonstrated 
in human serum during incubation with the bacteria.
In Chapter 5 non-viable A. pleuropneumoniae were found 
not to consume complement activity suggesting the 
ability of A. pleuropneumoniae to consume complement was 
dependant on bacterial viability. The extracellular 
secreted toxins of A, pleuropneumoniae were found not to 
affect consumption of complement activity and therefore 
some other function of viable A. pleuropneumoniae 
appeared to be responsible.
In Chapter 6 the ability of pig alveolar macrophages to 
phagocytose A . pleuropneumoniae was investigated. Both 
haemolytic and cytotoxic activities are known to be 
associated with 109 (haemolysin II, Hly II) and 120
(pleurotoxin, Ptx) kDa proteins respectively. Both HK 
361 (Hly II+, Ptx+) and mutant e (Hly II”, Ptx+) were 
found to rapidly destroy all macrophages when incubated 
with normal pig serum and any phagocytosis could not be 
determined. Mutant h (Hly II”, Ptx”) was found initially 
not to cause damage to alveolar macrophages. However, 
after prolonged incubation, a level of damage was
observed, although not to the same extent as seen with 
HK 361 and mutant e. A few phagocytosed mutant h were 
observed initially, however the numbers did not increase 
with time. No reduction of toxicity was seen for
macrophages incubated with HK 361 and mutant e in the 
presence of immune serum. The reduced toxicity of mutant 
h for alveolar macrophages was diminished following the 
addition of immune pig serum and the numbers of
phagocytosed mutant h greatly increased. The nature of 
the reduced toxicity of mutant h was compared to killed 
mutant h. No toxicity of killed mutant h (by heat or 
formaldehyde) was observed in the presence of normal pig 
serum, and similar levels of phagocytosed bacteria were 
seen. This suggested the toxicity associated with mutant
XXII
h was both heat labile and neutralised by immune pig 
serum.
In Chapter 7 the immunological relationships of the 
haemolytic and cytotoxic proteins (109 and 120 kDa 
respectively) of A . pleuropneumoniae serotype 2 strain 
HK 361 were investigated. Monoclonal antibodies (Mabs) 
were raised against both the 109 or 120 kDa protein 
secreted from HK 361.
Mabs raised against each protein cross-reacted with 
other proteins on Western blots suggesting they were 
immunologically related. Cross-reactive proteins were 
found in all the serotype reference strains of A . 
pleuropneumoniae, including some of the related 
pathogens. The presence of similar proteins in all 
serotypes of A. pleuropneumoniae suggested a similar 
virulence factor of A, pleuropneumoniae. The cross­
reaction seen with related pathogens was in agreement 
with others who suggested the similarity of the A . 
pleuropneumoniae toxins to the RTX (repeat in structural 
toxin) toxin-producing family.
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1.1 INTRODUCTION
Porcine pleuropneumonia is a disease that has only been 
acknowledged for the last 30 years and its increase in 
prevalence appears to be correlated to the increased 
intensity of swine herds (Sebunya & Saunders, 1983). The 
disease results in huge economic losses which are caused 
by deaths due to the peracute disease and the cost of 
both treatment of individual infected pigs and mass 
medication of feed and water (Wilson et al., 1986). 
Porcine pleuropneumonia is considered to be the second 
most important pig disease in terms of its worldwide 
location and resultant economic losses.
1.2 History and taxonomy of A . pleuropneumoniae
The first detailed description of porcine 
pleuropneumonia was documented in the early 1960's 
(Shope, 1964). Shope (1964) was the first to propose the 
name Haemophilus pleuropneumoniae for the causative 
organism of swine pleuropneumonia isolated from an acute 
outbreak in Argentina. It had been first thought that 
the Argentinian outbreak might be swine influenza 
(Shope, 1964). However, on direct observation the 
clinical signs and post-mortem appearance, together with 
failure to detect a virus, suggested it was not swine 
influenza. The morphological appearances and the 
characteristics of the bacteria isolated on blood agar 
did however strongly suggest a close similarity to 
Haemophilus influenzae suis. Further examination of the 
morphological, cultural and biological characteristics 
confirmed that the organism belonged to the genus 
Haemophilus, and because of its propensity to cause 
pleuropneumonia in swine was designated by Shope (1964) 
Haemophilus pleuropneumoniae.
Previous observations had been recorded detailing a 
Haemophilus-like organism isolated from pigs (Pittman,
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1953; Pattison et al,, 1957; Matthews & Pattison, 1961). 
Those organisms were grouped together with human 
isolates of either Haemophilus parainfluenzae (Rivers, 
1922) or Haemophilus parahaemolyticus (Pittman, 1953) 
depending on haemolytic activity (Olander, 1963). A 
Swiss outbreak, similar to the one described in 
Argentina, was documented by Nicolet and Konig (1966) 
and Nicolet (1968 & 1971). These isolates were found to 
be biochemically similar to that of Shope (1964) 
(Nicolet & Konig, 1966; Nicolet, 1968; Nicolet, 1971). 
However by rule of priority of publication, Nicolet 
(1968) along with Olander (1963), designated them H, 
parahaemolyticus. The same name was adopted in 
subsequent outbreaks reported in Denmark (Nielsen, 
1970a; 1970b), Great Britain (Little, 1970), Canada
(Radostits et al,, 1963; Schiefer & Greenfield, 1974; 
Schiefer et al., 1974), Australia (Mylrea et al,, 1974), 
Sweden (Biberstein et al,, 1977; Gunnarsson et al,, 
1977) and the German Democratic Republic (Kiupel, 1975).
In 1976, Kilian (1976a) revealed a number of cultural 
and biochemical differences between H. parahaemolyticus 
isolated from pigs (Kilian, 1976a) and the human strains
designated H, parahaemolyticus by Pittman (1953). These
porcine strains could be further divided into two 
groups, named major and minor, on the basis of 
biochemical characteristics, haemolytic activity and 
deoxyribonucleic acid (DNA) base composition. The major 
group comprised of the original strains of Olander 
(1963) and Shope (1964), which had the ability to 
ferment ribose, xylose and mannitol, were CAMP reaction 
positive and had significantly higher guanine and
cytosine content. In 1978 Kilian et al, proposed the
major group of organisms should be designated 
Haemophilus pleuropneumoniae (Matthews & Pattison, 1961) 
Shope 1964 and the strain Shope 4074 to be the neotype. 
Pohl et al, (1983) proposed the transfer of H, 
pleuropneumoniae along with a Pasteurella-like organism
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(Bertschinger & Seifert, 1978), which caused porcine 
necrotic pleuropneumonia, to the genus Actinobacillus. 
The Pasteurella-like organism was shown to be 
phenotypically similar to the V factor dependent strains 
of H. pleuropneumoniae (Matthews & Pattison, 1961) Shope 
1964, with the exception of being V factor independent. 
DNA-DNA hybridisation experiments suggested that the 
type and reference strains of these two taxa belonged to 
the same species and that neither should belong to the 
genus Haemophilus as there was no measurable relatedness 
with the type strain H, influenzae. They were however 
closely related to Actinobacillus lignieresii, both 
phenotypically and on DNA base sequence. The difference 
in host ranges suggested a new species be adopted, 
namely Actinobacillus pleuropneumoniae. A.
pleuropneumoniae was divided into two biotypes, biotype 
one consisting of the V factor dependent strains (Shope 
4074[=CCM 5869 (Czechoslovak Collection of 
Microorganisms, Brno, Czechoslovakia) = ATCC 27088 
(American Type Culture Collection, Rockville, Md)]) and 
biotype two, V factor independent strains (Bertschinger 
2008/76 [- Fredenksen P597 = HIM 677-3/4
(Bacteriological Culture Collection, Marburg, Germany)]) 
(Pohl et al., 1983).
1.3 Aetiology
The aetiological agent of swine pleuropneumonia is a 
gram-negative, non-sporeforming pleomorphic rod with 
predominantly coccobacillary forms. It can occur singly, 
in pairs or short chains with the filamentous form 
becoming more prominent with increasing age of culture 
(Olander, 1963; Shope, 1964). Capsules are commonly 
present (Sebunya et al., 1982; Jacques et al., 1988a). 
The organism grows rapidly on enriched media forming 
mucoid, and sometimes waxy, iridescent colonies reaching 
a diameter of 3mm (Shope, 1964; Nicolet, 1986; Mylrea et 
al., 1974; Sebunya et al., 1982). Colonies produce a
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zone of fl-haemolysis on calf or sheep blood agar 
(Kilian, 1976b). The zone of haemolysis is increased 
when the haemolysin acts synergistically with the 
Staphylococcus aureus D-toxin giving a positive CAMP 
reaction (Kilian, 1976b).
The organism is facultatively anaerobic and usually 
microaerophilic on primary isolation (Biberstein et al., 
1977). Subcultures normally do not require additional 
carbon dioxide (Pohl et al., 1983). Growth factor 
requirements differ between the two biotypes; biotype 1 
being V factor (B-nicotinamide adenine dinucleotide) 
dependent and biotype two V factor independent (Pohl et 
al., 1983). To date 12 serotypes of biotype 1 have been 
recognised based on specific antigenic capsular 
components (Gunnarson et al., 1977; Nielsen, 1985a;
Nielsen, 1985b; Nielsen, 1986a; Nielsen, 1986b; Nielsen 
& O'Connor, 1984; Rosendal & Boyd, 1982).
1.4 Epidemiology
Pleuropneumonia of the pig has been reported worldwide. 
Increased occurrence appears to be correlated with 
industrialisation of pig production (Nicolet, 1986). The 
potential transmission of A . pleuropneumoniae is
maximised in well stocked herds (Sanford & Josephson, 
1981; Davidson & King, 1980). The transfer of the 
disease is thought to be via the respiratory route by 
the inhalation of aerosol droplets containing the
bacterium (Sebunya & Saunders, 1983; Nicolet, 1986). The 
introduction of the disease appears to be associated
with the importation of infected animals (Greenway,
1981), either by carriers or chronically infected
animals (Nicolet, 1986). Moving, mixing and frequency of 
animals purchased increases the risk of pleuropneumonia 
in a herd (Rosendal & Mitchell, 1981). Infected animals 
do not always demonstrate clinical signs although they 
may carry the bacterium in the nose, tonsil or
5
sequestered in the lung within lung lesions (Kume et 
al., 1986a). In an infected herd certain stress factors 
can promote an outbreak of the disease (Maclnnes & 
Rosendal, 1988). These can include overcrowding, sudden 
climatic changes and poor ventilation. Seasonal changes 
have also been reported to influence intensity of the 
disease (Sanford & Josephson, 1981; Sebunya et al., 
1982). Pleuropneumonia can affect pigs of all ages. 
Losses occur more frequently in the feeder pigs which is 
thought to be due to additional stress associated with 
rapid growth (Maclnnes & Rosendal, 1988). The morbidity 
and mortality depends on the immune status of the herd. 
Elimination of A . pleuropneumoniae should be possible as 
it does not persist in the environment and pigs appear 
to be the only animal infected under natural conditions.
1.5 Serological typing
To date 12 serotypes of A. pleuropneumoniae have been 
recognised based on heat stable soluble surface 
polysaccharide or lipopolysaccharide antigens (Nicolet, 
1971; Gunnarson et al., 1977; Rosendal & Boyd, 1982; 
Nielson Si O'Connor, 1984; Nielsen, 1985a; Nielsen, 
1985b; Nielsen, 1986a; Nielsen, 1986b; Inzana, 1987). 
The serotypes can be grouped together according to 
shared type specific polysaccharide or
lipopolysaccharide antigenic determinants resulting in 
the following groups: the 3, 6, 8 group, the 1, 9, 11
group and the 4, 7 group. Serotypes 2, 5, 10 and 12 are 
homogeneous serotypes sharing no type specific 
determinants with other serotypes. Serotype 5 can be 
divided into two subtypes, a and b, based on 
polysaccharide capsular determinants specific for each 
subset (Nielsen, 1986b).
Certain serotypes may occur in only one country while 
others are present in several different regions. In 
Britain those most commonly found are serotypes 3, 6 ,8
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and some untypeable (Hunter et al., 1983; Taylor, 1989). 
Serotype 2 is dominant in Denmark (Nielsen, 1988). 
Elsewhere, in Canada for example serotypes 1, 2, 3 and 5 
are present and in America, serotypes 1, 2, 3 and 4
(Sebunya & Saunders, 1983). The serotype pattern of a 
particular region may however change (Nielsen, 1988). 
This is thought to be due to importation of animals for 
cross breeding programs. In Denmark for example between 
1970 and 1981, only serotypes 2 and 6 were isolated 
with serotype 2 being dominant. Between 1982 and 1986 
other serotypes emerged, in particular types 1, 5, 7, 8, 
10 and 12. Animals from imported stock were found to be 
seropositive to these serotypes suggesting that these 
imported animals were responsible for the emergence of 
the new serotypes.
Methods used for serological typing of A. 
pleuropneumoniae have included slide agglutination 
(Mittal et al., 1982; Rapp et al., 1985a), tube 
agglutination (Gunnarsson et al., 1977; Mittal et al.,
1982), immunodiffusion (Lombin et al., 1985; Nicolet, 
1971; Gunnarsson, 1979a), ring precipitation (Mittal et 
al., 1982; Hunter et al., 1983), indirect 
haemagglutination (Nielsen & O'Connor, 1984; Mittal et 
al., 1983b; Nielsen, 1985a), immunofluorescence 
(Nicolet, 1971; Rosendal & Boyd, 1982; Rapp et al., 
1985a), coagglutination (Mittal et al., 1983a; Hunter & 
Livingstone, 1986; Mittal et al., 1987) and 
counterimmunoelectrophoresis (Pieffer et al., 1986). The 
serotype-specific antigens of A. pleuropneumoniae are 
capsular polysacchaccarides and lipopolysaccharides 
(LPS) (Gunnarsson, 1979b; Neilsen & O'Connor, 1984; 
Fenwick et al., 1986c; Perry et al., 1990). The various 
methods employed different antigen preparations. Whole 
cells were normally used for coagglutination, slide 
agglutination, and indirect fluorescent antibody and 
cell extracts for agar gel precipitation, indirect 
haemagglutination and counterimmunoelectrophoresis
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(Nicolet, 1988). None of the methods were completely 
specific and therefore a combination of methods was 
normally used. Conflicting results were sometimes 
obtained using the different antigen preparations and 
the different methods (Nicolet, 1988) which resulted in 
different methods being favoured. Gunnarsson et al. 
(1978) found the best routine method to be tube 
agglutination. Agglutination however could not be used 
to serotype strains which polyagglutinate or 
autoagglutinate. Heat treatment of these strains to 
unmask the neccessary serotype specific antigens also 
exposed cross reactive common antigens (Mittal et al., 
1987). Cross reactions between serotypes 1 and 9 were 
shown to be due to common epitopes associated with the 
cell wall antigens (Mittal, 1990). The coagglutination 
test was simple to preform, reproducible, rapid, easier 
to read than the agglutination tests (Hunter et al., 
1983; Hunter & Livingstone, 1986; Mittal et al., 1987). 
To standardise serotyping, a working team within the 
International Pig Veterinary Society (IPVS) was set up 
to evaluate the various methods. The preliminary 
recommendations suggested coagglutination for field 
testing and either agar gel diffusion or indirect 
haemagglutination for final identification of the 
heterogeneous serotypes (Nicolet, 1988).
1.6 Pathogenesis
In order to be a successful pathogen there are certain 
virulence attributes required by invading bacteria. The 
pathogenicity requirements of A, pleuropneumoniae might 
be expected to include include colonisation of mucous 
surfaces, invasion of host tissues, survival and 
multiplication within the host, interference with the 
host defences and damage to the host. A. 
pleuropneumoniae possesses a variety of components that 
are thought to aid invasion. These include capsule, 
adhesion component structures, surface structures
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including outer membrane proteins and LPS and also 
secreted exotoxins. The involvement of these components 
in the successful production of swine pleuropneumonia 
has been documented to varying extents.
1.6.1 Lipopolysaccharide
Hani et al. (1973) proposed lipopolysaccharide (LPS) as 
the mediator of the acute pulmonary lesion in A.
pleuropneumoniae infection. This arose from the 
similarity of the lesions to those observed subsequent 
to endotoxic shock. The observation of bilateral renal 
necrosis in pigs given intravenous (IV) sterile
suspension of infected lung tissue led to the hypothesis 
of generalised Schwartmann's reaction (Hani et al., 
1973; Nordstoga & Fjostad, 1967). This was a
characteristic feature of endotoxic shock. Evidence for 
endotoxin was strengthened by a study by Fenwick et al. 
(1986a) in which pigs vaccinated with an E . coli rough 
mutant bacterin (killed bacterial preparation), strain 
J5, survived infection with A. pleuropneumoniae• In 
contrast 4\5 controls died. It was thought that antibody 
to lipid A and possibly LPS core antigens stimulated by 
E . coli J5, may have had a protective effect against 
septicemia and death in A. pleuropneumoniae infections. 
This provided indirect evidence for the role LPS. The 
protective efficiency of J5 against death had been 
previously reported in other Gram-negative bacteria 
(Ziegler et al., 1973). However, failure to protect the 
animals from A. pleuropneumoniae infection suggested the 
role of other virulence components.
Fenwick et al. (1986b) also reported that experimental 
infection with A. pleuropneumoniae in mice genetically 
altered to give a low response to endotoxin, resulted in 
less severe clinical signs than in mice with a normal 
response to endotoxin. 46% of the normal mice died 
compared to only 10% of the low endotoxin responder mice
suggesting endotoxin may be involved in acute death in 
A . pleuropneumoniae infections. Parallel to infection 
with A . pleuropneumoniae, mice were infected with E. 
coli strain 0111:B4 and its rough mutant J5. No deaths 
occurred in the mice inoculated with the E . coli 
strains. The different toxicity levels for E. coli and 
A. pleuropneumoniae suggested that the effects 
demonstrated by A, pleuropneumoniae infection were not 
due to LPS alone. The possibility of varying potency of 
LPS and the usage of live organisms, which may possess a 
range of pathogenicity factors, suggest that these 
experiments could not have satisfactorily assessed the 
involvement of LPS in A . pleuropneumoniae infection.
Intrabronchial administration of purified LPS from A, 
pleuropneumoniae induced lesions typical of acute 
pleuropneumonia in pigs (Fenwick et al., 1986c). This 
was in contrast to E . coli endotoxin which was not 
capable of producing lesions typical of acute A . 
pleuropneumoniae infection. These LPS fractions provoked 
dermal Schwartmann's reaction in rabbits and pigs 
(Fenwick et al •, 1986; Maudsley et al •, 1986). Rough
and smooth LPS from A. pleuropneumoniae serotype 5 were 
compared for toxicity in vivo (Fenwick et al., 1986c).
Both rough LPS and smooth LPS induced clinical signs 
typical of endotoxic shock (Kurtz & Quast, 1982). 
However, rough LPS induced more severe clinical signs at 
lower doses than smooth LPS. Similar reports in other 
Gram-negative bacteria have indicated rough LPS also to 
be more toxic than smooth LPS (Jones et al., 1976).
Differences in LPS structure were postulated to perhaps 
partly contribute to virulence (Jensen & Bertram, 1986). 
Comparison of LPS from a virulent A . pleuropneumoniae 
strain (1200) and an avirulent A . pleuropneumoniae 
strain (B8), both of serotype 5, revealed the virulent 
strain 1200 contained 1\3 more LPS and 12.8 times more 
galactose than the avirulent B8 strain. This increase in
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galactose may be relevant to virulence. Monosaccharide 
substitution in repeating units or differing repeating 
units in the 0 side chains of Salmonella tfrphimurium LPS 
has been proposed to infuence virulence of this 
Salmonella typhimurium (Makela et al,, 1973; Valtonen, 
1977). Apart from these two strains being unrelated, 
different haemolytic activities were also observed 
suggesting these 2 strains could not be compared for 
pathogenicity solely on LPS structure. The lack of 
necrosis and haemorrhage observed in mice and pigs 
inoculated with A. pleuropneumoniae LPS compared to 
intact A, pleuropneumoniae, supported the idea that 
endotoxin alone did not produce all the lung pathology 
typically observed in the acute form of naturally 
occurring or induced pleuropneumonia (Udeze et al., 
1987; Bertram, 1988).
While A. pleuropneumoniae purified LPS appears not to be 
wholly responsible for the pathology associated with A. 
pleuropneumoniae infection, it does appear, at least in 
part, to correlate with adhesion of A. pleuropneumoniae 
to the epithelium in tracheal rings. LPS profiles of A. 
pleuropneumoniae serotypes include smooth, rough and 
semi-rough LPS profiles. Serotypes 2, 4 and 7 being
smooth LPS (Rapp et al., 1986; Byrd & Kadis, 1989; 
Belanger et al., 1990), serotypes 1 & 5, semi-rough LPS 
(Byrd & Kadis, 1989; Belanger et al. 1990) and serotypes
3,6 & 10, rough LPS (Rapp et al., 1986; Byrd & Kadis,
1989). Belanger et al. (1990) found that those organisms 
possessing smooth LPS adhered in large numbers compared 
to those with semi-rough LPS which adhered poorly. This 
adhesion could be blocked by antibody to purified LPS 
confirming the involvement of LPS in adhesion to porcine 
tracheal rings. A. pleuropneumoniae has been shown to 
produce outer membrane blebs, along with other bacteria 
(Holt et al., 1980), apparently crossing capsular 
material and thus exposing the target cell surface to 
outer membrane components such as LPS (Jacques et al.,
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1988a) . LPS is known to have the capacity to interact 
with mammalian membranes, in particular membrane 
phospholipid (Morrison, 1985). These data together with 
Belanger's observations suggest that cell surface 
exposed LPS increases ability to adhere in vitro to 
tracheal rings. The significance of adherence appears 
not to be of primary importance in relation to the 
virulence of a particular serotype. Serotypes 1 and 5 
which were found in acute infection and considered 
virulent, adhered poorly to tracheal rings. In contrast 
serotypes 2 and 7, which were considered less virulent, 
adhered in large numbers. LPS therefore does appear to 
play a role in lesion development in mice and pigs, and 
death in mice. However, the involvement of other 
pathogenic mechanisms seems likely.
1.6.2 Capsule
Capsules are important to the virulence of pathogenic 
bacteria by providing the organism with a protective 
barrier against host defences. In many cases 
encapsulated bacteria, prior to development of specific 
antibody within a host, generally inhibit the 
bactericidal and opsonic activity of normal serum. In 
contrast non-encapsulated isogenic mutants are generally 
avirulent and are quickly cleared by the host. Capsules 
of A, pleuropneumoniae have been purified and 
characterised as being negatively charged, high 
molecular weight, acidic polysaccharide (Altman et al., 
1986; 1987a; 1987b; 1987c; 1988; Inzana, 1987).
A. pleuropneumoniae capsules have been reported to be 
non-toxic and do not produce any clinical signs of 
illness or lesion development (Fenwick et al., 1986c).
It has been suggested that differences in virulence 
observed between some serotypes (Rosendal et al., 1985; 
Rogers et al., 1990) may be related to differences in
the composition of the capsule. Jensen and Bertram
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(1986) found differences in the composition of the 
structure of capsular material between two non-isogenic 
serotype 5 strains. One A, pleuropneumoniae strain, 
1200, was found to be virulent and had a distinct 
adherent capsule. The other, strain B8 was avirulent and 
had a fragile easily removed capsule. They proposed that 
this difference in virulence was related to the 
difference in capsule thickness between these two 
strains. However, in addition to being unrelated 
strains, these two strains also had different LPS 
structures and haemolytic activities and therefore the 
results could not be conclusive.
Differences observed in capsule thickness between 
serotypes 1-10 were also proposed to account for the 
different virulence levels between some serotypes 
(Jacques et al.r 1988a). However, studies to detect a 
correlation between capsule thickness and virulence of a 
particular serotype was not carried out. More recently 
Rosendal and Maclnnes (1990) presented evidence that 
supported the relationship between capsule thickness and 
virulence. An A. pleuropneumoniae serotype 1 strain, 
CM5, isolated from a pig with pleuropneumonia and 
passaged once in vitro, was found to be virulent for 
pigs. A substrain of CM5 passaged 70 times in vitro, was 
found to be avirulent in pigs. No difference in LPS 
structure, production of LPS blebs, cytotoxic activity 
or resistance to serum could be detected between the 2 
strains. The only detectable difference was the capsule 
thickness. Presence, absence or amount of capsule did 
not appear to significantly alter the LD 50 in mice 
(Inzana et al., 1988). These findings were in contrast 
to reports of other bacteria, Haemophilus influenzae 
type b (Moxon & Vaughn, 1981; Zwahlen et al., 1983) and 
E . coli (Kim et al., 1986; Allen et al., 1987) that
nonencapsulation rendered them less virulent than their 
parent strains. Both the capsulated and nonencapsulated 
strains reported by Inzana et al. (1988) caused death
13
within 2 days. Only the encapsulated strain was capable 
of causing bacteraemia in mice indicating that death was 
not dependant on bacteraemia in the mouse model • It has 
been suggested that the capsule enables the bacteria to 
disseminate while toxins produced by the bacteria are 
responsible for death. Capsular material appears not to 
be toxic to pigs or involved in lesion development.
1.6.3 Haemolytic and cytotoxic activities
Over the last decade one of the major virulence factors 
to emerge has been the haemolytic/cytotoxic activity of 
viable bacteria and their secreted products. The work of 
Rosendal et al. (1980) which described that sonicated 
bacteria and bacterial culture supernatant induced lung 
lesions similar to those caused by natural infection of 
A . pleuropneumoniae prompted further research into the 
properties of the toxic activity and its role in 
pathogenicity.
Bendixen et al. (1981) demonstrated that both a heat- 
stable activity associated with culture supernatant and 
a heat-labile activity of viable bacteria of a serotype 
1 strain, CM-5, were toxic for both pulmonary lavage 
cells and cultured blood monocytes. These toxic 
activities could be neutralised by convalescent pig 
serum suggesting their secretion in vivo. Haemolytic 
activity was not determined. Nakai et al. (1983) was the 
first to report a heat-stable haemolysin associated only 
with bacterial supernatant suggesting an extracellular 
secreted activity. Toxic activity for horse, rabbit, 
sheep, guinea pigs and pigs red blood cells was 
unaffected by heat or proteolytic enzymes suggesting it 
was not a protein or enzyme. Following partial 
purification of this serotype 2 haemolysin by sucrose 
density gradients, it was also demonstrated to be lethal 
for pigs and for a proportion of guinea-pigs. The lack 
of endotoxin in the preparation ruled out its possible
i
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role in pathogenesis (Nakai et al,, 1984). Further
analysis of this serotype 2 haemolysin along with 
serotypes 1-5 haemolysins showed cytotoxic effects on 
guinea-pig macrophages. The serotype 2 haemolysin was 
further assessed and found to reduce the phagocytosing 
ability of cotton rat and pig macrophages but not mouse 
macrophages (Kume & Nakai, 1986). These cytocidal and 
anti-phagocytic effects of the haemolysin were 
associated with a heat-stable carbohydrate (Kume et al •, 
1986b).
Heat-labile haemolysins were also recorded that were 
sensitive to pronase and trypsin (Martin et al., 1985; 
Maudsley & Kadis, 1986; Rosendal et al., 1988; Frey &
Nicolet, 1988a; Lalonde et al., 1989;). The requirement 
of RNA for some A. pleuropneumoniae strains to produce 
detectable extracellular toxic activity (Martin et al •,
1985) suggested similarities with both the group A 
Streptococcus haemolysins, streptolysin 0 (Jeljaszewicz 
et al,, 1978), and the haemolysin produced by Treponema 
hyodysenteriae (Sahed et al,, 1981). Both of these 
haemolysins also required an RNA carrier molecule for 
extracellular activity. The heat labile haemolysin was 
also found to be cytotoxic for porcine macrophages 
(Pijoan, 1986; Udeze & Kadis, 1988; van Leengoed et al,,
1989) and both porcine and bovine neutrophils (Rosendal 
et al,, 1988). Supernatant preparations of different A. 
pleuropneumoniae strains appeared to have different 
cytotoxicity levels for porcine macrophages (Pijoan,
1986). The difference was proposed to be related to 
virulence. Studies revealed that two highly virulent 
strains, frequently isolated from field outbreaks, had 
strong cytotoxic activities for porcine macrophages. In 
comparison, a strain seldom associated with outbreaks 
and an avirulent strain incapable of producing lesions 
in susceptible animals, had an intermediate or no effect 
on porcine macrophages respectively. Considerable 
differences in the level of haemolytic and cytotoxic
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activities both between and within serotypes was seen by 
Rosendal et al. (1988). Strains tested were either
haemolytic and cytotoxic, cytotoxic only or negative for 
both haemolysin and cytotoxin. Attempts at purifying the 
haemolytic/cytotoxic activities resulted in
copurification of both the haemolytic and the cytotoxic 
activity (Kume et al., 1986b; Udeze & Kadis, 1988). 
Udeze & Kadis (1988) found the haemolytic activity 
corresponded to the first two protein peaks following 
anion exchange chromatography and eluted very close to 
the void volume in the Sephacryl S-300 column suggesting 
it was in an aggregated form. They appeared to recover 
most of the haemolytic activity following anion exchange 
chromatography and detected a major protein band of 130 
kDa along with three other proteins of lower molecular 
weights with a combined molecular weight of 133 kDa. 
Further characterisation of the haemolytic activity 
revealed its association with a 104, 105, 107, 109 and a 
110 kDa protein band respectively (Devenish & Rosendal, 
1989; Frey & Nicolet, 1988a; Frey & Nicolet, 1988b; Frey 
et al., 1988; Lalonde et al., 1989; Rycroft et al., 
1991; Fedorka-Cray et al., 1990). Devenish & Rosendal 
(1989) also identified the haemolysin with two major 
protein peaks using a Sephadex G-100 column. However 
they found half the haemolytic activity was lost 
following ammonium sulphate precipitation and a further 
80-90% was lost following gel chromatography with little 
or no recovery using anion exchange chromatography.
Different serotypes of A. pleuropneumoniae had different 
requirements of Ca++ for expression of haemolytic 
activity (Frey et al., 1988; Frey & Nicolet, 1988b). The 
haemolytic activities were put into four distinct 
groups. Serotype 1 required Ca++ for the induction of 
synthesis of haemolytic activity but not for activity. 
Serotypes 2, 4, 7 & 8 produced a relatively weak
haemolysin that required Ca++ for its activity but not 
for induction. Serotypes 5a, 5b, 9, 10, 11 & 12 required
16
Ca++ for both induction and expression of haemolytic 
activity. Serotype 3 & 6 produced very weak haemolytic 
activities which could not be further assessed (Frey et 
al., 1988b). No other bivalent ions could substitute the 
function of Ca++ in haemolysin expression. The threshold 
concentration of Ca++ for haemolysin expression was 
around 700mM, which is similar to that found free in 
blood (Frey & Nicolet, 1988b) . The requirement of Ca++ 
for expression of haemolytic activity in the serotypes 
mentioned by Frey et al. (1988) would perhaps explain 
why Rosendal et al. (1988) failed to detect haemolytic 
activity in serotypes 2, 7, & 8. He did detect
haemolytic activity in serotype 1, 3, 5, 9 and 10 in
which no additional Ca++ was added. However the combined 
Ca++ content of 5% heated calf blood added to the 
tryptone soya broth growth medium may have been 
sufficient to allow induction of haemolysin in these 
serotypes. In accordance with Frey & Nicolet (1988) 
other researchers noted the requirements of Ca++ for 
haemolytic activity (Lalonde et al., 1989; Kamp & van 
Leengoed, 1989; Devenish & Rosendal, 1989; Rycroft et 
al., 1991). These differences in requirement of Ca++ for 
haemolytic activity denoted two distinct haemolysins, 
haemolysin I (Hly I) which required Ca++ for its 
induction and haemolysin II (Hly II) requiring Ca++ for 
expression (Frey & Nicolet, 1990). A relationship 
between the type of haemolysin produced and virulence 
was suggested. Strains producing Hly I belonged to 
serotypes frequently isolated from severe outbreaks and 
considered more virulent than strains producing Hly II 
(Frey & Nicolet, 1990). Kamp & van Leengoed (1989) added 
Ca++ in both the growth medium and the haemolysin assays 
and found haemolytic activity could only be detected in 
serotypes 1, 5, 9, 10 & 11 and not in serotypes 2, 3, 4, 
6 & 7. The differences observed perhaps was due to the 
different protocols used in the production of the 
haemolysin and the time lapsed before haemolytic 
activity was assessed. Kamp & van Leengoed (1989)
assayed their haemolytic activity within 24 hours. 
Haemolytic activity has been found not to be very stable 
and perhaps the discrepancies observed were due to the 
delay before assessment.
The haemolysin has been shown to produce pores in 
phospholipid membranes (Lalonde et al., 1989). This 
activity resembles that of the alpha-haemolysin of E. 
coli which together with other organisms includes a 
growing number of Gram-negative organisms that produce 
pore forming toxins (Koronakis et al., 1987). Cloning of 
a haemolysin gene (Chang et al., 1989) of a serotype 5 
strain revealed high homology to the E. coli alpha 
haemolysin gene hly A and to the lkt A haemolysin gene 
of Pasteurella haemolytica. Analysis of the cloned 
genetic material displayed two open reading frames, 
designated appC and appA. The high homology of these 
appC and appA genes to both the E. coli and P. 
haemolytica hlyCA and lktCA genes respectively, together 
with the requirement of both the C and A genes for toxic 
activity placed A. pleuropneumoniae haemolysin in the 
RTX cytotoxin family (Strathdee & Lo, 1989). Isolation 
and DNA hybridisation of a serotype 1 haemolysin gene of 
107 kDa molecular weight (Gygi et al., 1990) revealed a 
similar close relationship, although with some sequence 
divergence, with the Hly determinant of other Gram- 
negative bacteria. These include Proteus spp., 
Morganella morganii (Koronakis et al., 1987; Koronakis & 
Hughes, 1988; Welch, 1987) and Actinobacillus 
actinomycetemcomitans (Kolodrubetz et al., 1989; Lally 
et al., 1989). Activation and export of the 
prohaemolysin gene Hly A by the E. coli Hly C, B and D 
genes confirmed the sustantial sharing of haemolysin 
structure and function (Gygi et al., 1990). 
Characterisation of a serotype 9 haemolysin determinant 
(Smits et al., 1990) showed it was almost identical to 
the serotype 5 appCA genes (Chang et al., 1989). The 
lysates containing protein of these clones containing
18
the serotype 9 DNA demonstrated both haemolytic and 
cytotoxic properties suggesting that both activities 
were present on the molecule (Smits et al., 1990). Lian 
et al. (1989) cloned a 29.5 kDA protein and detected 
haemolytic activity in the E. coli host. Its properties 
included heat-stability and non-regulation by Ca++. Its 
haemolytic activity was not neutralised by antiserum 
against the 105 kDa haemolysin. The activity was 
neutralised by antiserum against the recombinants that 
contained the 29.5 kDa proteins and also convalescent 
pig serum. The haemolytic activity was also not 
neutralised by antiserum of related organisms that 
produce haemolysins including E . coli, Streptococcus 
agalactiae and also purified streptolysin O. They 
concluded that although haemolytic activity could be 
detected in the E . coli recombinants they could not rule 
out the possibility that this 29.5 kDa protein was a 
regulator of haemolytic activity rather than a true 
haemolysin. The DNA sequencing showed no homology with 
any of the known haemolysins or toxins but it did have 
extensive homology with the E. coli fnr regulatory gene 
suggesting its probable role as a regulator.
Identification of a heat-labile cytotoxin distinct from 
haemolytic activity was next described (Rycroft & 
Cullen, 1990b; Rycroft et al,, 1991; Kamp et al,, 1990). 
Analysis of the crude concentrated cytotoxin by Kamp et 
al,, (1990) revealed the presence of two major bands of 
105 and 120 kDa. Monoclonal antibody to the crude 
formalised cytotoxin reacted only with the 120 kDa 
protein. Purification of the cytotoxin by a Superose 12 
column resulted in loss of cytotoxic activity. Analysis 
of the fractions showed presence of the 105 but not the
120 kDa protein. They suggested that the 120 kDa protein
was the heat-labile cytotoxin of serotype 2 strain 1536
and the 105 kDa protein the inactive form of the 120 kDa
protein. This was in contrast to Frey et al. (1990), 
who, using the same serotype 2 strain 1536, detected
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haemolytic activity. They did however agree on the 
presence of two major proteins following purification. 
They estimated molecular weights to be 105 and 125 kDa. 
Following neutralisation of the haemolytic activity with 
antiserum raised against the 105 but not the 125 kDa 
protein, the 105 kDa protein was identified as the 
haemolysin. In this laboratory the cytotoxin was also 
determined to be the 120 kDa protein and the 105 kDa 
protein the haemolysin (Rycroft & Cullen, 1990b; Rycroft 
et al., 1991). Mutants deficient in the type II
haemolysin of serotype 2 showed concurrent loss of 
either the 109 kDa protein or both the 109 and the 120 
kDa proteins. Mutants lacking only the 109 kDa protein 
still retained cytotoxic activity for porcine alveolar 
macrophages showing the two activities to be separate. 
The lack of both the 105 and the 120 kDa bands in the 
other mutants correlated with loss of both the 
haemolytic and the cytotoxic activities. Antiserum 
raised against the 120 kDa protein recognised the 120 
kDa but not the 105 kDa protein. Similarly this 
antiserum neutralised the cytotoxic activity but not the 
haemolytic activity. Following the relationship between 
the presence of the 120 kDa protein and cytotoxicity it 
was proposed that the 120 kDa protein represented the 
cytotoxin of A. pleuropneumoniae, it was designated 
pleurotoxin and was distinct from the haemolysin 
(Rycroft & Cullen, 1990b; Rycroft et al., 1991).
1.6.4 Camp factor
The CAMP factor is associated with a lytic phenomenon 
whereby a zone of lysis produced by certain bacterial 
strains cultured on blood agar is enhanced when the 
haemolysin acts synergistically with the D-toxin of 
Staphylococcus aureus. This CAMP factor, which is 
produced by A. pleuropneumoniae (Kilian, 1976b) , has 
been proposed to be a virulence factor in other 
bacteria. Injection (i.v.) of partially purified CAMP
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factor from Streptococcus agalactiae was found to be 
lethal for rabbits (Skalka & Smola/ 1981). Vaccination 
with CAMP factor also reduced the lethal dose of group B 
streptococci (Fehrenbach et al,, 1988). Jurgens et al,
(1987) found similarities to the way both CAMP factor 
and protein A of Staphylococcus aureus bound to 
immunoglobulins supporting its possible role in 
virulence. Cloning of total DNA from A. pleuropneumoniae 
revealed a cohaemolysin of 27 kDa (Frey et al,, 1989). 
This protein was a similar size to the CAMP protein of 
group B streptococci. Cross reaction of the S, 
agalactiae protein B with antiserum raised against the 
cloned A. pleuropneumoniae CAMP protein showed that they 
were similar. The presence of the CAMP factor in all the 
A, pleuropneumoniae serotypes suggested it could be a 
common virulence factor. However, haemolysin II and 
pleurotoxin negative mutants (109“, 120“ kDa) were found 
to possess the CAMP factor and yet possessed no toxicity 
in their bacterial culture supernatant and therefore the 
CAMP factor appears not to be responsible for a toxic 
effect (Rycroft & Cullen, 1990b; Rycroft et al,, 1991).
1.6.5 Outer membrane components
Certain outer membrane proteins (OMPs) are important for 
the expression of virulence. A continued supply of iron 
is essential for the maintenance of growth by most 
microorganisms (Weinberg, 1978). A common host defence 
mechanism against invading pathogens is to withold 
essential nutrients, including iron. The iron 
sequestering effect of transferrin or lactoferrin limit 
the free iron available to the microorganisms. Many 
pathogenic bacteria have developed high affinity iron 
uptake systems to combat this host defence mechanism. 
The two main components of this system include low 
molecular weight siderophores responsible for chelating 
iron and iron repressible OMPs which act as receptors 
for these siderophores (Braun, 1985; McIntosh et al.,
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1979; Neilands, 1982). Iron-repressible OMPs in the 
range of 64-76 kDa and 96-105 kDa have been described 
for A . pleuropneumoniae (Deneer & Potter, 1989a; Niven 
et al., 1989; Gonzalez et al., 1990; Ricard et al., 
1991). These have been suggested to serve as receptors 
for free haeme compounds and mediate transport into the 
cell (Ricard et al., 1991). Both OMPs are expressed both 
in vivo and under iron restricted conditions in vitro, 
and therefore may be important immunogens. The function 
of A. pleuropneumoniae haemolysin, which lyses 
erythrocytes, is perhaps to supple an adequate source of 
iron for in vivo growth. A. pleuropneumoniae has been 
shown to possess receptors specific for porcine 
transferrin only and can only use this species specific 
transferrin for growth (Niven et al., 1989; Gonzalez et 
al., 1990; Schryvers & Gonzalez, 1990; Ricard et al., 
1991). This strict species specificity for host 
transferrin has been seen in other pathogens including 
Haemophilus influenzae (Schryvers, 1988). The inability 
to utilise iron in transferrins from other species has 
been suggested to perhaps partly explain the inability 
of certain pathogens to cause infection in other hosts.
A maltose inducible protein has also been described for 
some strains of A. pleuropneumoniae (Deneer & Potter, 
1989b) . This 42 kDa protein has been proposed to act as 
a porin in the maltose transport system. Although all 
the strains tested did not induce the 42 kDa OMP, all 
strains utilised the maltose as demonstrated by the 
increased yields when grown in the presence of maltose. 
The ability to induce this 42 kDa OMP appears not to be 
essential for pathogenicity since all strains tested 
were isolated from pigs.
1.6.6 Permeability factor
A permeability factor produced by A. pleuropneumoniae 
has been described which induces dermal oedema in
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rabbits (Lallier et al., 1987). The factor was produced 
at 2 stages of the growth cycle and determined not to be 
haemolytic or proteolytic. Cytotoxic activity was not 
determined and antiserum to formalised cells did not 
neutralise the activity of the permeability factor. It 
has been found that although antiserum raised against 
formalised A. pleuropneumoniae possesses reactive 
antibodies, they are not capable of neutralising toxic 
activities associated with the secreted haemolytic and 
cytotoxic factors (this thesis, Chapter 6). This may 
therefore also be true for the permeability factor 
discussed here.
1.6.7 Adhesion factors
Colonisation of the pig lung is the initial virulence
mechanism required to cause infection. Surface
properties of A. pleuropneumoniae have been suggested to 
allow bacteria to attach to the nasopharynx in order to 
colonise the host. These surface properties have 
included smooth LPS profile (Belanger et al., 1990),
haemaggulutination (HA) properties (Jacques et al., 
1988b) and the presence of fimbriae (Utrera & Pijoan, 
1990). Preliminary evidence for pilus-like structures 
was documented by Inzana et al. (1988) on A.
pleuropneumoniae phagocytosed by polymorphonuclear 
cells. Utrera and Pijoan (1990) demonstrated fimbriae on 
78% of isolates recovered from experimentally infected 
pigs after one passage. No fimbriae could be detected 
after 2 passages on artificial medium or after 1 passage 
on enriched media, suggesting production of fimbriae is 
strictly dependent on the environment.
Differing HA activities have been described for A. 
pleuropneumoniae (Jacques et al., 1988b). The ability of 
bacteria to attach to and agglutinate erythrocytes has 
been documented to serve as a useful model for bacterial 
attachment to epithelial cells (Old, 1985). Both
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pilation (Duguid et al., 1979) and hydrophobic 
interactions (Garber et al.r 1985) can be involved in HA 
reactions. A . pleuropneumoniae HA activities did not 
appear to be due to either fimbriae or to hydrophobic 
reactions. The differences in HA activities could not be 
attributed to different serotypes and their relationship 
to virulence was not examined (Jacques et al., 1988b).
1.6.8 Immunoglobulin A proteases
Invading organisms must withstand the mucosal cleansing 
mechanisms in order to colonise the host. Secretory IgA 
plays a major role in the immune system at mucosal 
surfaces. 80% of the antibody secreted at these sites is 
IgA. Secretory IgA has antibody activity against 
bacteria, toxins, viruses and enzymes. Certain bacteria 
secret an IgA protease which inactivates the antibody by 
cleaving it into intact Fc alpha and Fab alpha 
fragments. By this mechanism they can avoid the 
detrimental effects of antibody binding and recognition 
by the host immune system. Members of the Haemophilus 
species responsible for respiratory disease have been 
shown to produce IgA protease (Kilian et al., 1979).
Non-pathogenic organisms were found to lack this enzyme. 
Conflicting reports have been documented on the ability 
of A . pleuropneumoniae strains to cleave pig IgA. Kilian 
et al. (1979) detected IgA protease activity in the 2 A. 
pleuropneumoniae strains tested. A later study by Mulks 
et al. (1984) could not confirm the presence of IgA 
protease activity in any of the strains tested including 
one previously tested by Kilian et al. (1979). Also no 
homology was shown between the A. pleuropneumoniae 
strains and both H. influenzae chromosomal DNA and the 
gene which codes for IgA protease activity in this 
species suggesting A. pleuropneumoniae does not contain 
this enzyme. The lack of recognition with the H. 
influenzae DNA probe has been suggested to be due to the 
A. pleuropneumoniae IgA protease being significantly
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unique to prevent hybridisation. This would explain the 
differences observed between the groups on the presence 
of an IgA protease in A . pleuropneumoniae.
1.6.9 Plasmids
Virulence of a number of bacterial pathogens has been 
shown to be dependent on genes located on 
extrachromosomal genomes of plasmids or phage, for 
example the E . coli heat labile exotoxin (Stephen & 
Pietrowski, 1981). No high molecular weight plasmids 
have been detected in A . pleuropneumoniae (Huether et 
al., 1987; Hirsh et al., 1982). Low molecular weight 
plasmids conferring resistance to streptomycin and 
sulfonamide (Willson et al., 1989) and ampicillin, 
streptomycin and sulfadiazene (Hirsh et al., 1982) have 
been reported. The lack of genetic material to promote 
transmission has suggested the appearance of these 
plasmids was due to enviromental selective pressure 
(Bertram, 1990; Vaillancourt et al., 1988; Willson et 
al., 1989). The recent development of a shuttle vector 
and a conjugative transfer system for A. 
pleuropneumoniae (Lalonde & 0 'Hanley, 1989) may allow 
the study of A. pleuropneumoniae genetics to develop.
1.7 Pathological description of lung lesions
Lesions induced by A. pleuropneumoniae infection are 
confined to the lung region. In peracute cases the lungs 
are swollen, firm, dark red in colour (Fig. 1.1b) in 
contrast to the usual pink colour (Fig. 1.1a). Fluid and 
blood may ooze from the cut surface. Blood stained froth 
may be present in the trachea and also the nasal and 
pleural cavities. Thickening of the interlobular septae 
and presence of oedema due to fibrinous exudate are 
common. Pericarditis may also occur. Necrosis and 
fibrinous pleural adhesions are frequently present. In 
chronic cases the lesions become encapsulated and can be
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Fig. 1.1 Comparison of lungs from pleuropneumonia 
infected and pleuropneumonia-free pigs.
a) Lungs from a pleuropneumonia-free pig
b) Typical lung lesion from a pig with 
pleuropneumonia
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Fig. 1.1
seen as firm greyish nodules (Shope, 1964; Sanford & 
Josephson, 1981; Bertram, 1988; Blood & Radostits, 1989; 
Taylor, 1989).
1.8 Lesion development
Liggett and Harrison (1987) followed the development of 
lung lesions from 3 hours post infection to 7 days. 
Within 3 hours oedema with multifocal petechial 
haemorrhages could be seen. Microscopic examination 
revealed neutrophilic bronchiolitis and alveolitis. 
There was a predominance of neutrophils in the exudate 
indicating a major involvement of these cells in early 
infection. This corresponded with the development of 
neutropaenia and leucopaenia in the pigs. Lobular 
haemorrhages and necrotising pneumonia with pleurisy 
could be seen at 12 to 18 hours. 1 to 2 days post 
infection there was fibrinous pleurisy and lobar 
pneumonia together with acute necrotising pneumonia. 
Lung abscesses and fibrous pleurisy with pleural 
adhesions were predominant at 4 to 7 days.
In previous studies neutrophils appeared not to be 
present in the exudate (Shope, 1964; Schiefer et al., 
1974; Sanford & Josephson, 1981; Sebunya et al., 1982). 
Large numbers of degenerate elongated cells in swirling 
patterns were seen, however their cell type could not be 
determined. It was suggested that mononuclear cells were 
primarily involved in clearance of A. pleuropneumoniae. 
However, A. pleuropneumoniae produces a potent toxin for 
alveolar macrophages along with monocytes and 
neutrophils (Bendixen et al., 1981; Udeze & Kadis, 1988; 
Rosendal et al,, 1988, Rycroft et al., 1991). The toxin- 
affected macrophages are therefore thought to be 
incapable of phagocytosing the large influx of 
neutrophils which are normally responsible for the 
clearance of these cells and thereby prevent neutrophil- 
mediated injury. The release of toxic products from both
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the degenerate neutrophils and macrophages may also play 
a role in inflammation and lesion development.
1.9 Clinical signs
The clinical signs of porcine pleuropneumonia can range 
from chronic to peracute depending on the immune status 
of the animal (Sebunya & Saunders, 1983; Nicolet, 1986; 
Blood & Radostits, 1989; Taylor, 1989). Morbidity and 
mortality can both reach 100%, again depending on immune 
status of the herd. High mortalities and morbidities are 
usually seen in herds not previously infected with A. 
pleuropneumoniae (Nicolet, 1971; Nielsen, 1974). The 
peracute signs include one or more pigs becoming very 
ill with high fever (41.5°C) being anorexic and 
apathetic (Fig. 1.2). Some pigs that showed no signs of 
being ill can be found dead (Shope, 1964). Severe
dyspnoea with blood stained froth from the nose and 
mouth can be seen later. The skin becomes cyanotic
initially on the legs, ears and nose and later on the 
whole body (Nicolet, 1986). Death can occur within 4-36 
hours (Shope, 1964; Nicolet, 1968; Nielsen & Mandrup, 
1977). Abortions may occur (Sanford & Josephson, 1981; 
Wilson & Kierstead, 1976) and occasionally septicaemia 
in young piglets (Thomson & Ruhnke, 1963). The number of 
pigs noticeably affected with the acute form is greater 
than the peracute. The raised body temperature, up to 
41°C, together with lethargy and inappetance, are
characteristic. The animals usually show severe
respiratory distress. The acute disease may last for up 
to five weeks in the herd (Shope, 1964). Following the 
acute phase animals may die or develop the subacute or 
chronic forms. Transition from the acute phase to the 
chronic or subclinical can be both spontaneous (Shope, 
1964; Mylrea et al., 1974) and following antibiotic 
treatment (Schiefer et al., 1974). The course the
disease follows will depend on the extent of the lung 
affected. If sufficient lung tissue is available for
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Fig. 1 2 Pig with pleuropneumonia.
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Fig. 1.2
respiration the subacute or chronic forms may follow, if 
not the animal dies. Chronically infected animals 
usually show lack of fever, loss of appetite and develop 
a persistent cough. Some chronically infected animals 
show very few clinical signs. Subclinically affected 
animals may show clinical signs following infection with 
other respiratory pathogens including Pasteurella 
multocida (Nicolet, 1986).
1.10 Diagnosis
1.10.1 Pathological/clinical diagnosis
The clinical signs and pathological findings normally 
indicate which respiratory disease is present prior to 
identification of the organism by microbiological 
culture (Blood & Radostits, 1989; Taylor, 1989). The 
swiftness of onset together with the clinical symptoms 
of fever, anorexia, severe dyspnoea and the high 
mortality differentiates A. pleuropneumoniae from most 
other respiratory diseases of pigs. Swine influenza also 
has a very rapid onset with 100% of pigs normally being 
infected, however mortality is much lower, usually less 
than 1%. This together with lack of response to 
antimicrobial treatment is indicative of swine 
influenza. Enzootic pneumonia usually does not produce a 
fever or respiratory distress. The appearance of the 
lesions is also distinct. Pasteurellosis is normally 
associated with a necrotising bronchopneumonia. Mulberry 
heart disease can display similar clinicial signs 
however there is no pneumonia. Glasser's disease 
normally occurs in young pigs and is characterised by 
serositis, arthritis and meningitis.
1.10.2 Serodiagnostic tests
Serodiagnostic tests are important in establishing the 
infecting serotype in order that effective prophylaxis
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can commence as soon as possible. This is usually in the 
form of killed bacterial vaccines of the serotypes 
identified. Although these bacterins do not prevent 
disease, they do reduce mortality, and because they are 
serotype-specific, it is important to determine the 
infecting serotype quickly to prevent further deaths. 
Serotyping is also important to establish and monitor 
the epidemiology of the infection.
The complement-fixation test was popular for many years 
in Denmark, Canada, USA and Switzerland as a means of 
serotyping A. pleuropneumoniae (Nicolet, 1971; Lombin et 
al., 1982; Gunnarsson, 1979b; Nielsen, 1988). Phenol- 
water extraction of whole cells gave the most serotype- 
specific reactions (Gunnarsson, 1979b). Although it was 
used fairly successfully, cross reactions did occur 
between some A. pleuropneumoniae serotypes and also the 
related pathogen Actinobacillus suis (Rapp et al., 
1985b; Rosendal & Mittal, 1985). Cross reactions with A. 
suis were due to shared epitopes on outer membrane 
proteins (Maclnnes & Rosendal, 1987). The 2- 
mercaptoethanol tube agglutination test was easier to 
perform and detected active infection in piglets earlier 
than the complement-fixation test. It also could not 
detect maternal antibody after 4 weeks and therefore 
indicated recent infection after this age (Mittal et 
al., 1984). Enzyme linked immunosorbent assay (ELISA) 
was found to be as specific and more sensitive than both 
complement-fixation and 2-mercaptoethanol tube 
agglutination (Nicolet, 1981; Inzana & Mathison, 1987; 
Goyette et al., 1986; Willson et al., 1988; Stenbaek, 
1990; Nakai et al., 1990). The first ELISA developed 
employed an EDTA-extracted antigen. Serotypes 1 to 5 
were tested and the test was found to be serotype- 
specific, provided the appropriate antiserum was used 
(Nicolet, 1981). The later identification of serotypes 6 
to 12 have not been tested in this system for cross 
reactivity. Saline extract at 100°C was found to be as
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satisfactory as EDTA-extracted antigen and was more 
specific due to destruction of heat-labile antigens 
(Goyette et al,, 1986). Cross reactions were still 
observed between heterogeneous serotypes. This cross 
reaction was probably due to the fact that the tests 
employed antibodies to whole cells and crude cellular 
extracts for detection of antibody. Increased 
specificity was obtained using purified capsule or 
monospecific serum to capsule in both ELISA and double­
label radio-immunoassay respectively (Inzana & Mathison, 
1987; Inzana et al,, 1990). Double-label radio­
immunoassay could be used to detect both antibody or 
antigen. This was developed to detect capsular antigens 
or antibodies to A, pleuropneumoniae (Inzana et al,,
1990). The test was found to be highly sensitive and 
serum had to be diluted at least 1:100 to avoid 
detection of cross reacting antibodies to common 
antigens. The use of radioisotopes made it unsuitable 
for field testing and the purification of capsule 
antigens was not within the capacity of all 
laboratories.
ELISAs have also been developed using Mabs (Nakai et 
al,, 1990; Stenbaek, 1990). Nakai et al, (1990) detected 
serotype 2 specific antigen using a Mab sandwich ELISA 
against serotype 2 with no cross reactivity from other 
serotypes or related gram-negative bacteria. Specific 
antigen patterns were seen for all 12 serotypes 
(Stenbaek, 1990). Mab directed against these serotype 
specific antigens would overcome the cross reactivity 
seen between the heterogeneous groups of A. 
pleuropneumoniae. Latex agglutination was reported to be 
as specific and sensitive as the other tests currently 
used (Mitui et al,, 1981; Inzana, 1990), although it was 
not as sensitive as radioimmunoassay (Inzana et al,,
1990). Both cell extract (Mitui et al,, 1981) and 
purified capsule or affinity purified antibody to 
capsule have been used respectively (Mutui et al,, 1981;
32
Inzana, 1990). The fact that the test can be used for 
serotyping and identification of infection, together 
with its rapidity, make it potentially very useful for 
both field and laboratory testing.
Outer membrane proteins common to all the serotypes of 
A. pleuropneumoniae could also be useful for detection 
of A, pleuropneumoniae infection (Nielsen, 1990). Common 
proteins in serotypes 1-5 and 7 expressed under iron 
restricted conditions were demonstrated when probed with 
convalescent pig serum (Deneer & Potter, 1989a). Ma and 
Inzana (1990) developed an ELISA system for the 
detection of the 110 kDa haemolysin protein. This 
haemolysin protein was common to all 12 serotypes (Frey 
& Nicolet, 1990; Devenish et al., 1989) and therefore 
had the potential to screen for A. pleuropneumoniae 
infection. However this haemolysin protein cross reacts 
with proteins of similar size in other organisms 
including A. suis, A. pleuropneumoniae "minor group", 
the P. haemolytica leukotoxin and E . coli alpha- 
haemolysin (Devenish et al,, 1989). The use of Mabs in 
the ELISA system did not increase specificity which is 
thought to be due to the sequence homology that was 
demonstrated between these cross reacting organisms 
(Chang et al., 1989; Gygi et al., 1990).
Both tests incorporating the use of Mabs and latex 
agglutination have the potential both for increased 
specificity and speed.
1.10.3 Bacterial isolation
Bacterial culture has also been used to diagnose A. 
pleuropneumoniae infection. This technique is specific 
but not sensitive. Failure to isolate organisms from 
infected animals can be due to the presence of small 
numbers of organisms, for example in recovering animals, 
or the tissue containing the bacteria is not usually
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sampled. Overgrowth by other bacteria and the need
sometimes for special culture techniques can result in 
failure to detect A . pleuropneumoniae (Willson et al., 
1987). Selective media for isolation of A.
pleuropneumoniae alone was useful in slaughter pigs
where the contamination was higher. There was no 
advantage when experimentally infected pigs were sampled 
(Gilbride & Rosendal, 1983).
1.11 Treatment and control
1.11.1 Antibiotic therapy
The value of antibiotic treatment in controlling 
infection depends largly on administration early on in 
the clinical disease. Willson and Osborne (1985) studied 
the effect of different antibiotics in the prevention of 
A. pleuropneumoniae infection and treatment of both
acute and chronic disease. Pigs given long-acting 
oxytetracycline 24 hours prior to challenge showed no 
mortality or fever. No lung lesions were detected in any 
of the pigs examined by post-mortem at 2 , 6 and 10 weeks 
post challenge. In contrast treatment with 
chloramphenicol and/or oxytetracycline only reduced the 
number of animals that died or developed fever and lung 
lesions. Antibiotic treatment given following the onset 
of clinical signs did significantly reduce mortality 
although lung lesions did occur. Penicillin reduced the 
number of pigs that became carriers assessed by failure 
to isolate bacteria as compared to the isolation of 
bacteria from pigs treated with long-acting 
oxytetracycline and chloramphenicol. None of the 
antibiotics tested reduced the numbers of carriers in 
chronically infected animals or improved the average 
daily weight gain. Increase in average daily weight gain 
and reduction of lesions was demonstrated in infected 
pigs following water mediation using Tiamulin (Schultz 
et al., 1983). Numerous antibiotics have been used in A.
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pleuropneumoniae infection. These include ampicillin, 
amoxycillin, cephalexin, chloramphenicol, enrofloxacin, 
lincospectin, gentamicin, penicillin, oxytetracycline, 
trimethoprim sulphonamide, tiamulin and
chlortetracycline (Taylor, 1989).
The sensitivities of A. pleuropneumoniae to certain 
antibiotics has been shown to vary based on geographical 
location (Didier et al., 1984; Gilbride & Rosendal,
1984). Plasmid mediated resistance to antibiotics has 
been documented (Hirsh et al., 1982; Huether et al., 
1987; Willson et al., 1989). Antibiotic sensitivities of 
the infecting strain of A. pleuropneumoniae should be 
evaluated prior to commencement of treatment. Antibiotic 
treatment can therefore help reduce mortality and lung 
lesions in pigs already infected with A. 
pleuropneumoniae. The problem to date has been the 
inability to eradicate the organism from chronically 
infected animals which remain a source of continued 
infection. Recently, antibiotics which appear to 
eliminate as well as help prevent A. pleuropneumoniae 
infection have been described. Therapeutic effectiveness 
of cephalosporin (NaxcelR) was shown after three 
treatments in pigs with pleuropneumonia and it was also 
very successful in the prevention of infection (Bilic & 
Sudaric-Grgurec, 1990). Treatment with ceftiofur in 
experimentally infected animals resulted in failure to 
isolate the organism (Hus et al,, 1990) and it may 
therefore prove useful in chronically infected animals. 
Antibiotic treatment alone is not thought to the best 
long term solution to control pleuropneumonia on the 
basis of cost, antibiotic resistance and the increased 
public awareness about the effects of antibiotic 
residues (Maclnnes & Rosendal, 1988).
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1.11.2 Vaccines
1.11.2.1 Active immunisation
a) Inactivated whole cell vaccines (bacterins)
Vaccines using killed bacteria as antigen have had 
various success rates in reducing the mortality and 
morbidity. Bacterins can prevent mortality although the 
animals still show severe respiratory disease when 
challenged with the same serotype (Higgins et al.,
1985). Mason et al. (1982) showed only a 17% reduction 
in mortality in piglets vaccinated with a formalin 
inactivated alum vaccine. Prevention of acute 
pleuropneumonia was demonstrated in pigs vaccinated with 
a combination of bacteria and adjuvant (Rosendal et al., 
1981). However the adjuvant itself was toxic for some 
pigs. Mineral oil adjuvants, and to a lesser extent 
aluminium hydroxide, caused irritation resulting in 
abscesses and granulomas (Mason et al., 1982; Straw et 
al., 1985). Bacterins usually do not elicit cross 
immunity between other infecting serotypes (Nielsen, 
1984). However a high degree of cross protection with 
parenteral killed vaccines was demonstrated between 
heterologous serotypes 3, 6 and 8 in an experimental
study (Nielsen, 1985c). These serotypes are known to 
possess cross-reacting serotype antigens. This suggests 
perhaps cross immunity between heterologous serotypes 
may in fact occur in the field. Their use is limited in 
the field unless the infecting serotype is known. The 
rapid onset of clinical symptoms in A. pleuropneumoniae 
infection suggests that efficient preparation and 
administration is required to have an effect on reducing 
acute pleuropneumonia.
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b) Live vaccines
Pigs intranasally inoculated with live bacteria resisted 
challenge and showed no clinical signs (Nielsen, 1974), 
They did however show a range of clinical signs and lung 
pathology following the initial vaccination. The age of 
the culture together with the adjuvant used affected the 
degree of protection obtained. A 6 hour culture in 
Freunds incomplete adjuvant gave better protection than 
in an alhydrogel adjuvant or a 18 hour culture in either 
of the adjuvants (Nielsen, 1976). Intranasal inoculation 
of live bacteria offered cross protection against 
clinical symptoms when challenged with other serotypes 
and reduced the severity of lung lesions (Nielsen, 
1979). In contrast, parenteral vaccines with killed 
bacteria did not elicit cross immunity suggesting a 
clear difference between immunity to vaccination with 
killed bacteria and natural infection or experimentally 
with live organisms (Nielsen, 1984). Vaccination with 
live A. pleuropneumoniae therefore appears to be 
sufficient to provide protecting against both homologous 
and heterologous serotypes. The harmful effects of 
vaccination with live A. pleuropneumoniae makes its 
extensive use in the field unlikely.
1.11.2.2 Passive immunisation
Passive immunisation with hyperimmune rabbit serum to 
formalised whole cells gave 100% protection in mice 
against both homologous and heterologous serotypes only 
when certain serotypes were used (Bhatia et al., 1990). 
When cross protection studies were carried out with 
different serotypes, no protection was demonstrated when 
challenged with heterologous serotypes. Serum raised 
against formalised cells does not possess neutralising 
antibody against the secreted toxins of A. 
pleuropneumoniae (Chapter 6 ) and this may contribute to 
the lack of protection. The use of the mouse model has
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also been shown not to reproduce the disease 
satisfactorily (Fenwick et al., 1986b). Smith and Lida 
(1990) found only a reduction in mortality and severity 
of lesion following challenge in pigs previously having 
received immunisation with Mab to the challenge strain. 
No protection was seen following challenge with a 
heterologous serotype. The amount of antibody given via 
passive immunisation is perhaps important. Piglets 
receiving colostrum from chronically infected sows are 
completely protected against infection by both 
homologous and heterologous strains until the decline of 
maternal antibody. Similarly, passive transfer of serum 
raised against live bacteria results in full protection 
(Inzana et al., 1988). This suggests that in theory, 
passive immunisation should be sufficient to provide 
complete protection against both homologous and 
heterologous serotypes providing the material possesses 
all the important immunogens.
1.11.2.3 Active/passive immunisation with cellular 
components
A cell extract containing protein, carbohydrate and 
endotoxin that exhibited both haemolytic and cytotoxic 
activities conferred partial protection against the 
homologous serotype by decreasing the severity of 
clinical signs and lung lesions in pigs (Fedorka-Cray et 
al., 1990). Bhatia et al. (1990) also demonstrated 
partial protection in mice actively immunised with crude 
capsular material or crude lipopolysaccharide against 
both homologous and heterologous serotypes 1 and 5. 
Partial protection was obtained by passive immunisation 
of hyperimmune serum to capsule, lipopolysaccharide or 
haemolysin. Heat labile components were also important 
as demonstrated by the inability of boiled or autoclaved 
bacteria to protect. Byrd & Kadis (1990) also 
demonstrated partial protection against mortality and 
development of lung lesions in pigs immunised with a
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combination of LPS, capsular material and haemolysin. 
Antibodies specific for A. pleuropneumoniae LPS were not 
capable of providing immunity to A. pleuropneumoniae 
infection in mice (Inzana et al,, 1988). In contrast 
partial protection against A. pleuropneumoniae infection 
was demonstrated in pigs immunised with E . coli J5 LPS 
(Fenwick et al., 1986c). These discrepancies were 
thought to be due to differences in immunising antigens 
or alternatively that immunisation with E . coli J5 may 
induce a non-specific protective immune factor not 
induced by A. pleuropneumoniae LPS (Warren et al., 
1987). Protection against mortality and reduction in 
lesion size was shown in pigs following 4 parenteral 
exposures to a liposome-LPS vaccine (Bertram, 1988). 
This would suggest that LPS does play a part role in A. 
pleuropneumoniae infection in pigs. Again the amount of 
antibody received by the animal may determine the level 
of protection obtained. Antibody to capsular 
polysaccharide is sufficient to protect the host against 
disease by a variety of bacterial pathogens (Robbins,
1978). Inzana et al. (1988) found that mice were not 
protected against intranasal challenge with homologous 
or heterologous serotypes after immunisation with a 
capsular-protein conjugate vaccine although antibody to 
capsule was detected. Mice were protected from infection 
with both homologous and heterologous serotypes after 
immunisation with live encapsulated and nonencapsulated 
bacteria. This suggests protection of mice against 
lethal challenges was not dependent on antibody to 
capsule, it was not serotype-specific and not induced by 
killed cells. Passive transfer of mouse IgM Mab to 
capsule protected 4\11 mice against lethal infection and 
delayed death in the others (Inzana et al., 1988). This 
partial protection by passive transfer of antibody to 
capsule has also been documented by Korvuo et al. 
(1988). The explanation given for these differences 
suggested mice may have received more antibody to 
capsule by passive transfer than by active immunisation.
39
Capsular material was found earlier to be a poor
immunogen from A. pleuropneumoniae (Inzana, 1987), This 
has also been found to be true for other organisms 
(Robbins et al, 1980) and could also explain the results 
found in mice. Non-immune pigs, passively immunised with 
monospecific serum to capsule, were protected from
lethal infection but not from development of lung 
lesions. The pathology was similar to that seen with
immunisation with killed bacteria (Nielsen, 1976). In 
contrast 2/3 pigs that received serum to live A, 
pleuropneumoniae did not develop lesions and bacteria 
were not recovered. Both Lenser et al. (1988) and 
Rosendal et al. (1986) reported protection against 
homologous strains using a capsular extract vaccine that 
contained protein together with carbohydrate. Removal of 
protein from the vaccine rendered it non-protective 
(Lenser et al., 1988). Protein carriers have been 
reported to increase immunogenicity (Inzana et al., 
1988; Anderson et al., 1985). Therefore it appears that 
antibody to capsule provides partial protection against 
mortality but not infection.
Analysis of outer membrane proteins (Rapp et al., 1986; 
Rycroft & Taylor, 1987; Maclnnes & Rosendal, 1987) 
demonstrated outer membrane proteins common to 
heterologous serotypes. An antibody response to outer
membrane proteins was demonstrated during infection with 
A. pleuropneumoniae (Rapp & Ross, 1986a). Immunisation 
with an outer membrane enriched vaccine reduced 
mortality and severity of pneumonia (Rapp & Ross, 
1986b). Following the increased interest in the 
haemolysins of A. pleuropneumoniae, their immunogenicity 
and protective ability was examined. Pigs vaccinated 
with the 104 kDa haemolysin protein were all protected 
from death following challenge. 2/5 of the vaccinated 
pigs that had neutralising antibody titre of over 
1:10,000 to haemolysin, also had no lung pathology. The 
three remaining vaccinated pigs had increasing lung
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pathology that corresponded to decreasing neutralising 
antibody titres to haemolysin (1:4,800, 1:3,900,
1:3,000) (Devenish et al., 1990a), More recently a 
subunit vaccine containing the haemolysin protein of 105 
kDa and a outer membrane protein of 42 kDa, completely 
protected pigs against both death and lung lesions when 
challenged with both homologous and heterologous 
serotype 1, 5a and 5b (van den Bosch et al., 1990). 
Vaccination with each of the components singly protected 
against death but not lung pathology.
Subunit vaccines containing important immunogens 
therefore appear to be the way forward, providing cross 
immunity is obtained against all the serotypes. A 
potentially useful vaccine might contain both the 
haemolytic and cytotoxic activities, an adhesive 
structure such as pili and the iron repressible 
proteins. This would in theory protect against firstly, 
possible adhesion of the organism, secondly, toxic 
activity by A. pleuropneumoniae and thirdly, curtail the 
growth of the organism by restricting iron uptake.
1.12 Host immune defences
The first major host defence against invading organisms 
is the skin and exposed epithelial surfaces. Continuous 
renewal of the outer most layer of skin and mucosal 
epithelium of the intestinal, respiratory and genital 
tracts reduces the number of bacteria colonising these 
surfaces. A. pleuropneumoniae is known to be present on 
the tonsils of healthy carrier pigs (Kume et al., 
1986a). This suggests it is able to overcome the 
continual renewal of epithial surfaces. The possession 
of pili by A, pleuropneumoniae (Utrera & Pijoan, 1991) 
may aid in the initial colonisation of the upper 
respiratory mucosal region. The body also has a range of 
physiological factors that inhibit bacterial growth. 
Enzymes such as proteases and lysozyme are capable of
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lysing bacteria and disrupting the petidoglycan in 
bacterial cell walls and therefore allowing osmotic 
lysis. Low pH found on the skin and in certain parts of 
the body including the stomach prevent multiplication of 
some organisms. Following the successful bypass of these 
first line defences, bacteria next face both specific 
and non-specific defence mechanisms within body tissues. 
These mechanisms include the action of complement, 
antibody, phagocytic cells and the B and T lymphocytes.
1.12.1 Complement
The main functions of complement are in mediating 
inflammatory responses and controlling bacterial 
infection. The complement system consists of a group of 
20 or so proteins found in tissue fluids, plasma and 
freshly isolated serum which form a triggered enzyme 
cascade (Fig. 1.3). Once activated, the complement 
system can result in opsonisation, cellular activation 
and lysis of bacteria. In general gram-positive bacteria 
are resistant to the bactericidal effects of complement 
and gram-negative bacteria are sensitive. However 
certain pathogenic gram-negative bacteria are in fact 
resistant to complement-mediated damage (Taylor, 1983).
Gram-negative bacteria can activate both the alternative 
and classical complement pathways in the absence of 
specific antibody (Pluschke & Achtman, 1984). However, 
increased efficiency of classical pathway activation 
generally occurs in the presence of specific antibody. 
Certain bacterial cell wall components can non- 
specifically activate complement (Morrison & Kline, 
1977; Vukajlovich et al., 1987). Activation of 
complement via either pathway results in C3b deposition 
on the bacterial surface. This acts as an opsonin 
stimulating bacterial uptake by phagocytes. Release of 
anaphylatoxins C4a, C3a and C5a following complement 
activation chemotactically stimulates PMNs, macrophage
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Fig. 1.3 Classical, alternative and lytic complement 
pathways. Adapted from Roitt et al. (1987).
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and mast cell degranulation together with vasodilation. 
This results in an influx of these cell types to the 
site of infection increasing the phagocytic uptake of 
bacteria by these cells. Bacterial lysis can also occur 
following complement activation by causing damage to the 
plasma membrane of the bacteria.
1.12.2 Phagocytes
The second major defence system available in the lung 
region is the phagocytic system. Following recruitment 
of phagocytes to the site of inflammation these cells 
must then be able to recognise the infectious agent in 
order to eliminate it. These cells have surface 
receptors capable of recognising various organisms. If 
these organisms have previously been opsonised their 
attachment to both PMNs and macrophages which both have 
receptors for C3b is greatly increased. Activation of 
the phagocyte membrane following attachment of the 
organism leads to it being internalised within a 
phagosome. Fusion with lysosomes to form a phagolysosome 
follows. The organisms can then be killed by a variety 
of bactericidal mechanisms.
1.12.3 Antibody
Antibody is involved in numerous mechanisms to 
neutralise and eliminate both the organism and its 
products. Antibody binding to the bacteria can disrupt 
attachment to epithelial surfaces hence preventing 
colonisation. Antibody efficiently activates the 
classical complement pathway. Binding of antibody to the 
bacteria in conjunction with C3b deposition increases 
the efficiency of bacterial uptake by phagocytes. 
Antibody can also be involved in neutralisation of 
toxins or components which interfere with immune 
function. It can also block the transport of essential
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nutrients into the bacterial cell by binding to their 
receptors.
1.12.4 Cell-mediated immunity
Cell-mediated immunity is usually important in organisms 
that survive intracellularly where antibody has no 
effect. Following re-exposure of an antigen, previously 
sensitised B and T lymphocytes undergo clonal expansion. 
T lypmhocytes also release lymphokines including 
macrophage activating factor (MAF) which increases the 
capacity of macrophages to kill ingested bacteria. 
Interferons can also be released from the stimulated T 
cells. This non-specifically enhances killing of 
infectious agents. B lymphocytes release antibody 
specific for the stimulating antigen. This increased 
antibody response enhances opsonisation and 
neutralisation of the invading bacteria.
Other host defences include the action of fibrin 
formation and activation of the clotting system which is 
stimulated following tissue injury by the bacteria. This 
limits the spread of bacteria to other locations in the 
body. Stimulated PMNs release lactoferrin which chelates 
free iron. Iron is essential for microbial growth and 
hence its proliferation is limited by the action of 
lactoferrin.
1.13 Bacterial mechanisms of evading the host immune 
system
1.13.1 Complement
Bacteria employ several different mechanisms to avoid 
destruction by the complement system and these may be 
mediated at various stages of the cascade. These 
mechanisms include failure to activate complement, 
blockage of activation prior to C5b-9 formation,
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formation of a non lytic C5b-9 complex, microbial 
shedding of molecules that activate or destroy 
complement, synthesis or acquistion of regulatory
molecules, and the microbial use of complement and
complement receptors to gain access to obligatory
intracellular locations (Joiner, 1988).
1.13.2 Phagocytes
There are several ways that bacteria can avoid being 
killed by phagocytes (Roitt et al., 1991). Firstly
bacteria can prevent phagocytes from arriving on the 
scene. This can be achieved by releasing molecules which 
are toxic or can block chemotaxis and inflammatory 
responses. Other bacteria possess surface coats which 
can resist phagocyte attachment. If bacteria are 
phagocytosed, other methods within the phagocyte include 
prevention of lysosome fusion and phagolysosome 
formation, and resistance of the cell wall to anti­
bacterial components of the phagocytes. Certain bacteria 
can also escape from the phagolysosome into the 
cytoplasm where they can no longer be attacked by 
lysosomes.
1.14 Aims
The overall aim of the work described in this thesis was
to study the role of humoral and cellular defences of
the pig against A. pleuropneumoniae.
The disease caused by A. pleuropneumoniae is generally 
confined to the respiratory tract. Two of the major non­
specific host defences available in the lung are the 
complement system and the phagocytic system. At the
onset of the work described here, there had been no 
information published on the complement system and A. 
pleuropneumoniae. The first aim was therefore to examine 
the interaction of A, pleuropneumoniae and pig
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complement. This involved the determination of the 
resistance or sensitivity of A . pleuropneumoniae to 
complement bactericidal activity. The ability of viable 
or killed bacteria and secreted bacterial products, to 
consume or activate complement activity via the 
classical and alternative pathways was then examined.
The second major host defence system available in the 
pig lung is the phagocytic system. The role of removing 
invading organisms from the lung constitutes a major 
immune defence mechanism of the host. The initial aim 
was to examine whether A. pleuropneumoniae was 
phagocytosed by porcine alveolar macrophages. There was 
information available describing the toxicity of A. 
pleuropneumoniae for phagocytic cells (Bendixen et al., 
1981; Udeze & Kadis, 1988; Rosendal et al., 1988; van 
Leengoed et al., 1989). However, there was other 
information stating that A. pleuropneumoniae could be 
phagocytosed (Inzana et al., 1988; Udeze & Kadis, 1988). 
It was therefore decided to examine phagocytosis of A. 
pleuropneumoniae both in the presence and absence of 
these toxic activities using mutants deficient in one or 
both of the toxic activities.
The final aim was to look at the relationship of the 
toxic activities associated with A. pleuropneumoniae by 
producing Mabs against them. The relationship between 
the toxins of A. pleuropneumoniae and related pathogens 
was also examined.
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CHAPTER 2 
GENERAL MATERIALS AND METHODS
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his chapter describes the materials used throughout the 
tudy. The majority of techniques and materials used 
ere related to individual studies and are described in 
he appropriate chapters or appendices.
.1 Bacterial strains
ctinobacillus pleuropneumoniae strain 6664 (serotype 3) 
as isolated from a typical lesion in a pig belonging to 
herd chronically infected with pleuropneumonia. A, 
leuropneumoniae strains HK 353, HK 358 (serotype 2) and 
166-1920-HAE (serotype 5) were obtained from Professor 
. Kilian, The Royal Dental Hospital, Denmark (Kilian et 
I., 1978). A, pleuropneumoniae strain HK 361 was
btained from the National Collection of Type Cultures 
Colindale, U.K.). HK 361 mutants, e and h, were 
roduced within this laboratory (Rycroft et al., 1991). 
utant e possesses cytotoxin activity only, associated 
ith a 120 kDa protein (pleurotoxin) , and mutant h is 
jeficient in both Hly II (haemolysin type II, 109 kDa 
protein) and pleurotoxin. No other phenotypic 
ifferences were found. Growth rates, colony morphology, 
uter membrane protein profiles and lipopolysaccharide 
,f both mutants were found to be identical to the parent 
train. Escherichia coli CIO was obtained from the
trebrospinal fluid of an infant with meningitis and was  ^ailable within the laboratory (Bjorksten et al., 1976). E . coli strains RY21, a Kl-negative mutant of 
10, and RY22, a 07-negative mutant of RY21 were also 
vailable within the laboratory (Rycroft et al,, 1983).
.2 Storage of bacterial strains
. pleuropneumoniae strains were stored both lyophilized 
nd at -70°C in 10% v/v sterile skimmed milk solution.
\
j. coli strains were maintained on Dorset Egg slopes at 
bom temperature.
I
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.3 Bacterial culture conditions
outine culture was made on heated blood agar (prepared 
ith 7%, (w/v), horse blood (Oxoid) and liquid cultures
ere grown in Tryptone Soya Broth (TSB; Oxoid) 
upplemented with 2piq/ml NAD (Sigma Chemical Co Ltd). 
. coli strain RY22 was stored on a Dorset Egg slope, 
outine culture was made on nutrient agar and liquid 
ultures were also grown in TSB. A. pleuropneumoniae was 
rown overnight on solid medium followed by overnight 
ulture with aeration (100 rpm) in TSB containing NAD. 
ubcultures were then made (1 in 25) into fresh TSB/NAD 
nd grown for a further 2 hours until logarithmic phase 
if the growth was reached. Optical densities of
lacterial cultures were determined by measuring the OD
I
t 650nm using a spectrophotometer (Beckman, DU 64). By 
revious assessment, an OD650 of 0.1 corresponded to 
0®/ml A. pleuropneumoniae organisms.
.4 Sera
j. 4.1 Pig
lood samples were collected from pigs by the aseptic 
jenipuncture of the cranial vena cava. The blood was 
.llowed to clot at 37°C for 30 minutes and then held for 
jO minutes on ice. Serum was separated following 
ntrifugation at 2000 x g at 4°C, stored at -70°C and 
rking volumes were held at 4°C. Pig sera were obtained 
om specific-pathogen-free (SPF) (normal pig serum). 
joth of these sera contained no detectable agglutinating 
jr precipitating antibody against A . pleuropneumoniae as 
jetermined by standard tube agglutination of whole 
peteria (Cruikshank, 1962), and by
mmunoelectrophoresis against soluble surface antigens 
Rycroft et al., 1983). Convalescent pig serum was
btained from a pig with a natural chronic infection
50
aused by serotype 3 strain, 6664 and had an 
gglutination titre of 1:16 against this strain.
.4.2 Rabbit
yperimmune rabbit sera were raised in New Zealand White 
:abbits by repeated intravenous inoculation using 
tandard methods (Harlow & Lane, 1988) with formalin- 
:illed cells of either 6664 or HK 361 which had been 
reated with 0.5% (v/v) formalin overnight, and washed
jhree times in phosphate-buffered saline. The 
|yperimmune rabbit serum raised against 6664, had a 
ftrong precipitation reaction and an agglutination titre 
f 1:256.
.4.3 Human
formal human serum was obtained from a pool of healthy 
olunteers. The sera contained no antibody against A . 
\leuropneumoniae as detected by the methods previously 
>sed.
|he rabbit and human sera were processed and stored as 
reviously described for pig serum. Heat-inactivated 
erum was treated at 56°C for 30 minutes.
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CHAPTER 3
IN VITRO SERUM RESISTANCE OF A. PLEUROPNEUMONIAE
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I
3.1 INTRODUCTION
| Gram-negative bacteria have been reported to be both
sensitive and resistant to the bactericidal and 
bacteriolytic properties of serum. The factor in serum 
responsible for this is the complement system as 
discussed in Chapter 1. Serum resistant strains are
| often associated with their ability to cause infection,
and insensitivity to serum has been suggested to be an 
important virulence mechanism of resistant bacteria 
(Taylor, 1983). A. pleuropneumoniae has the ability to 
cause disease rapidly (Nicolet, 1986). At the beginning1
of these experiments there was no published information 
available regarding the status of A . pleuropneumoniae in 
the complement-mediated bactericidal system. The aim of 
the work described in this chapter was to assess the 
sensitivity or resistance of 4 A. pleuropneumoniae 
strains to a variety of sera. Bactericidal activity can 
occur with and without the presence of antibody. The 
sera used ranged from that of the host animal, the pig,
i
I to those from other mammals including man. The effect of
specific antibody against A. pleuropneumoniae was alsoi
investigated for its ability to induce or enhance
j bactericidal activity.
The common method used to determine serum bactericidal 
activity is to expose the organism to serum that 
contains a suitable concentration of complement with or 
without antibody. The theoretical basis of this type of 
assay is straightforward, however there are a number of 
important parameters that must be maintained to ensure 
the correct evaluation of true serum sensitivity or 
resistance. The bacterial inoculum should be in early 
exponential growth phase. There have been reports of 
serum susceptible organisms being resistant or having 
reduced susceptibility to the bactericidal activity of 
complement if harvested before logarithmic growth phase 
(Davis & Wedgwood, 1965; DeMatteo et al., 1981). The
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method used to wash the bacterial cells may have the 
opposite effect of making the cells more sensitive to 
the bactericidal effects of serum. Cells should not be 
cooled to 0°C to avoid possible temperature shock, and 
should not be washed excessively (Wright & Levine, 1981; 
Fierer et al., 1974). A high percentage of serum is 
advisable to ensure availability of complement 
components to kill the bacteria. High serum 
concentrations are also helpful to limit the high pH 
value of certain serum-buffer mixtures which may be 
disadvantageous to complement killing (Taylor et al., 
1972). The buffer used has also been found to be 
important and should contain calcium and magnesium ions 
at concentrations optimum for complement activity. 
Another important point is the sampling time at which 
serum sensitivity or resistance is assessed. Certain E • 
coli strains show little difference after 1 hours' 
incubation, however after 3 hours, less than 1% of the 
inoculum remains (Taylor, 1974). It is therefore 
important to study serum resistance over a 3 hour 
period.
With these points to consider, initial serum resistance 
studies were carried out using 3 well-defined E • coli 
strains, which represented serum resistance, 
intermediate sensitivity to serum and full sensitivity 
to serum in order to optimise the assay.
The second section of the work described in this chapter 
involves attempts to sensitise those strains of A. 
pleuropneumoniae, found to be serum resistant, to the 
bactericidal effects of serum. Certain Gram-negative 
bacteria have been sensitised to the bactericidal 
effects of serum under environmental conditions which 
have a disruptive effect on their lipopolysaccharide 
layer (Reynolds & Pruul, 1971a; Reynolds & Pruul, 1971b; 
Fierer & Finley, 1979; Pruul & Reynolds, 1972). 
Polymyxin B, an antibiotic principally active against
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Gram-negative bacteria, potentiates sensitivity to serum 
by disrupting both the outer (Warren et al., 1957) and
inner (Teuber, 1969) membranes of Gram-negative 
bacterial cell envelopes.
Synergy between complement and polymyxin B has been 
documented in killing bacteria (Davis et al,, 1971; 
Traub & Sherris, 1970; Pruul & Reynolds, 1972; Fierer & 
Finley, 1979). The conformational changes induced by 
polymyxin B are thought to make the LPS more susceptible 
to attack perhaps by exposing the core phospholipid 
material which may be a target for complement action 
(Wilson & Spitznagel, 1971).
The mode of serum resistance of A, pleuropneumoniae is 
unknown. The serum resistance of A, pleuropneumoniae was 
compared therefore, with that of other gram-negative 
bacteria. Various serum resistant strains of E • coli 
have been sensitised to complement following treatment 
with polymyxin B (Dixon & Chopra, 1986; Fierer & Finley,
1979). This chapter describes the attempts to sensitise 
A . pleuropneumoniae to pig complement via polymyxin B 
treatment, and to compare it to the sensitisation of a 
serum resistant E. coli strain by the same methods.
3.2 MATERIALS AND METHODS
Details of buffers and solutions can be found in 
Appendix 1.
3.2.1 Serum bactericidal assay
The ability of bacteria to survive the bactericidal 
effects of serum was determined using a modification of 
the method of Taylor et al. (1972). Bacterial strains 
were grown overnight in TSB/NAD at 37°C with aeration 
(100 rpm) in an orbital incubator. Samples of overnight 
bacterial cultures were diluted 1:25 in fresh prewarmed
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TSB/NAD. The cultures were incubated in static culture 
at 37°C for 15 minutes, followed by a further 90 minutes 
with aeration (100 rpm), or until logarithmic growth 
phase had been reached. 1ml of bacterial culture was 
sedimented in a sterile Eppendorf tube at 11,600 x g for 
1 minute. Following centrifugation the supernatant was 
discarded and the bacterial pellet resuspended to 10ml 
in a sterile phosphate, gelatin buffer (buffer M, 
appendix 1) . 0. 5ml of this suspension was mixed with
1.5ml of freshly thawed serum which had been warmed to 
37°C, and contained 2^g NAD/ml. The suspension was mixed 
by vortexing and a 50pil sample immediately taken. The 
sample was diluted 10“  ^ and 10”  ^ in buffer M. lOOjul 
aliquots of these dilutions were mixed with Isosensitest 
agar (Oxoid) , which had been held at 46°C and 
supplemented with l\iq of NAD/ml, using the pour-plate 
method. The agar was allowed to set before incubation at 
37°C for 24-48 hours. Further samples were taken after 
1, 2, 3 and sometimes 4 hours' incubation. Bacterial
viability was determined by counting the number of 
colony forming units following incubation. The log 
percent viability was determined for each strain over 
the entire incubation period and compared to any 
controls that had been included in the experiment.
Samples were taken in duplicate and all A. 
pleuropneumoniae and E . coli strains were tested a 
minimum of 3 times in each of the experiments 1-6 
(sections 3.2.4-3.2.9)
3.2.2 Complement inactivation
Serum was held at 56°C for 30 minutes in order to 
inactivate complement activity.
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3.2.3 Serum absorption
Human serum was absorbed by mixing with approximately 2 
x 1010 fresh, live bacteria/ml (grown in TSB/NAD as 
previously described for serum bactericidal assays) for 
60 minutes at 0°C. Sera were centrifuged at 2,000 x g at 
4°C to pellet the bacteria and the supernatant filtered 
through a filter of 0.22pm pore size (Millipore). Sera 
were used immediately or stored frozen at -20°C. Control 
sera were similarly treated but not mixed with bacteria.
3.2.4 Experiment 1 - bacterial viability in normal pig 
serum
A. pleuropneumoniae strains HK 353, HK 358, 6664 and
266-1920-HAE were assessed for resistance or sensitivity 
to the bactericidal activity of normal pig serum by the 
serum bactericidal method described in section 3.2.1. 
Strains were simultaneously incubated in heat- 
inactivated serum possessing no complement activity.
In order to confirm the presence of normal bactericidal 
activity in the pig serum, the serum was tested for 
bactericidal activity using a known serum sensitive E . 
coli strain, RY22 (Rycroft et al., 1983). This strain
has been characterised as being sensitive to human 
serum. To ensure that the strain would behave similarly 
in pig serum, it was assessed along with parent strains, 
E. coli RY21 and CIO, which are partly serum sensitive 
and serum resistant respectively.
3.2.5 Experiment 2 - bacterial viability in immune pig 
serum
The 4 A, pleuropneumoniae strains HK 353, HK 358, 6664 
and 266-1920-HAE were assessed for viability in serum 
which was obtained from a pig with natural chronic 
pleuropneumonia attributable to serotype 3 strain, 6664,
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using serum bactericidal assays. This serum contained 
specific antibodies to that strain and the methods used 
to determine this are discussed in the general materials 
and methods in Chapter 2. E . coli strain RY22 was also 
assessed for viability in this serum.
3.2.6 Experiment 3 - bacterial viability in rabbit and 
human serum
All A, pleuropneumoniae strains were tested for survival 
in normal rabbit serum, hyperimmune rabbit serum raised 
against serotype 3 strain, 6664, and normal human serum 
using the serum bactericidal assay. Both normal rabbit 
serum and normal human serum contained no detectable 
antibodies against A . pleuropneumoniae as described in 
Chapter 2. Hyperimmune rabbit serum contained antibodies 
against A, pleuropneumoniae.
3.2.7 Experiment 4 - bacterial viability in normal human 
serum absorbed with A. pleuropneumoniae
The 3 strains of A . pleuropneumoniae HK 353, HK 358 and 
6664 were incubated in 75% of human serum that had 
previously been absorbed with the corresponding strain 
using the method described in section 3.2.3, and 
assessed by the serum bactericidal assay as described 
previously in 3.2.1. Controls included incubation of A . 
pleuropneumoniae strains with filtered human serum to 
ensure that any loss of bactericidal activity seen in 
the absorbed serum was not due to the process of 
filtration.
Serum sensitive E. coli RY22 was also incubated in 
absorbed human serum to assess for loss of bactericidal 
activity by the absorption method.
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3.2.8 Experiment 5 - bacterial viability in normal pig 
serum containing additional heated human serum as a 
source of antibody
To assess whether the absorbable component in human 
serum was antibody, it was proposed to add a volume of 
heated human serum, which would contain any antibody 
present, to normal pig serum. This was done in an 
attempt to both identify the component in human serum 
responsible for A. pleuropneumoniae sensitivity to this 
serum, and to sensitise A . pleuropneumoniae to pig 
serum. 10% of heated human serum was added to 65% normal 
pig serum and the serum bactericidal assay carried out 
as described in 3.2.1.
3.2.9 Experiment 6 - bacterial viability in absorbed 
human serum following preincubation with heat- 
inactivated human serum
The absorbable component in human serum may not be 
compatible with the pig complement system. To assess 
whether the lack of sensitisation of A. pleuropneumoniae 
to pig serum containing heated human serum, as a 
possible source of antibody, was due to incompatibility, 
it was tested using human serum. Heated human serum was 
added to absorbed human serum in an attempt to 
reintroduce the factor responsible for bactericidal 
activity back into the absorbed human serum.
A modification of the serum bactericidal method 
previously described in 3.2.1 was used. Bacteria were 
grown and treated as described for the serum 
bactericidal assay (3.2.1). 0.5ml of bacteria in buffer 
M was incubated with 1.5ml of heat-inactivated human 
serum and incubated at 37°C for 30 minutes. The bacteria 
were pelleted by centrifugation, washed once with buffer 
M, and resuspended in 1.5ml of the absorbed human serum 
and tested in the serum bactericidal assay (3.2.1).
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Controls included strains being incubated with heated 
human serum prior to incubation with normal pig serum. 
Any difference between the 2 different conditions above 
would suggest that human antibody is not compatible with 
the pig complement system. Other controls included a. 
treatment with absorbed human serum followed by 
incubation again with absorbed human serum, and b. 
incubation with normal pig serum prior to assessment of 
growth in normal pig serum. These were used to determine 
any differences which the prior incubation with absorbed 
human serum might impose on the subsequent incubation in 
the known systems of absorbed human serum and normal pig 
serum. A final control of incubation with human serum 
followed by growth assessment in human serum was used to 
portray the expected sensitivity of A. pleuropneumoniae 
strains incubated in this serum.
3.2.10 Polymyxin B treatment of bacterial strains
In an attempt to localise the area or components of A. 
pleuropneumoniae that are responsible for the observed 
resistance to pig serum, A . pleuropneumoniae was treated 
with sub-lethal concentrations of a membrane 
disorganising component, polymyxin B. Providing this is 
the site responsible for the observed serum resistance, 
the membrane will become permeable to complement 
components allowing the complement cascade to be 
completed and result in the death of the organism. 
Bacteria were incubated in both normal and heat- 
inactivated pig serum following treatment with polymyxin
B. A reduction of growth rate in normal pig serum could 
then be said to be due to the action of polymyxin B on 
the membrane allowing entry of the complement components 
and thus identifying the site responsible for serum 
resistance in A. pleuropneumoniae.
Initial experiments were aimed at sensitising the serum 
resistant organism, E . coli CIO, to pig complement
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following exposure to polymyxin B. Although certain E. 
coli strains have successfully been sensitised to serum 
by polymyxin B treatment, other strains have not (Vaara 
et al,, 1984). The E, coli strain being tested here had 
not been tested for polymyxin B sensitisation in pig 
serum and the first aim was therefore to establish a 
suitable control.
Bacteria were grown as described for serum bactericidal 
assays (3.2.1). 1.0ml of bacterial samples were
centrifuged for 1 minute at 11,600 x g (3 spins of 15 
seconds each with rotation through 180° for each spin) 
and the resultant pellet resuspended in 1ml of buffer M. 
0.1ml aliquots were mixed with 0.9ml of polymyxin B 
(Sigma Ltd.) solution at 0°C to give final 
concentrations of 1.25, 2.5, 5, 10, 20, 40, 80, 160 and 
320pg of polymyxin B/ml. Bacteria were immediately 
pelleted by centrifugation, the supernatant discarded 
and the pellets resuspended in 1.0ml of buffer M. 50pl 
of the suspensions were mixed with 2 00pl of prewarmed 
normal or heated pig serum. Bottles containing the serum 
and bacteria were incubated for 30 minutes at 37°C in a 
water bath. Samples were taken at time 0 and 30 minutes 
and viable counts determined as previously described for 
the bactericidal assays (3.2.1). Bacterial counts 
obtained from incubation with normal pig serum were 
compared to those obtained during incubation with heated 
pig serum and expressed as a percentage of the latter.
Duplicate samples were taken at each concentration and 
experiments were repeated a minimum of 3 times for each 
strain.
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3.3 RESULTS
3.3.1 Experiment 1 - viability of A . pleuropneumoniae 
isolates in normal pig serum
All 4 A. pleuropneumoniae strains appeared to be 
resistant to the bactericidal effects of normal pig 
serum. Viable bacterial numbers were shown to increase 
over time during incubation with normal pig serum (Figs. 
3.1-3.4). Consistently higher viability was observed for 
A, pleuropneumoniae strains HK 353, HK 358 and 6664 in 
normal pig serum compared to the control of heat- 
inactivated pig serum (Figs. 3.1-3.3). Strain 266-1920- 
HAE demonstrated greater growth in heat-inactivated pig 
serum than in the normal pig serum after 2 hours 
incubation (Fig. 3.4).
The 3 E, coli strains incubated in pig serum were found 
to behave in an identical fashion to their described 
behaviour when incubated with human serum. Serum 
sensitive E. coli strains, RY21 and RY22, were also 
found to be sensitive to pig serum. The viable bacterial 
numbers of RY22 were reduced to less than 0.1% of the 
original inoculum after the first hours' incubation 
(Fig. 3.5). Serum resistant strain CIO, was found to be 
fully resistant to normal pig serum. The death of the 
serum sensitive RY22 strain also confirmed that the 
normal pig serum possessed adequate bactericidal 
activity.
3.3.2 Experiment 2 - viability of A. pleuropneumoniae 
isolates in immune specific pig serum
All 4 A. pleuropneumoniae strains were found to be 
resistant to immune pig serum that contained specific 
antibodies against A. pleuropneumoniae strain 6664. The 
4 strains all increased in bacterial numbers over the 3 
hours incubation to a similar extent, and the results
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Fig. 3.1 Viability of A. pleuropneumoniae
HK 353 in normal pig serum
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Fig. 3.2 Viability of A. pleuropneumoniae 
HK 358 in normal pig serum
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Fig. 3.3 Viability of A. pleuropneumoniae
6664 in normal pig serum
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Fig. 3.4 Viability of A. pleuropneumoniae 
266-HAE-1920 in normal pig serum
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Fig. 3.5 Viability of £  coli strains
in normal pig serum
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Fig. 3.6 Viability of A. pleuropneumoniae 
strains in immune pig serum
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Fig. 3.7 Viability of A. pleuropneumoniae
strains in rabbit and human serum
L
0
G
%
V
I
A
B
L
T
Y
50 2 3 41
TIME (HOURS)
NRS - 5 -  IRS NHS
Fig. 3.8 Viability of A. pleuropneumoniae 
266-HAE-1920 in normal human serum
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fourth strain, 266-1920-HAE, survived in normal human 
serum and increased in bacterial numbers throughout the 
4 hour incubation. This strain also showed greater 
growth rates in heat-inactivated human serum than in 
normal human serum (Fig. 3.8). As previously discussed, 
all sera were tested for bactericidal activity using the 
serum sensitive E . coli strain RY22, and all 
demonstrated sufficient bactericidal activity against 
this strain.
3.3.4 Experiment 4 - the role of an absorbable
component(s) in the sensitivity of A. pleuropneumoniae 
to human serum
Since 3 of the 4 A, pleuropneumoniae strains were found 
to be sensitive to the bactericidal effects of normal 
human serum, it was decided to absorb the human serum 
with each A. pleuropneumoniae strain in an attempt to 
remove any non-specific antibody that may be responsible 
for this sensitivity seen in human serum.
All 3 strains tested were found to be resistant to the 
absorbed human serum (Fig. 3.9) compared to normal human 
serum. This suggested that the absorbed human serum had 
lost its bactericidal activity. Serum sensitive E • coli 
strain RY22 displayed the same sensitivity to the 
absorbed human serum as to the normal human serum, 
indicating complement activity had not been lost during 
absorption and filtration (Fig. 3.9). To assess whether 
this loss of bactericidal activity against A. 
pleuropneumoniae was due to absorption alone, or as a 
result of the filtration process, control serum was 
similarly held at 0°C, filtered and tested using the A. 
pleuropneumoniae strains. The strains showed the same 
sensitivity in filtered human serum as in normal human 
serum (Fig. 3.9). Fig. 3.9 is representative of strains 
HK 353, HK 361 and 6664.
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Fig. 3.9 Viability of A. pleuropneumoniae
£  coli strains in absorbed human serum
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Fig. 3.10 Viability of A. pleuropneumoniae 
strains in pig serum supplemented 
with absorbed human serum
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3.3.5 Experiment 5 - the role of heated human serum 
added as a source of non-specific antibody to normal pig 
serum
To assess whether the absorbable component in human 
serum was antibody, 10% heated human serum was added to 
65% normal pig serum prior to the addition of the A.
pleuropneumoniae strains being tested for viability by 
the previously described serum bactericidal assays. If 
the absorbable component in the human serum was 
antibody, then it should be able to be reintroduced into 
the serum in the form of heated human serum. The heated 
serum would still contain any antibody that may be 
present, however no complement activity would remain. 
1 0% of heated human serum was considered to be an
adequate amount, as antibody is only required in 
extremely small amount to induce antibody-mediated 
killing by the complement pathways.
All 3 A . pleuropneumoniae strains were found to be 
resistant to pig serum containing 10% heated human 
serum. There was no difference in the bacterial growth 
rates seen in pig serum containing heated human serum
and normal pig serum alone (Fig. 3.10). The presence of
the heat-inactivated human serum also did not retard the 
growth rates of the A. pleuropneumoniae strains, which 
were equivocal to the pig serum alone (Fig. 3.10). Fig. 
3.10 is representative of A. pleuropneumoniae strains HK 
353, HK 361 and 6664.
3.3.6 Experiment 6 - bacterial viability in absorbed 
human serum following pretreatment with heat-inactivated 
human serum
The aim of this experiment was to reintroduce the 
component depleted in absorbed human serum by 
preincubation of bacteria with heated human serum prior 
to incubation in absorbed human serum.
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All strains were resistant to all combinations of sera 
except the pretreatment with normal human serum followed 
by incubation in normal human serum (Fig. 3.11). 
Pretreatment with the heated human serum did not 
sensitise the A. pleuropneumoniae strains when incubated 
with the absorbed human serum, suggesting heat- 
inactivated human serum did not restore bactericidal 
activity to the absorbed human serum.
3.3.7 Experiment 7 - bacterial sensitisation to normal 
pig serum following polymyxin B treatment
Attempts to sensitise A . pleuropneumoniae isolates to 
pig serum following treatment with polymyxin B were not 
successful. None of the 4 A. pleuropneumoniae strains 
were sensitised to the bactericidal effects of normal 
pig serum following treatment with sub-lethal 
concentrations of polymyxin B. A» pleuropneumoniae 
strains HK 353, HK 358 and 6664 were found to have 
higher viable bacterial counts in normal pig serum than 
in heat-inactivated pig serum over a range of polymyxin 
B concentrations (Figs. 3.12-3.14). A, pleuropneumoniae 
strain 266 showed increased viability in both normal pig 
serum and heat-inactivated pig serum over a range of 
polymyxin B concentrations (Fig. 3.15).
In contrast serum resistant E . coli strain CIO was 
sensitised to normal pig serum following treatment with 
a range of polymyxin B concentrations. A reduction in 
viability in normal pig serum was observed compared to 
that seen in heat-inactivated pig serum (Fig. 3.16). A 
summary of the results obtained from A. pleuropneumoniae 
and E. coli is shown in Fig. 3.17.
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Fig. 3.11 Viability of A. pleuropneumoniae 
in absorbed human serum following 
pretreatment with heated human serum
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Fig. 3.13 Sensitivity of A. pleuropneumoniae 
HK 358 to pig serum following 
treatment with polymyxin B
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Fig. 3.14 Sensitivity of A. pleuropneumoniae 
6664 to pig serum following treatment 
with polymyxin B
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Fig. 3.15 Sensitivity of A. pleuropneumoniae 
266-HAE-1920 to pig serum following 
treatment with polymyxin B
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Fig. 3.16 S ensitiv ity  of £  coli C10 to pig
serum following treatm ent with polymyxin B
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Fig. 3.17 Sensitivity summary of A. pleuropneumoniae 
and E. coli strains to pig serum following 
treatment with polymyxin B
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3.4 DISCUSSION
3.4.1 Serum bactericidal assays
The aim of the work described in this chapter was to 
determine whether the non-specific humoral defence 
mechanism, complement, could mediate a bactericidal 
action against A. pleuropneumoniae. All strains of A. 
pleuropneumoniae were found to be resistant to pig serum 
even in the presence of specific antibody against one of 
the strains (Figs. 3.1-3.4 & 3.6). This suggests that
the pig complement system is not bactericidal against A. 
pleuropneumoniae. Resistance to both complement and 
specific antibody has been documented in other Gram- 
negative bacteria including Salmonella minnesota• This 
organism was not killed in any concentration of human 
serum containing high titres of agglutinating antibody 
(Joiner et al., 1982a; Joiner et aim, 1982b). Since the 
onset of this work, serum resistance using a serotype 5 
strain of A. pleuropneumoniae has also been documented 
(Inzana at al., 1988). Similarly it was also found to be 
resistant to pig bactericidal activity in the presence 
of specific antibody against that strain.
The lack of bactericidal activity in the pig serum
against A. pleuropneumoniae appears not to be due to an 
inadequate killing system as demonstrated by the rapid 
death of the E . coli sensitive strain in pig sera (Fig. 
3.5). The increased growth observed with A. 
pleuropneumoniae strains incubated in normal pig serum 
compared to the heat-inactivated pig serum, devoid of 
complement activity, has also been described for other 
bacteria (Fig. 3.1-3.3). Certain strains of E . coli have 
been reported to increase in numbers in the presence of 
complement and antibody (Taylor, 1978; Hughes et al.
1982) perhaps suggesting the loss of certain heat-labile 
component(s) which enhance bacterial growth. This trend
was observed for A. pleuropneumoniae strains HK 353, HK
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358 and 6664 throughout the incubation. It was also 
observed in strain 266-1920-HAE during the first 2 hours 
incubation after which slightly greater growth was seen 
in the heated pig serum (Fig. 3.4).
The difference in the degree of resistance to both the 
immune pig serum and hyperimmune rabbit serum and that 
of normal pig and rabbit serum, can probably be
attributed to the presence of specific antibody against 
A . pleuropneumoniae. Both immune pig serum and the 
hyperimmune rabbit sera contained detectable antibodies 
against A, pleuropneumoniae and showed similar reduced 
growth trends compared to the higher growth observed for 
all the strains in normal pig and rabbit serum, which 
contained no detectable antibodies against A .
pleuropneumoniae (Figs. 3.6 & 3.7). The lower increase 
in growth in the immune pig and rabbit serum may have 
been due to the effect of agglutinating antibody, which 
can sometimes lead to the underestimation of survival 
rates (Melching & Vas, 1970).
3 of the 4 A. pleuropneumoniae strains were found to be 
sensitive to the bactericidal action of human serum, but 
only after a delay of 2 hours (Fig. 3.7). Delayed 
killing has also been seen for Serratia marcescens which 
was the result of selective activation of the 
alternative pathway (Traub & Kleber, 1976). Killing by
activation of the alternative pathway has been shown to
proceed at a lower rate than that by classical pathway
activation (Root et al., 1972). The different results
obtained for strain 266-1920-HAE and the other A. 
pleuropneumoniae strains in their sensitivity to human 
serum was perhaps due to strain 266-1920-HAE having a 
much slower growth rate than the other strains (personal 
observations) (Fig. 3.8). Bacterial metabolism has been 
shown to influence serum sensitivity (Griffiths, 1974; 
Taylor & Kroll, 1983). These researchers demonstrated 
that normally serum sensitive bacteria can become serum
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resistant when assessed in non-logarithmic growth phase, 
Taylor and Kroll (1983) found that optimal killing of 
gram-negative bacteria required bacterial adenosine 
triphosphate (ATP) and that killing was inhibited by 
substances such as choramphenicol which inhibit 
bacterial growth. These results suggested that bacterial 
growth is required for optimal killing by complement 
perhaps by exposing sites for the C5b-9 attack complex 
which may not be present on stationary-phase organisms 
(Joiner et al., 1984).
The absorption by A. pleuropneumoniae of the factor(s) 
responsible for the delayed sensitivity to human serum 
suggested that antibody or certain complement components 
necessary to mediate bactericidal activity against A. 
pleuropneumoniae, were being removed by this process 
(Fig. 3.9). Serum having undergone the filtration 
process, without being absorbed with bacteria, retained 
full bactericidal activity against A. pleuropneumoniae 
strains. This suggested loss of killing activity was 
attributable to the absorption of component(s) 
responsible for bactericidal activity rather than by the 
process of filtration. The absorbed serum was found 
however to have retained its level of bactericidal 
activity for the E. coli serum sensitive strain (Fig. 
3.9), suggesting that the component (s) was not 
complement. The addition of 10% heat-inactivated human 
serum, as a source of antibody, to normal pig serum had 
no effect on the growth rate (Fig. 3.10). This may also 
suggest that the absorbable component was not antibody, 
or alternatively that the human component(s) responsible 
for A. pleuropneumoniae serum sensitivity was not 
compatible with the pig complement system. This 
phenomenon of incompatibility has been seen previously 
with serum proteins of one species and antibodies of 
another (Rowley, 1973).
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i Bacterial preincubation with heat-inactivated human
I
serum, followed by incubation in absorbed human serum, 
also did not sensitise A . pleuropneumoniae (Fig. 3.11), 
which suggests that the factor responsible for the 
killing effect of human serum on A . pleuropneumoniae was 
not present in heat-inactivated human serum. This would 
also suggest that the component(s) was not antibody as 
this would still be expected to be present in heated 
serum. The component(s) responsible for the delayed 
sensitivity of A, pleuropneumoniae therefore appears to 
be neither antibody nor complement, and is both 
absorbable and heat-labile. There have been other 
reports of non-antibody, non-complement factors required 
for complement killing (Goldman & Austen, 1974; Clas & 
Loos, 1982). The 21 kDa factor described by Clas & Loos 
(1982) was also heat-labile and was inactivated by J3- 
glucosidase, pronase, proteinase K. It could not be 
replaced by either IgG or IgM directed against the 
organism, Salmonella minnesota Re 595. The extra factor 
was thought to be required for either C4 or C2 binding. 
Kawakami et al. (1982) also reported a factor that was 
both heat and 2-mercaptoethanol sensitive, with a 
molecular weight of 28 kDa that reacted specifically 
with only some chemotype strains of Salmonella. The 
apparent lack of shared biochemical or functional 
activity between these factors has been suggested that 
these non-antibody, non-complement factors that enhance 
or are required for complement-mediated killing 
demonstrate organism specificity (Joiner et al., 1984). 
The different sensitivities observed between both the 
human and the pig and rabbit serum may suggest that 
human serum contains an additional factor(s) lacking in
i
| both pig and rabbit serum or alternatively that A.
| pleuropneumoniae has adapted to be resistant to the 
i  ,
equivalent factor in pig serum.
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3.4.2 Polymyxin B sensitisation
Following the observation that the A, pleuropneumoniae 
strains tested were resistant to the bactericidal 
activity of pig complement, it was decided to compare 
the mode of serum resistance with other Gram-negative 
serum resistant bacteria. The organism used for 
comparison was a serum resistant E. coli strain. The 
mode of serum resistance in certain E . coli strains has 
been attributed to the outer membrane. This has been 
found following studies using conditions that disrupt 
the outer membrane, followed by the testing of that 
strain for sensitivity to complement (Fierer & Finley, 
1979; Vaara & Vaara, 1983; Vaara et al., 1984; Vaara &
Viljanen, 1985; Viljanen et al., 1986). Methods used to 
disrupt the outer membrane have involved treatment with 
polymyxin B.
E. coli strain CIO was found to be a suitable control 
following its sensitisation to pig serum after treatment 
with sub-lethal concentrations of polymyxin B (Fig. 
3.16). This was in contrast to all 4 A. pleuropneumoniae 
strains which were not sensitised to the bactericidal 
effects of pig serum following similar exposure to 
polymyxin B (Figs. 3.12-3.15). A . pleuropneumoniae 
strain 266-1920-HAE was found to be less viable in 
normal pig serum following exposure to 20 and 40 ug/ml 
of polymyxin B (Fig. 3.15). However, following exposure 
to a concentration of 80 ug/ml, higher counts were 
observed in the normal pig serum suggesting that the
I bacteria were not sensitised to complement following
i
polymyxin treatment. Also strain 266-1920-HAE has been
|
; previously found to have a slower growth rate in normal
i
j  pig serum compared to heated pig serum (Fig. 3.4), m
! contrast to the other 3 strains of A. pleuropneumoniae
(Figs. 3.1-3.3). The lower growth rates seen initially 
following exposure to 20 and 40 pig/ml to polymyxin B may 
be due to this effect. The resistance of 266-1920-HAE to
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complement activity following treatment with 80 pq/ml of 
polymyxin B demonstrates that, like the other 3 A . 
pleuropneumoniae strains, it is resistant to 
sensitisation to pig complement by polymyxin B 
treatment.
Polymyxin B resistant gram-negative bacterial strains 
have also been reported including strains belonging to 
Proteus, Morganella, Providencia and Neisseria species 
(Koike et al., 1969; Teuber, 1969; Atkinson, 1980; Storm 
et al., 1977) and also many strains of Serratia 
marcescens (Traub, 1982). Resistance to polymyxin B has 
been shown to be attributed to the outer membrane in the 
case of Proteus mirabilis (Storm et al., 1977). The LPS 
of Proteus mirabilis is completely substituted by 4- 
aminoarabinose (Sidorczyk et al., 1983) resulting in the 
LPS being less acidic. This reduced acidity apparently 
reduces the degree to which polycations are bound by the 
LPS and this has been suggested to account for the 
polycation resistance seen with polymyxin B (Vaara & 
Viljanen, 1985). Salmonella typhimurium pmrA mutants 
were found to contain 4-6 times more 4-aminoarabinose in 
their lipid A making 60-70% of their LPS in a less 
acidic form (Vaara et al., 1981). These mutants were 
found to have a low level of resistance to polymyxin B 
compared to their sensitive parents and also bound 4 
times less polymyxin B (Vaara, 1981; Vaara et al., 
1979). The differences in the amount of 4-aminoarabinose 
in the LPS of P. mirabilis and S. typhimurium has been 
suggested to explain the differences in the level of 
resistance to polymyxin B (Vaara & Viljanen, 1985).
The mechanism of complement resistance following 
incubation with polymyxin B appears not to be due to 
resistance to polymyxin B mediated damage as 
demonstrated by the killing of A. pleuropneumoniae at 
higher concentrations of polymyxin B (personal 
observations). This is in agreement with Vaara et al.
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(1984) who reported an E. coli strain was resistant to 
treatment with polymyxin B nonapepetide (PMBN) and 
serum, but was nevertheless sensitive to the outer 
membrane permeability increasing action of PMBN, This 
was demonstrated by showing the strain's sensitivity to 
fusidic acid following treatment with PMBN.
Disruption of the outer membrane by polymyxin B has been 
shown not to be lethal in itself. It has been reported 
that polymyxin B nonapeptide, which lacks the terminal 
diaminobutyric acid residue and the attached fatty acid 
of the parent compound, induces similar changes to the 
outer membrane structure and permeability (Dixon & 
Chopra, 1986a; Vaara et al., 1984; Viljanen et al., 
1986; Vaara & Vaara, 1983). Polymyxin B nonapeptide has 
drastically reduced or no antibacterial activity (Dixon 
& Chopra, 1986a; Nikaido & Vaara, 1985; Vaara & Vaara,
1983) compared with its toxic parent, and therefore it 
has been suggested the outer membrane damage caused by 
polymyxin B is unlikely to be directly responsible for 
its bactericidal activity (Dixon & Chopra, 1986b). Since 
polymyxin B disrupts both the outer and inner membranes, 
it has been proposed that its lethality arises as a 
result of cytoplasmic membrane disruption (Dixon & 
Chopra, 1986b).
Polymyxin B is reported to cause outer membrane damage 
at similar concentrations to those having a lethal 
effect on the bacterial cytoplasmic membrane (Viljanen 
et al., 1986). It is possible that the sub-lethal 
concentrations used to sensitise A. pleuropneumoniae 
were not sufficient to cause outer membrane damage in 
this study. This however is doubtful as many serum 
resistant gram-negative bacteria are sensitised by sub- 
lethal concentrations of polymyxin B. It is more likely 
that the mechanism of serum resistance in A. 
pleuropneumoniae is not wholly dependent on the outer 
membrane acting as a barrier to complement components.
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The use of polymyxin B nonapeptide would have overcome 
the problems of toxicity whilst still retaining the 
ability to disorganise the outer membrane, however this 
compound was not commercially available at the time. 
Also, the results of the experiments indicated that 
sensitisation of the controls could be achieved using 
sub-lethal concentrations of polymyxin B and therefore 
it was found not to be necessary to prepare polymyxin B 
nonapeptide.
The method of synergy between polymyxin B (& PMBN) and 
serum has been suggested to be due to its disruptive 
action on the outer membrane ie. to expose the deep 
structures of the outer membrane to antibodies, or other 
components in serum, that lead to the activation of 
complement, and hence allow the membrane attack complex 
(MAC) access to the hydrophobic region. It would also 
allow MAC complexes that had formed at a distance from 
the hydrophobic region, to have access to it (Vaara et 
al., 1984).
The resistance of A. pleuropneumoniae to the 
bactericidal activity of normal pig serum, following 
exposure to sub-lethal concentrations of polymyxin B, 
suggests that perhaps the outer membrane is not 
important in the serum resistance of A. 
pleuropneumoniae• This may be due to the lack of 
complement activation, even in respect of the opening of 
the outer membrane. Alternatively, complement may be 
being activated but is blocked at a further stage in the 
cascade. For example in for some bacteria the MAC forms 
but incorrectly assembles preventing correct insertion 
into the membrane to cause sufficient loss of nutrients 
and eventual death. Lastly, perhaps the nature of the 
lipopolysaccharide of the strains being studied is such 
that it is resistant to polymyxin B sensitisation as in 
the case of P. mirabilis (Sidorczyk et al., 1983).
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CHAPTER 4
IN VITRO ACTIVATION AND CONSUMPTION OF COMPLEMENT BY A,
PLEUROPNEUMONIAE
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4.1 INTRODUCTION
As discussed in the previous chapter, the A. 
pleuropneumoniae strains tested were resistant to pig 
complement even in serum that contained antibodies 
against one of these strains. Resistance to complement- 
mediated bactericidal activity has been achieved by 
various bacteria that employ a range of mechanisms 
enabling them to evade the detrimental actions of 
complement (Joiner, 1988). One mechanism of evasion used 
by bacteria is to avoid activating the complement 
cascade pathways, thereby escaping bactericidal 
activity.
The aim of this chapter was to determine if the 
mechanism by which A. pleuropneumoniae avoided pig 
complement damage was by its inability to activate the 
complement cascade by either or both of the pathways.
Complement-mediated damage of bacteria can proceed via 
activation of either the classical (CCP) or the 
alternative (ACP) pathway, resulting in consumption of 
complement components. Consumption and activation of the 
complement pathways were assessed in both pig and human 
serum which had been previously incubated with A. 
pleuropneumoniae. Consumption of complement activity can 
be assessed using functional haemolytic assays. These 
functional haemolytic assays (CH50 and AP-CH50 assays) 
measure the functional activity of both the classical 
and the alternative pathways respectively including the 
terminal components (C3-C9). Utilisation of any 
complement components by activation of either pathway, 
or by other mechanisms discussed later, may, depending 
on the degree of usage, deplete that particular 
component (s) . This in turn can result in a gap in the 
complement pathway, preventing future completion of the 
cascade. Analysis of activated serum for remaining 
complement activity by functional haemolytic assays, may
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result in an inability or a reduced ability to lyse the 
blood cells due to a shortage of one or more of the 
components required for each step in the cascade. This 
lack of lysis can be expressed as complement consumption 
of a particular pathway.
The basis of the functional haemolytic complement test 
is to incubate a fixed quantity of red blood cells with 
varying amounts of complement and buffer for a fixed 
period of time. Once the reaction is stopped, the
percentage lysis of the red blood cells can be 
calculated. The percentage lysis and the equivalent 
volume of serum responsible are plotted to obtain a 
sigmoid dose-response curve. The central part of the 
curve, usually between 20 and 80% lysis, is steep and 
the percentage of cells lysed is sensitive to small 
changes in the amount of complement in the serum. For 
this reason the endpoint of the titration is taken as 
50% haemolysis ■ 1 CH50 (AP-CH50) unit. The sigmoid
curve can be mathematically described using the van
Krogh equation (Whaley, 1985).
X = K (Y/l-Y)1/n
X = amount of serum added to tube (jil)
K = a constant which is the 50% unit of complement
At 50 % haemolysis 1-Y = 1, hence X = K. The value of K
can be obtained by plotting log X against log Y/l-Y.
Complement consumption by bacteria in the serum is 
evaluated by the calculation of the number of CH50 
(classical pathway) (AP-CH50, alternative pathway) units 
and comparing it to the control serum which has not been 
incubated with bacteria. A reduction in the number of 
CH50 (AP-CH50) units in the serum previously incubated 
with bacteria, compared to the bacteria-free control
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serum, indicates that consumption of complement has 
occurred in the bacteria-treated serum.
Immunoelectrophoresis of test serum can be carried out 
to assess activation of a certain component by the 
identification of activation cleavage proteins. 
Immunoelectrophoresis measures the presence of the 
proteins in question whether they are functionally 
active or not. Using specific antiserum against these 
proteins, changes following incubation with bacteria, 
can be detected either by the presence of additional 
antigen/antibody precipitation arcs or by the distortion 
of the original arc. From the results obtained one can 
assess whether activation of a particular protein has 
occurred. It can then be concluded that the complement 
cascade has been activated or partly activated at this 
particular point.
The human complement system has been well characterised 
to allow evaluation of the individual components, 
enabling each to be assessed for reduction and the 
broken link can therefore be determined. The pig 
complement system however has not yet been as well 
characterised, and only one antiserum was commercially 
available against purified complement component C3. The 
extent of the information which could be evaluated in 
the pig serum was firstly, whether complement 
consumption occurred via either the classical or the 
alternative pathways using functional haemolytic assays 
and secondly, whether there was cleavage of C3 which can 
occur via both pathways and is indicative of C3 
activation. As a comparison, A . pleuropneumoniae treated 
human serum was also evaluated for complement 
consumption and activation of both C3 (via both 
pathways) and factor B (via ACP only) . All assays were 
also determined using three well characterised E • coli 
strains, CIO, RY21 and RY22, which have been described 
previously in Chapter 2.
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4.2 MATERIALS & METHODS
All buffer solutions used in both the functional 
haemolytic assays and immunoelectrophoresis are 
described in Appendix 1.
4.2.1 Functional haemolytic complement consumption 
assays
4.2.1.1 Serum
All serum used in the complement assays was stored at - 
70°C. Pig and human sera were obtained from healthy pigs 
and humans, and processed as previously described in 
Chapter 2. Neither serum was found to possess antibodies 
against A. pleuropneumoniae by the methods described in 
Chapter 2•
4.2.1.2 Red blood cells
Sheep red blood cells (SRBC) were obtained commercially 
(Becton Dickinson) and diluted in an equal volume of 
Alsever's solution prior to storage at 4°C. Rabbit red 
blood cells (RRBC) were obtained using the method of 
Whaley (1985). Rabbit blood was collected by bleeding 
from the marginal ear vein of New Zealand White rabbits. 
The blood was collected in an equal volume of Alsever's 
solution, centrifuged at 2,000 x g for 10 minutes at 
4°C, and the plasma and buffy coat removed by 
aspiration. The cells were washed three times in EDTA 
(lOmM) GVB= buffer and resuspended in the same volume. 
RRBC were then incubated at 37°C for 15 minutes in a 
water bath, and washed a further three times in Mg-EGTA 
buffer. The cells were resuspended in the same buffer 
and stored at 4°C for a maximum of 2 weeks.
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4.2.1.3 Serum absorption
Normal pig and human serum was absorbed three times by 
incubating 1ml of pig or human sera with 0.05ml packed 
volume of either washed SRBC or RRBC, for 15 minutes at 
0°C (Platt-Mills & Ishizaka; 1974). The blood cells were 
removed by centrifugation (11,600 x g for 5 seconds) and 
the absorbed sera were either used immediately or stored 
at -70°C.
4.2.1.4 Antibody sensitisation of SRBC (EA)
Sensitisation of SRBC was performed using a modified 
method based upon that of Whaley (1985) and Palmer & 
Whaley (1986). SRBC were removed from the stock 
suspension in Alsever's solution and centrifuged at 
2,000 x g for 10 minutes at 4°C. The supernatant plasma 
and the buffy coat were removed by aspiration and washed
_  q
twice in GVB buffer. The SRBC were adjusted to 1 x 10^ 
cells/ml using the following method. 1ml of SRBC 
suspension was added to 29ml of deionised water, and the 
optical density of the lysate measured using a 
spectrophotometer at a wavelength of 541nm. An OD 
reading of 0.385 corresponds to a concentration of 1 x 
10^ SRBC/ml (Whaley, 1985). The volume of SRBC was 
adjusted to 1 x 10^/ml using the equation,
Volume of SRBC required = Initial volume x (OD 
measured/0.385)
The SRBC were then warmed in a water bath at 37°C. 
Antibody to SRBC (Gibco) was diluted in an equal volume 
of GVB- buffer and prewarmed to 37°C. The antiserum was 
slowly added to the swirling SRBC suspension and the 
mixture agitated for 20 minutes in a 37°C water bath by 
hand. The resultant antibody sensitised SRBC (EA) were 
centrifuged at 2,000 x g for 5 minutes at 4°C. EA were 
washed twice in GVB= buffer, once in GVB^+ buffer and
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. . .  • 9 +resuspended in their original volume in GVB^ buffer. EA
were stored at 4°C for a maximum of 1 week.
4.2.1.5 SRBC antiserum titration
A modified version of the methods employed by Palmer & 
Whaley (1986) were used. EA were prepared as previously 
described using a range of antiserum dilutions prepared 
in GVB^+ buffer in a total volume of 300jil. EA were
incubated with 450^1 of GVB^+ buffer containing a final
concentration of 1:20 of either normal pig or human 
serum. The reaction mixture was incubated for 60 minutes 
at 37°C in a water bath and shaken once after 30 
minutes. 2ml of ice cold saline (0.87% NaCl) was added 
to all tubes to stop the reaction, followed by 
centrifugation at 1,000 x g for 5 minutes at 4°C. The 
optical densities (OD) of the resulting supernatants 
were read at 541nm, and the percentage lysis of the SRBC 
calculated. The optimal concentration of antiserum can 
be calculated by plotting a graph of the concentration 
of antiserum used against the corresponding percentage 
lysis. An acceptable curve should produce a plateau when 
the percentage lysis of the SRBC is not increased with 
increasing concentrations of antiserum to the SRBC 
(Palmer & Whaley, 1986). The optimal concentration of 
antiserum to use corresponds to the second point on the 
plateau.
4.2.1.6 Bacterial preparation for complement consumption 
assays
Bacterial strains were grown as previously described for 
the serum bactericidal assays in Chapter 3. Bacterial 
numbers were assessed by reading the OD of the bacterial 
suspension at 650nm. An OD reading of 1.0 corresponds 
approximately to 1 x 10^ CFU/ml of A. pleuropneumoniae 
(personal observations). The suspensions were adjusted 
to give an OD of 0.75 at 541nm which corresponds to 7.5
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x 10 CFU/ml of bacteria. The bacteria were washed once 
in either VBS^+ buffer for the classical pathway assays 
or Mg-EGTA buffer for use in the alternative pathways 
assays, and resuspended in the appropriate buffers.
4.2.1.7 CH50 determination
The generally accepted CH50 unit is the amount of 
complement that causes 50% iysis of antibody sensitised 
SRBC via the classical complement pathway. Sera diluted 
over a range of concentrations with GVB^+ buffer in a 
total volume of 225jj1 were incubated with 150pl of 
sensitised SRBC (EA) . The mixture was incubated at 37°C 
in a water bath for 60 minutes and shaken once after 30 
minutes. 1ml of ice-cold saline was added to all tubes 
and the suspensions were centrifuged at 1,000 x g for 5 
minutes at 4°C. The OD of the resulting supernatants was 
assessed at 541nm and the percentage lysis calculated by 
comparison with the 100% lysis control. The percentage 
lysis was plotted against the corresponding serum 
concentration. The amount of serum that caused 50% lysis 
could be calculated from this graph for both the 
controls and the test sera. The volume of serum that 
caused 50% lysis, together with the additional 
information in Table 4.1, were used to calculate the 
number of CH50 or AP-CH50 units in the each serum using 
the formulae described in Table 4.2.
4.2.1.8 Complement consumption by bacteria via the 
classical pathway
Complement consumption by A . pleuropneumoniae isolates 
HK 361, HK 353 and 6664 of both pig and human serum was 
assessed using functional haemolytic assays based upon 
the method of Wilson et. al., (1985). A volume of serum 
containing 30 CH50 units was mixed with 7.5 x 10® 
bacteria in GVB buffer to a final reaction volume of 
225pl, and the mixture held at 37°C for 30 minutes.
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Serum Dilution ■ 5 CH50(AP -CH50)
PIG HUMAN
CCP ACP
iii
CCP ACP
A. pleuropneumoniae 
strains
1/6
if
I 1/1.8
iiiit
1/6 1/5.2
E. coli strains neat
ii
I 1/1.8iII
1 /6 1/5.2
Reaction volume(jjl) 225 100
i
\I
225 100
Table. 4.1 -  Serum dilutions and reaction volumes 
used for the classical and alternative pathways 
titrations.
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Table. 4.2 - Formulae to calculate CH50 (AP-CH50) 
units and percentage complement consumption.
1. Ca l cu l a t i on  of the nu mb er  of C H 5 0  ( A P - 5 0 )  uni ts in 
both cont rol  s e r a  and sera  incubated wi th  ba ct er i a
|
a. Ca l cu la t ion  of f inal  di lut ion a 1 C H 5 0  unit.
res t  v o l u m e  or  s e r u m  i n i t i a l  f i na l  1 C H 5 0
| = 1 C H 5 0  u n i t  X d i l u t i o n  = d i l u t i o n  = u n i t / m l
Ii
r e a c t i o n  v o l um e
i
b. C a l cu la t ion  of C H 5 0  Uni ts in react ion volume
C H 5 0  u n i t s  in u n d i l u t e d  
s e r u m  in r e a c t i o n  v o l um e = d i l u t i o n  f a c t o r
I
c. C a l cu la t ion  of C H 5 0  units in 1 ml of
undi luted serum.
C H 5 0  u n i t s / m i  in D i l u t i o n  
u n a i l u t e a  s e r u m  = Fa c t o r
1 0 0 0
X -----------------------
r e a c t i o n  v o l ume
2. Ca l cu l a t io n  of p e r c e n t a g e  c om p l e m e n t  consumpt ion in 
s e r a  incubated wi th  bacter ia  c o m p a r e d  to a ba ct er ia  
f re e  cont rol
1 -  (Tes t  C H 5 0  u n i t s / m l ) X 1 0 0
( C o n t r o l  C H 5 0  u n i t s / m l )
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Following centrifugation at 11, 600 x g for 1 minute to 
remove the bacteria, the supernatant was diluted 1 in 6 
to give a final concentration of 5 CH50 units per 
original volume (Table 4.1). The residual complement 
activity of the samples was assessed by the 50% 
haemolytic titration for complement (CH50) described in 
section 4.2.1.7. The amount of complement activity 
remaining in the test sera was expressed as a percentage 
of the total remaining in the bacteria-free serum 
control using the following formula, [1-(CH50 test/CH50 
control)] x 100. Included in these experiments were 3 E. 
coli control strains, CIO, RY21 and RY22, which are 
described in Chapter 2.
4.2.1.9 AP-CH50 determination
The generally accepted AP-CH50 unit is the amount of 
complement that causes 50% lysis of RRBC via the 
alternative complement pathway. This was performed using 
a modification of the method of Whaley (1985). Serial 
dilutions of the sera to be tested were prepared in MG- 
EGTA (lOmM) buffer in a final volume of lOOpl. lOOjil of 
1 x 10° RRBC/ml were added to each tube and incubated in 
a 37°C water bath for 90 minutes, and the tubes shaken 
once after 45 minutes incubation. 1ml of ice cold saline 
was added to all tubes to terminate the reaction, 
followed by centrifugation at 1,000 x g for 5 minutes in 
the cold. The OD of the supernatants was assessed at 
414nm. The percentage lysis was calculated, and the 
number of AP-CH50 units determined as described for the 
assessment of CH50 units in section 4.2.1.7.
4.2.1.10 Complement consumption by bacteria via the 
alternative pathway
A modified method based on that of Whaley (1985) was 
used. Sera containing 5 AP-CH50 units were incubated 
with 7.5 x 10° organisms in Mg-EGTA in a total volume of
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350^1. Following incubation at 37°C for 30 minutes, 
bacteria were removed by centrifugation and samples 
assessed for residual complement activity by the 50% 
haemolytic titration for the alternative pathway (AP- 
CH50) as described in section 4.2.1.9. Consumption of 
complement via the alternative pathway was assessed in 
serum preincubated with each of the three A. 
pleuropneumoniae strains, HK 361, HK 353 and 6664 
together with E . coli control strains, CIO, RY21 and 
RY22.
4.2.1.11 Controls
All individual assays were carried out in duplicate. The 
results shown are the mean of 2 or more experiments. 
Positive and negative controls included:
1 . 1 0 0% lysis - red blood cells in distilled water
2 . red blood cells in buffer only
3. buffer and serum only
The positive control, 100% lysis, indicated the maximum 
OD reading obtained from lysis of all the available red 
blood cells. The negative control of red blood cells and 
buffer only, assessed the stability of the red blood 
cells following all the test procedures. Any lysis above 
the acceptable level for spontaneous lysis resulted in a 
fresh batch of red blood cells being tested. Once an
acceptable batch of red blood cells was found, the
percentage spontaneous lysis was determined and
subtracted from both the 1 0 0% lysis control and the test 
samples. The buffer and serum control assessed the total 
complement activity available following incubation in 
the absence of bacteria. This was the positve complement 
control. The buffer and serum control also assessed the 
OD reading that was attributable to serum colour. Any 
readings that were high, were again subtracted from the 
positive control and all the test samples prior to
percentage lysis being determined in the test samples.
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4.2.2 Immunoelectrophoresis
4.2.2.1 Antiserum
Goat anti-human C3b proactivator (factor B) and goat 
anti-human C3 (ICN Immunobiologicals) were used at 1:4 
and 1:8 dilutions respectively. Rabbit anti-pig C3 
(Cappel) was used at 1:25 dilution.
4.2.2.2 Zymosan preparation
This was prepared using the method of Whaley (1985). 
lOOmg zymosan A (Sigma Ltd.) was suspended in 10ml of 
VBS buffer and boiled for 30 minutes. The suspension was 
centrifuged at 11,600 x g for 1 minute to pellet the 
zymosan. The supernatant was discarded and the pellet 
washed a further twice in VBS buffer. The zymosan was 
resuspended in 10ml VBS buffer giving a solution of 
10mg/mlf and stored at 4°C.
4.2.2.3 Zymosan treated serum
lml of the zymosan suspension (lOmg) was washed twice in 
VBS buffer and the supernatants discarded. The pellet 
was resuspended in 10ml of serum and incubated at 37°C 
for 60 minutes. The mixture was centrifuged at llf600 x 
g for 1 minute. The serum was then removed and frozen at 
-70°C until used.
4.2.2.4 Slide preparation
Standard microscope slides were rinsed in reverse 
osmosis (ro) water followed by 95% alcohol before use. 
Slides were precoated with agar solution by adding a few 
drops of molten agar to the slide, and preparing a smear 
using a second microscope slide. Precoating prevents the 
agar strip being detached from the slide during the 
washing procedure. 2 .5ml of molten agar was pipetted
onto the slide and allowed to set at room temperature, 
followed by refrigeration for 30 minutes. A trough was 
prepared by removing an agar strip 65mm long by 2mm 
across. The agar was not removed until after 
immunoelectrophoresis was performed. 2 wells 4mm in 
diameter were prepared 4mm from either side of the 
trough and 25mm from the end of the slide. The agar 
plugs were removed by aspiration.
4.2.2.5 Determination of C3 activation
Serum preincubated with bacteria was assessed for 
activation of C3. Bacteria were grown as previously 
described for the serum bactericidal assays (3.2.1). 5 x
p ,
10° washed bacteria were suspended in lOOpl of VBS 
buffer and lOOpl of either pig or human serum. Following 
incubation for 30 minutes at 37°C, the bacteria were 
removed by centrifugation at 11,600 x g for 1 minute and 
the serum recovered. EDTA was added to the sera to give 
a final concentration of lOmM (23jil of 86mM EDTA) . The 
sera were either used immediately or stored at -70°C.
Sera, previously incubated with bacteria, were then 
assessed for the presence of complement activation 
components by immunoelectrophoresis. The serum was 
diluted 1 in 4 and 20pl of the diluted sera was then 
added to one of the two wells on each slide. The other 
well was filled with control sera that had been 
incubated for 30 minutes at 37°C without bacteria. The 
slides were placed in the tank and wet filter paper 
wicks attached to either end of the slides to make 
contact with the buffer. Serum samples were 
electrophoresed for 5 hours at lOV/cm until the free 
bromophenol blue marker had migrated to within 1cm of 
the anode wick. The marker consisted of a drop 0.5% 
bromophenol blue solution which was added to a control 
well containing serum.
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The agar strip was removed from the trough and filled 
with 150^1 of either rabbit anti-pig C3 or goat anti­
human C3. The agar slides were placed in a moist 
enviroment at room temperature for 24-48 hours to allow 
diffusion to occur. Slides were then washed overnight in 
saline solution to remove any non-precipitated protein 
from the gel. This was followed by washing the slides in 
roH20 (reverse osmosis water) for 2 hours to remove the 
salt solution. The slides were covered with 3mm Whatman 
filter paper and dried under a stream of warm air. The
filter paper was removed and the dried slides stained
with Coomassie Brilliant Blue R (Sigma) in
methanol :H2 0 : acetic acid (5:4:1) for 10 minutes and 
destained in the above solvent solution. The three E . 
coli isolates were also assessed for their ability to 
activate C3.
4.2.2.6 Determination of factor B activation
Serum preincubated with bacteria was assessed for
activation of factor B. Activation of factor B can occur 
only via the alternative pathway, unlike C3 which can 
occur via both the classical and the alternative 
pathways. Factor B activation could only be assessed in 
human serum because the porcine reagent for the 
determination of factor B was not available. Activation 
of factor B in human serum was initially found to 
proceed in the buffer and serum controls, suggesting 
that the procedure used was capable of activating factor 
B. Different incubation times of the serum and buffer 
controls were assessed for the activation of factor B 
during the incubation process. Small quantities of 
factor B were found to be activated during the 20 minute 
incubation with activation increasing after 30 minutes 
incubation (Appendix 2, Fig. 4.1a). No activation was 
seen in the 5 and 10 minute incubation samples. The 
incubation period for determination of factor B
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activation by the bacteria was therefore reduced from 30 
to 15 minutes.
Bacteria were grown as described for the serum 
bactericidal assays (3.2,1), 5 x 10® washed bacteria
were suspended in lOOjil of Mg-EGTA buffer and lOOjil of 
human serum. Following incubation for 15 minutes at 
37°C, the bacteria were removed by centrifugation at 
11,600 x g for 1 minute and the serum recovered. EDTA 
was added to the sera to give a final concentration of 
lOmM (23^1 of 86 mM EDTA). The sera were either used 
immediately or stored at -70°C. Each of the sera 
incubated with bacteria was then assessed for the 
presence of factor B activation components by 
immunoelectrophoresis as described in section 4.2.2.5. 
Development and staining of the slides was carried out 
with 150^1 of goat anti-human C3b proactivator (factor 
B) as described above. The three E • coli isolates were 
also assessed for the ability to activate human factor 
B.
4.2.2.7 Controls
The controls used were serum and buffer alone and this 
was processed in the same way to those sera incubated 
with bacteria. To assess whether spontaneous activation 
of complement occurred in the serum and buffer control, 
a second control was included in which EDTA was added 
prior to incubation and immunoelectrophoresis. EDTA 
chelates Ca++ and Mg++ ions which are necessary for 
activation of the classical and alternative pathways. 
This prevents any activation during the incubation and 
immunoelectrophoresis procedures. Any differences 
between these two first controls would suggest 
activation of complement was occurring in the absence of 
bacteria invalidating the test results. The third 
control was zymosan treated serum. Zymosan is an 
activator of the alternative complement pathway and
therefore provides a reference positive control for 
complement components C3 and factor B. Controls of serum 
and buffer alone were added to one of the wells in each 
slide containing the test serum. Any differences seen 
between the test and the control could therefore be said 
not to be due to different electrophoretic conditions. 
All experiments were carried out a minimum of 3 times 
and the mean of the results are shown.
4.3 RESULTS
4.3.1 Functional haemolytic assays
4.3.1.1 Consumption of complement via the classical 
pathway in pig serum incubated with A, pleuropneumoniae
All 3 A. pleuropneumoniae strains consumed high levels 
of the classical complement pathway. Figure 4.1 shows 
the percentage haemolysis of each serum incubated with 
A. pleuropneumoniae treated serum and also of the 
control serum (incubated without bacteria) over a range 
of serum volumes. The volume of serum required to 
produce 50% lysis (1 CH50 unit) of red blood cells,
depicted by the arrows, was calculated from the graph 
and the total number of CH50 units in each sera was
assessed as described in Table 4.2. These figures showed 
a difference in the number of CH50 units present between 
the controls, which were not incubated with bacteria, 
and each of the three test sera incubated with A • 
pleuropneumoniae strains (Table 4.3). The percentage 
consumption of all the sera was calculated as described 
in Table 4.2. HK 358 test serum consumed 82.2% of the 
available complement activity. The reduction in 
complement activity in test serum incubated with both HK
353 and 6664 was such that 50% haemolysis could not be
reached even using the maximum reaction volume of serum 
(Fig. 4.1, denoted # in Tables 4.3, 4.5-4.7). The part 
of 1 CH50 unit that corresponded to the maximum amount
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Fig. 4.1 Titration of classical
complement activity remaining in pig
serum incubated with A. pleuropneumoniae
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Table. 4.3 Number of CH50 units in pig serum 
incubated with A. pleuropneumoniae and E. coli
Buffer control
Volume of 
sera ( i^l)
- 1 CH50
Part of 1 CH50 
unit-maximum 
lysis in (#)
No. of
CH50
units/ml
18.8 ■ 316.0
A. pleuropneumoniae 
Strains
HK 353 #
!
0.268 I 7.1
!
HK 358 105.5
j
56.3
6664 # 0.180 4.8
Buffer control 10.9 91.7
E. coli Strains
C10 21.9 45.7
RY21
i
#  0 . 0 0 0 0.0
RY22 # 0 . 0 0 0 0.0
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of lysis obtained using the maximum reaction volume of 
serum for both the HK 353 and the 6664 treated serum was 
calculated and shown in Table 4.3. From this, the number 
of CH50 units in 1ml of undiluted serum could be 
assessed, and the percentage consumption calculated. The 
percentage consumption of the classical complement 
pathway for HK 353 and 6664 were found to be 97.8% and 
98.5% respectively (Table 4.4).
The 3 E, coli control strains consumed complement 
activity in the pig serum when compared to the control 
serum incubated without bacteria (Table 4.3). The volume 
of serum required to produce 50% lysis was assessed 
(Fig. 4.2) and the corresponding number of CH50 units 
calculated (Table 4.3). There was however, a difference 
in the levels of complement consumed between the 3 E. 
coli strains (Table 4.4). The E. coli parent strain CIO 
consumed complement activity but at a reduced rate 
compared to its two mutant strains, RY21 and RY22. E . 
coli CIO consumed 50.2% of the available complement 
activity via the classical pathway whilst both CIO 
mutants, RY21 and RY22, consumed 100% of the complement 
activity. The consumption of the parent strain E, coli 
CIO test serum was also in sharp contrast to the 
previously tested A . pleuropneumoniae test sera. 
Consumption for the CIO strain, which was calculated to 
be 50.2%, is between 30 and 48.3% less than that 
consumed by the three A. pleuropneumoniae strains, HK 
361, HK 353 and 6664.
4.3.1.2 Consumption of complement activity via the 
classical pathway in human serum incubated with A.
pleuropneumoniae
Again all 3 A. pleuropneumoniae strains consumed high 
levels of available complement activity in the normal 
human serum, compared to that present in the bacteria- 
free control serum as depicted by the volumes of serum
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Table. 4.4 Percentage of complement activity 
consumed by bacteria via classical and alternative 
pathways
COMPLEMENT PATHWAYS
Classical Alternative
A. pleuropneumoniae 
Strains Pig Human Pig Human
HK 353 97.8 72.7 98.0 96.7
HK 358 82.2 76.4 97.9 96.3
6664 98.5 97.0 100 98.2
E. coli Strains
i
i
i
C10 50.2 36.3 41.8 97.5
RY21 100 97.4 99.1 97.9
RY22 100 96.5 98.7 97.8
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Fig. 4.2 Titration of classical
complement activity remaining in pig
serum incubated with E. coli
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Fig. 4.3 Titration of classical
complement activity remaining in human
serum incubated with A. pleuropneumoniae
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required to produce 50% lysis (Fig. 4.3). The number of 
CH50 units were calculated as described before and are 
shown in Table 4.5. The percentage consumption was 
calculated to be 72.7%, 82.3% and 97.0% for HK 353,
HK358 and 6664 respectively (Table 4.4). HK 353 had 
reduced consumption in the human serum, 72.7%, compared 
to 97.8% in normal pig serum, a reduction of 25.8%. Both 
the other serotype two strains, HK 358, and 6664 had 
very similar consumption rates to those in pig serum.
Similarly all 3 E . coli control strains consumed a 
degree of complement activity. The amount of human 
complement activity consumed by the individual strains 
was comparable to the amount of pig complement as 
described in section 4.3.1.1. The volume of serum 
required to produce 50% lysis was determined (Fig. 4.4) 
and the corresponding number of CH50 units were 
calculated and shown in Table 4.5. The corresponding 
consumption of complement activity (Table 4.4) showed 
that parent strain CIO did consume complement activity 
but at a much reduced rate compared to both the E . coli 
mutant strains. RY21 and RY22 had extremely high 
consumpton rates of 97.4 and 96.5% respectively compared 
to only 36.3% consumption by CIO. The 36.3% consumption 
rate by E. coli CIO was between 36.4 and 60.7% less 
than the A. pleuropneumoniae test human serum. Both the 
E, coli mutant strains showed similar consumption rates 
to both the A. pleuropneumoniae treated pig and human 
serum.
4.3.1.3 Consumption of complement via the alternative 
pathway in pig serum incubated with A . pleuropneumoniae
All 3 A, pleuropneumoniae strains consumed almost all 
the available alternative complement activity. 50% lysis 
could not be calculated in any of the A. 
pleuropneumoniae test serum suggesting very little 
activity was available following incubation with the
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Table. 4.5 Number of CH50 units in human serum 
incubated with A. pleuropneumoniae and E. coli
Buffer control
Volume of 
sera (pi)
- 1 CH50
Part of 1 CH50 
unit-maximum 
lysis in (#)
No. of
CH50
units/ml
41.7 142.4
A. pleuropneumoniae 
Strains
ij
HK 353 163.2 36.4
HK 358 #
i
0.902 23.8
i
6664 # 0.158 4.4
Buffer control 61.8
•
96.1
E. coli Strains
C10 97.1 61.2
i
!
RY21 # 0.092 2.5
RY22 # 0.126 3.4
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Fig. 4.4 Titration of classical
complement activity remaining in human
serum incubated with E. coli
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Fig. 4.5 Titration of alternative
complement activity remaining in pig
serum incubated with A. pleuropneumoniae
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bacteria (Fig, 4.5). The number of AP-CH50 units was 
calculated for the control, and the part AP-CH50 unit 
for the test sera as described previously (Table 4.2) 
and are shown in Table 4.6. The percentage consumption 
values demonstrated that all the A, pleuropneumoniae 
strains showed almost complete consumption of the 
available complement activity in the treated pig serum 
compared to the control. HK 353, HK 358 and 6664 
consumed 98%, 97.9 and 100% respectively (Table 4.4).
The consumption rates were slightly higher in all the A, 
pleuropneumoniae strains than those tested in pig serum 
for classical pathway consumption.
Results similar to those previously demonstrated by the 
E. coli strains in classical complement consumption in 
both pig and human serum were obtained. All E . coli 
strains consumed complement activity. The volume of 
serum required by the control to produce 50% lysis was 
significantly less than all E . coli treated serum (Fig.
4.6). This was reflected in the number of CH50 units 
available in the control serum as compared to the E. 
coli treated serum (Table 4.6). The percentage 
consumption was 41.8%, 99.1% and 98.7% for CIO, RY21 and 
RY22 treated serum repsectively (Table 4.4). The parent 
strain CIO again showed the least complement consumption 
(41.8%), more than 50% less than the mutant strains RY21 
and RY22, which displayed almost complete consumption of 
the available complement activity. The consumption rates 
of the E. coli mutant strains RY21 and RY22 were similar 
to those observed in A. pleuropneumoniae treated pig 
serum.
4.3.1.4 Consumption of complement via the alternative 
pathway in human serum incubated with A.
pleuropneumoniae
High complement consumption rates where observed in the 
human serum incubated with the 3 A . pleuropneumoniae.
Ill
Table. 4.6 Number of AP-CH50 units in pig serum 
incubated both A. pleuropneumoniae and E. coli
Pig serum -  Alternative Pathway
Volume of 
sera (pi)
- 1 CH50
Part of 1 CH50  
unit»maximum 
lysis in (# )
No. of 
AP-CH50  
units/ml
Buffer control 23.9 75.3
A. pleuropneumoniae 
Strains
HK 353 # 0 .0 8 4 1.5
HK 358 # 0.090 1.6
6664 # 0.000 0.0
E. coli Strains
C10 41.1 43.8
RY21 # 0.040 0.7
RY22 # 0.054 1.0
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50% lysis could only be calculated for the control (Fig,
4.7). The AP-CH50 units were calculated as before (Table 
4.2) and are shown in Table 4.7. The consumption rates 
were 96.7% for HK 353, 96.3% for HK 358 and 98.2% for 
6664, demonstrating almost complete consumption of all 
the complement activity by all three A, pleuropneumoniae 
strains (Table 4.4).
All three F . coli strains consumed almost all the 
activity available. 50% lysis could only be calculated 
for the control serum and buffer (Fig. 4.8). There was a 
large difference in the number of available AP-CH50 
units between the control and the F. coli treated sera 
(Table 4.7). The F. coli parent strain, CIO consumed 
97.5% and the mutants, RY21 and RY22 consumed 97.9% and 
97.8% of the available activity (Table 4.4). Both the 
mutant strains RY21 and RY22 showed similar consumption 
rates in the alternative pathway with those observed in 
pig serum and also with the A. pleuropneumoniae strains 
in both pig and human serum. Parent strain CIO also 
displayed similar consumption rates with both the mutant 
strains in the pig and human serum and with the A. 
pleuropueumoniae strains in both the sera. The high 
percentage of alternative pathway complement activity 
consumed by F. coli CIO in human serum was different 
from that previously seen. Both alternative pathway 
consumption in the pig serum and classical pathway 
consumption in both pig and human serum showed lower 
consumption levels of 41.8%, 50.2% and 36.3%
respectively.
4.3.2 Immunoelectrophoresis
4.3.2.1 C3 activation in pig serum incubated with A •
pleuropneumoniae
Activation of pig complement component C3 was 
demonstrated by the elongation of the original C3 arc.
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Fig. 4.7 Titration of alternative
complement activity remaining in human
serum incubated with A. pleuropneumoniae
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Table. 4.7 Number of AP-CH50 units in human serum 
incubated with A. pleuropneumoniae and E. coli
Human serum - Alternative pathway
Volume of 
sera (ul)
» 1CH50
Part of 1CH50 
unit-maximum 
lysis in (# )
No. of
AP-CH50
units/ml
Buffer control 25.5 202.0
A. pleuropneumoniae 
Strains
HK 353 # 0.128 6.7
HK 358 0.142 7.4
6664 # 0.070 3.6
E. coli Strains
C10 # 0.096 5.0
RY21 0.082 4.3
RY22 # 0.084 4.4
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Fig. 4.8 Titration of alternative
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This elongation of the arc towards the anode ( + ) 
indicated that a part of the C3 molecule had been 
activated, and hence broken down into smaller proteins, 
which migrate faster towards the anode. This thereby 
gives an elongated appearance to the arc. The 
visualisation of individual arcs produced by the 
different breakdown components was not possible due to 
the lack of specificity of the commercial anti-pig C3 
serum.
All test sera previously incubated with the three A . 
pleuropneumoniae strains showed an elongation of the C3 
arc towards the anode (Fig. 4.9, slides 1-3). This was 
similar to that observed in the positive control (Fig.
4.9, slide 4) . Elongation was not seen in the negative 
controls of serum and buffer alone incubated in the 
absence of bacteria shown on the bottom of each slide 
(slides 1-5). These negative controls of serum and 
buffer alone also demonstrated that no spontaneous 
activation of complement C3 had occurred during 
incubation and immunoelectrophoresis as shown by their 
similar profiles to the serum and buffer control that 
contained EDTA prior to electrophoresis (slide 5).
Some degree of elongation was present in the test sera 
incubated with each of the three E . coli strains (Fig.
4.10, slides 1-3) demonstrating at least part of C3 had 
undergone activation.
4.3.2.2 C3 activation in human serum incubated with A .
pleuropneumoniae
All test sera incubated with A, pleuropneumoniae also 
demonstrated elongation of the arc suggesting activation 
of C3 in human serum. Figure 4.11 shows elongation of 
the upper arc in slides 1-3 for HK 353, HK 358 and 6664 
respectively. Controls are as as described above.
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Fig, 4.9 Immunoelectrophoretic patterns of pig serum
following incubation with A. pleuropneumoniae 
and developed with anti-pig C3.
Slides
la. Pig serum incubated with A. pleuropneumoniae 
HK 353
2a. Pig serum " " "
HK 358
3a. Pig serum " " "
6664
4a. Pig serum incubated with zymosan (positive 
control)
5a. Addition of EDTA to control pig serum prior to 
immunoelectrophoresis (negative control) 
l-5b. Control pig serum incubated without bacteria 
(negative control)
Fig. 4.10 Immunoelectrophoretic patterns of pig serum 
following incubation with £. coli and 
developed with anti-pig C3.
Slides
la. Pig serum incubated with E. coli CIO 
2a. " " " " " RY21
3a. " " " " " RY22
4a. " " " " zymosan (positive
control)
5a. Addition of EDTA to control pig serum prior to 
immunoelectrophoresis (negative control) 
l-5b. Control pig serum incubated without bacteria 
(negative control)
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Fig. 4.11 Immunoelectrophoretic patterns of human serum 
following incubation with A. pleuropneumoniae 
and developed with anti-human C3.
Slides
la. Human serum incubated with A. pleuropneumoniae 
HK 353
2a. Human serum " " "
HK 358
3a. Human serum " " "
6664
4a. Human serum incubated with zymosan (positive 
control)
5a. Addition of EDTA to control human serum prior to 
immunoelectrophoresis (negative control) 
l-5b. Control human serum incubated without bacteria 
(negative control)
Fig. 4.12 Immunoelectrophoretic patterns of human serum 
following incubation with E. coli and 
developed with anti-human C3.
Slides
la. Human serum incubated with E . coli CIO 
2a. " " " " " RY21
3a. " " " " " RY22
4a. " " " " zymosan (positive
control)
5a. Addition of EDTA to control human serum prior to 
immunoelectrophoresis (negative control) 
l-5b. Control human serum incubated without bacteria 
(negative control)
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All the test sera incubated with the E. coli strains 
CIO, RY21 and RY22 showed partial activation of C3 
indicated by the elongation of the arcs (Fig. 4.12).
4.3.2.3 Factor B in human serum incubated with A .
pleuropneumoniae
Activation of factor B is denoted by the appearance of a 
second arc (Bb) located at the cathode side of the 
original nonactivated protein (B), usually together with 
some of the naive protein remaining. The smaller \ 
cleavage protein, Ba, can sometimes be seen overlapping 
the original factor B protein arc.
The three test sera incubated with each A. 
pleuropneumoniae all demonstrated the presence of 
additional arcs indicative of activation (Fig. 4.13, 
slides 1-3) similar to those seen in the zymosan 
positive control (slide 4). The negative controls of 
buffer and serum alone, and EDTA, were both negative 
indicating no spontaneous complement activation (slide
5).
(Fig. 4.14) indicated also that factor B activation had 
resulted during incubation of the human serum with all 
three E . coli isolates. Results for the controls 
resembled those described above, validating the test 
results (slides 4 & 5).
4.3.2.4 Determination of the pathway responsible for C3 
activation
Attempts to assess by which pathway C3 activation 
occurred were unsuccessful. The process used to degrade 
factor B (described in Appendix 2) and thereby 
eliminating the alternative pathway as a route for C3 
activation, also appeared to activate C3. Activation of
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Fig, 4,13 Immunoelectrophoretic patterns of human serum 
following incubation with A. pleuropneumoniae 
and developed with anti-human factor B.
Factor B activation fragments are denoted by Ba and Bb.
Slides
la. Human serum incubated with A. pleuropneumoniae 
HK 353
2a, Human serum " " "
HK 358
3a. Human serum " " "
6664
4a. Human serum incubated with zymosan (positive 
control)
5a. Addition of EDTA to control human serum prior to 
immunoelectrophoresis (negative control) 
l-5b. Control human serum incubated without bacteria 
(negative control)
Fig. 4.14 Immunoelectrophoretic patterns of human serum 
following incubation with E . coli and 
developed with anti-human factor B.
Factor B activation fragments are denoted by Ba and Bb.
Slides
la. Human serum incubated with E . coli CIO 
2a. " " M " " RY21
3a. " " " " RY22
4a. " " " " zymosan (positive
control)
5a. Addition of EDTA to control human serum prior to 
immunoelectrophoresis (negative control) 
l-5b. Control human serum incubated without bacteria 
(negative control)
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C3 exclusively via the classical pathway could therefore 
not be determined. The methods used to evaluate C3 
activation via alternative pathway activation alone in 
the pig serum (described in Appendix 2) could not 
produce reproducible results.
4.3.2.5 Determination of C3 activation exclusively via 
the classical pathway in human serum
As described for the pig serum, activation of C3
occurred in the factor B depleted serum prior to
incubation with bacteria preventing assessment of C3 
activation via the classical pathway alone.
4.3.2.6 Analysis of C3 and factor B activation fragments 
in both human and pig serum by SDS-PAGE and Western 
blotting
Attempts were made to visualise and quantify the C3 and 
factor B activation fragments produced by 
immunoelectrophoresis using SDS-PAGE and Western 
blotting techniques. These attempts were unsuccessful 
due to the lack of sensitivity of the detection antisera
for use in the above analysis methods.
4.4 DISCUSSION
Many Gram-negative bacteria have been shown to be 
resistant to the bactericidal effects of the complement 
system (Taylor, 1983; Joiner et al., 1984; Joiner,
1988). Serum resistance has been related to several 
factors including the presence of a capsule, composition 
of lipopolysaccharide, plasmid mediated factors and also 
certain outer membrane proteins (Taylor, 1983). A. 
pleuropneumoniae has previously found to be resistant to 
pig complement even in the presence of specific antibody 
(Chapter 3, Rycroft & Cullen, 1990a; Inzana et al,, 
1988). The outer membrane appears not to be the site of
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the observed resistance (Chapter 3, Rycroft & Cullen, 
1990a) however the presence of a capsule is thought to 
be involved in serum resistance (Inzana et al,, 1988). 
The mode of complement resistance by A. pleuropneumoniae 
is not known.
One of the mechanisms that complement resistant 
organisms employ to evade the detrimental actions of 
complement, is to avoid activating the complement system 
(Joiner, 1988). The first aim of this work was to assess 
whether this was the mode of complement resistance 
employed by A. pleuropneumoniae.
The loss of activity of the complement pathways, 
depicted by the non-lysis of red blood cells in the 
functional haemolytic assays, is usually a result of the 
absence of one or more component(s) of either the 
alternative, or the classical pathway, or of the 
terminal components, which are utilised by both pathways 
(Whaley, 1985). Classical pathway activation can lead to 
the consumption of the early components Cl, C4 and C2, 
and alternative pathway activation to B, D and properdin 
consumption. Activation of either pathway leads to the 
cleavage of C3, C5 and the incorporation of C6 , Cl, C8 
and C9 into the C5b-C9 membrane attack complex.
The initial aim of the work described in this chapter 
was to assess whether A, pleuropneumoniae strains were 
capable of activating complement via the classical and 
the alternative pathways. The very low lysis levels of 
red blood cells in the functional haemolytic assays, 
which can be correlated with the amount of complement 
activity present, found for both the classical and the 
alternative pathway assays, demonstrated extensive 
complement consumption in the presence of A, 
pleuropneumoniae (Table 4.4). Similar results in human 
serum via both the classical and the alternative 
pathways suggest that A. pleuropneumoniae may behave in
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a similar fashion in both pig and human serum (Table
4.4) .
The E . coli K1 positive CIO control behaved as expected, 
consuming around half of the complement activity via the 
classical pathway (Table 4.4) (van Dijk et al., 1979).
These lower consumption levels in the human (36.3%) 
serum are in agreement with others who found between 10 
and 50% of complement had been consumed via the 
classical pathway by a Kl positive E . coli (van Dijk et 
al., 1979). This is thought to be due to the presence of 
a Kl type capsular material which can block the 
activation of complement by the layer of LPS below the 
capsule to varying degrees (van Dijk et al., 1979). The 
50.2% consumption seen in the pig serum (Table 4.4) is 
also similar to that previously seen with human serum 
suggesting that E. coli behaves similarly in both sera. 
The difference in the consumption of alternative pathway 
by E. coli CIO in pig (41.8%) and human (97.5%) serum 
may represent differences in the alternative pathway 
between the two sera (Table 4.4). Although the Kl 
capsule is a homopolymer of sialic acid and thus 
represents a molecule incapable of activating the 
alternative pathway, it has been shown that its presence 
does not completely block subcapsular activation by the 
LPS. Similar high percentages of alternative pathway 
consumption by a Kl E. coli strain have also been 
reported (van Dijk, 1979). The E. coli RY22 mutant which 
does not possess capsular material, is a much more 
efficent activator of complement, consuming most, if not 
all of the available complement activity, in both the 
pig and human serum by both pathways and as also seen 
with RY21 (Table 4.4).
Complement consumption can however occur without 
activation. One of the important complement components 
is C3, which can be activated via the classical or the 
alternative pathways. The activation of this component
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would assess whether the complement cascade was 
functional at least up to the C3 stage. 
Immunoelectrophoresis confirmed that C3 was activated in 
both pig and human serum by all the A. pleuropneumoniae 
strains tested (Fig. 4.9 & 4.11). As explained
previously, C3 can be activated via the alternative or 
the classical or both pathways. Factor B activation was 
assessed only in the human serum due to the availability 
of reagents. All A. pleuropneumoniae strains activated 
factor B yeilding its two cleavage proteins, Ba and Bb 
(Fig. 4.13). Treatment to remove the alternative pathway 
in the human serum to evaluate C3 via the classical,
resulted in the non-specific activation of C3. Similar 
attempts to selectively remove each pathway in the pig 
serum also non-specifically activated of C3 by the 
methods used and were therefore abandoned.
In summary each of the three A. pleuropneumoniae strains 
tested consumed the majority of the available complement 
activity via both the classical and the alternative 
pathways in both pig and human serum determined using 
the functional haemolytic assays (Table. 4.4). 
Activation of the complement component C3, which can be 
activated via either the classical or the alternative 
pathway, was demonstrated in both the pig and human
serum incubated with each of the A. pleuropneumoniae 
strains (Fig. 4.9 & 4.11). Activation of factor B,
indicative of alternative pathway activation, was shown 
in human serum incubated with all the A.
pleuropneumoniae strains (Fig. 4.13).
The ability of A. pleuropneumoniae to avoid complement 
mediated bactericidal activity therefore appears not to 
be a result of non-activation of the complement cascade 
consumption, at least up to the C3 stage, as shown by 
the consumption of complement activity and activation of 
complement up to C3.
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CHAPTER 5
THE ROLE OF BACTERIAL VIABILITY AND HAEMOLYTIC ACTIVITY 
SECRETED BY A. PLEUROPNEUMONIAE IN COMPLEMENT
CONSUMPTION
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5.1 INTRODUCTION
As discussed in the previous chapter, the inability of 
A . pleuropneumoniae to activate complement, at least to 
the C3 stage, appears not to be the mechanism used to 
avoid complement bactericidal activity. A second 
mechanism utilised by certain serum resistant bacteria 
to avoid complement damage, is to release molecules that 
can activate, deplete or destroy complement (Joiner, 
1988) .
Some of the these mechanisms employed by microorganisms 
to avoid complement mediated damage, may or may not be 
dependent on cell viability. The first aim was therefore 
to examine whether viable and non-viable bacteria alike 
were capable of consuming complement activity. The next 
question was: if complement consumption was dependent on 
bacterial viability, were the secreted products of
metabolism, which include the haemolytic activity type 
II (Hly II), involved in complement consumption by A. 
pleuropneumoniae?
5.2 MATERIAL AND METHODS
5.2.1 Total complement-mediated bactericidal capacity
The total complement-mediated bactericidal activity in 
serum, previously incubated with A. pleuropneumoniae 
(test serum), was assessed by incubating this serum with 
a serum sensitive E . coli strain, RY22. The
concentration of serum incubated with A. 
pleuropneumoniae, was the lowest concentration that 
adequately killed E. coli RY22 at a cell concentration
of 5 x 10^ cells in a 1ml reaction volume and after 1
hours' incubation period. Any consumption of complement 
activity in the test sera following incubation with the 
A. pleuropneumoniae strains, HK 353, HK 361 and 6664, 
would therefore result in an increase in the number of
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CFU of the serum sensitive strain, RY22. Alternatively, 
if no complement activity had been consumed by 
preincubation with the A . pleuropneumoniae strains, this 
would result in a decrease or death of the serum 
sensitive E • coli strain, RY22. Heat inactivated serum 
containing no complement activity, and serum 
preincubated without A. pleuropneumoniae, were used as 
controls. lOOpl of test serum was incubated with 900 pi 
of buffer M containing 5 x 10® E. coli RY22. The 
reaction mixture was incubated at 37°C for 1 hour. 
Samples were taken at time 0 and 1 hour, and the 
viability (CFU) of E . coli RY22 was assessed by the pour 
plate technique (3.2.1).
5.2.2 Inactivation of bacteria
Bacteria were grown as previously described in 3.2.1. 
and inactivated either for 2 minutes at 100°C, or with 
0.5% v/v formalin overnight.
5.2.3 Consumption of complement activity by non-viable 
bacteria
Viable and non viable bacterial cells (grown and 
processed as described in 3.2.1 and above respectively) 
were adjusted to 7.5 x 10® cells in lOOpl of buffer M 
(3.2.1) and incubated with an equal volume of serum for 
30 minutes at 37°C. Following centrifugation to remove 
the bacteria, lOOpl of the test serum was assessed for 
complement-mediated bactericidal activity against the 
indicator serum sensitive E. coli strain RY22 as 
described in the assessment of total complement mediated 
bactericidal activity (5.2.1).
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5.2.4 Production of haemolytic activity by A, 
pleuropneumoniae in culture supernatant
A. pleuropneumoniae strains were first grown to 
logarithmic phase as described in 3.2.1. Bacterial 
cultures were then subcultured (1/25) into fresh TSB/NAD 
and grown for a further 2.25 hours in an orbital 
incubator at 80 rpm. Following centrifugation (10,000 x
g for 10 minutes at 4°C) to remove the bacteria, the
<
supernatant was used immediately or stored frozen at - 
20°C.
5.2.5 Haemolytic activity assessment and quantification
50pl of culture supernatant was diluted and added to 
350/j1 of haemolysin assay buffer in a microcentrifuge. 
400^1 of 5% (v/v) sheep erythrocytes, washed twice in
saline, was added and the mixture incubated at 37°C for 
60 minutes. Tubes were then gently mixed, centrifuged 
for 5 seconds at 11,300 x g, and the absorbance of the 
resultant supernatants was measured at 541nm.
5.2.6 Complement consumption by the extracellular 
haemolysin of A. pleuropneumoniae
Bacteria-free culture supernatant (100^1) was incubated 
with an equal volume of serum at 37°C for 30 minutes. 
Remaining complement bactericidal activity in the test 
serum was determined as described in the assessment of 
total complement-mediated bactericidal assay. To ensure 
that the reduction of E, coli RY22 observed in the pig 
serum treated with haemolytically active supernatant was 
not due to any detrimental effect of the haemolytic 
substance, E . coli RY22 was incubated in the presence of 
the haemolytic supernatant only.
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5.3 RESULTS
5.3.1 Complement consumption by viable and non-vlable 
bacteria
All test sera pretreated with non-viable A. 
pleuropneumoniae bacteria killed the serum sensitive E . 
coli RY22 strain after incubation for 1 hour (Fig. 5.1). 
The two procedures for rendering cells non-viable gave 
identical results. Neither resulted in the consumption 
of complement activity as shown by the death or decline 
of E. coli RY22 (Fig. 5.1). This was in contrast to the 
test serum preincubated with viable A. pleuropneumoniae 
(as previously demonstrated in the complement 
consumption assays using viable cells in Chapter 4). The 
test sera treated with the corresponding viable bacteria 
resulted in an increase in the survival of serum 
sensitive E. coli RY22. Control serum containing no 
complement activity, allowed survival of E. coli RY22 
numbers comparable to those with serum preincubated with 
viable A, pleuropneumoniae strains. Control normal serum 
preincubated without viable A. pleuropneumoniae resulted 
in the death of E. coli RY22 (Fig. 5.1).
5.3.2 Complement consumption by extracellular haemolytic 
activity
Bacterial supernatants from 3 A. pleuropneumoniae 
strains were assessed for haemolytic activity. A. 
pleuropneumoniae strain, HK 361 produced high levels of 
haemolytic activity compared to HK 353 and 6664, which 
both produced very poor detectable levels of haemolytic 
activity by the same method (Table 5.1). The culture 
supernatants from all three strains were tested for the 
ability to consume complement activity.
All sera, pretreated with the A. pleuropneumoniae 
culture supernatants, killed the serum sensitive
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A. Dleurooneumoniae Strains OD 541 nm
HK 361 1.388
HK 353 0.091
6664 0.073
Controls
Saline 0.015
Culture broth 0.023
100% Lysis 1.445
Table. 5.1 Haemolysin levels in A. pleuropneumoniae 
culture supernatants
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indicator E. coli strain. Both haemolytic and non- 
haemolytic culture supernatant alike resulted in the
complete killing of RY22 after 1 hour (Figs. 5.2, 5.3 &
5.4). This suggested there was no relationship between
the amount of complement consumption and the level of
haemolytic activity in the culture supernatant. As 
demonstrated previously in Chapter 4, viable bacteria 
consumed all the available complement activity resulting 
in survival of the indicator serum sensitive E . coli 
RY22 (Figs. 5.2, 5.3 & 5.4). The serum control which
possessed full complement activity demonstrated the 
decline of E . coli RY22 in this serum (Figs. 5.2, 5.3 &
5.4) and was again in sharp contrast to the large 
increase seen in the heat inactivated serum which 
possessed no complement activity (Figs. 5.2, 5.3 & 5.4). 
No inhibition of E. coli RY22 growth was observed when 
incubated in haemolytically active supernatant for 1 
hour (Fig. 5.2). The bacterial growth rate was similar
to that in heat-inactivated serum.
The results shown in Figs. 5.1-5.4 and Table 5.1 are 
representative of 3 separate experiments.
5.4 Discussion
Many pathogenic bacteria are resistant to the 
bactericidal effects of the complement system. There are 
a range of mechanisms by which bacteria achieve this 
resistance to complement activity. Certain bacteria do 
not activate or consume complement activity. However 
this was found not to be the mechanism used by A .
pleuropneumoniae as detailed in the last chapter. A
second mechanism used by certain serum resistant 
bacteria to avoid complement damage is to release
molecules that can activate, deplete or destroy
complement components (Joiner, 1988).
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Examples of these 3 different classes of molecules 
include firstly, components shed by microorganisms that 
can activate the classical or alternative pathways 
resulting in the microbial surface becoming inert to the 
complement cascade. The parasite, Schistosoma mansoni 
has been shown to shed molecules capable of consuming C3 
from serum resulting in them being non-activators of the 
complement cascade (Marikovsky et al., 1986; Rasmussen & 
Kemp, 1987; Samuelson et al., 1980). The molecules shed 
from the parasitic surface include residual cercarial 
glycocalyx, which is a known C3 acceptor (Samuelson & 
Caulfield, 1986).
Secondly, other microorganisms release substances 
capable of depleting complement components both close to 
and at a distance from the cell membrane. Examples of 
these include the capsule of type la group B 
Streptococci which has been suggested to reduce Cl using 
this mechanism (Levy et al., 1984) and the 
mucoexopolysaccharide slime of Pseudomonas aeruginosa 
which activates the alternative pathway cleaving C3 and 
factor B (Lambris et al., 1982). Soluble techoic acid 
produced by Staphylococcus aureus has also been shown to 
consume early classical pathway components from immune 
serum (Joiner, 1988).
Lastly, certain microbial products can also inactivate 
or destroy complement components other than by 
conventional complement activation. These include the 
local high levels of ammonia produced by P. aeruginosa 
(Hostetter et al., 1986). Microbial proteases are also 
involved in inactivating complement components including 
elastine from P. aeruginosa which cleaves a number of 
complement molecules (Schultz & Miller, 1974). Other 
proteases are non-specific, attacking a range of 
complement and non-complement substrates (Catanese & 
Kress, 1984; Markham et al., 1979; Nilsson et al., 1985;
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Schultz & Miller, 1974; Sundqvist et al., 1985; Ward et 
al., 1973).
As discussed in the introduction, some of the above 
mentioned mechanisms employed by the microorganisms may 
or may not depend on cell viability. It has been 
previously shown in Chapter 4 that viable A. 
pleuropneumoniae are capable of activating and consuming 
complement activity. The next aim was therefore to 
assess whether non-viable A. pleuropneumoniae were also 
able to consume complement activity.
Non-viable A. pleuropneumoniae, unlike their viable 
counterparts, were unable to consume complement 
activity. This was shown by the decrease in the numbers 
of CFU of the serum sensitive E . coli.
The difference observed between viable and non-viable 
bacteria in their ability to consume complement activity 
may suggest that metabolically active bacteria are 
necessary to consume activity. Alternatively, the 
component(s) responsible for complement consumption may 
be located on both viable and non-viable cells alike and 
treatment with heat or formaldehyde, used to kill the 
bacteria, may in some way damage or destroy those 
components rendering them unable to consume complement 
activity.
Assuming that the difference in the ability of A. 
pleuropneumoniae to consume complement was due to its 
viability and not to the inactivation process, it was 
decided to look at the products of metabolism in an 
attempt to identify the responsible component(s) for 
complement consumption. Certain A. pleuropneumoniae 
strains have been documented to possess haemolytic 
activity in their culture supernatant (Nakai et al., 
1983; Kume & Nakai, 1986; Rosendal et al., 1988; Frey & 
Nicolet, 1990). This haemolytic activity has been
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associated with toxicity against a range of cell types 
(Kume & Nakai, 1986; Kume et al., 1986b; Udeze & Kadis, 
1988; Rosendal et al., 1988). The culture supernatants 
of some A. pleuropneumoniae strains being studied in 
this laboratory were also found to possess haemolytic 
activity (Rycroft et al., 1991). It was therefore 
decided to assess whether this toxic activity may also 
be involved in the observed consumption of complement 
activity by viable A. pleuropneumoniae.
It was found however that haemolytically active
bacterial supernatant was unable to consume complement 
activity. This would suggest that the haemolytic
activity present in A. pleuropneumoniae culture 
supernatants was not responsible for the observed 
complement consumption by viable bacterial cells. The 
two culture supernatants that produced very low, if any 
haemolytic activity, also did not consume complement 
activity. The lack of difference in complement
consumption observed between haemolytically active and 
non-active supernatant also confirms the lack of 
involvement of the haemolytic activity in complement 
consumption.
These strains also produce a cytotoxin (pleurotoxin) 
which would also have been present in the supernatants 
(Rycroft et al., 1991). It can therefore be concluded 
that neither Hly II nor pleurotoxin is responsible for 
the apparent consumption of complement. This failure of 
culture supernatant to consume complement does not 
necessarily preclude the involvement of other secreted 
products. Certain secreted components remain intimately 
associated with the bacterial cell membrane (Joiner,
1988) .
The mode of complement evasion of A. pleuropneumoniae 
still remains unknown. Nevertheless, it is clear from 
the results that both the failure to activate complement
140
CHAPTER 6 
PHAGOCYTOSIS OF A, PLEUROPNEUMONIAE
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6.1 INTRODUCTION
The process of phagocytosis is a defence mechanism of 
major importance in removing pathogens from the lung. 
Since the beginning of the 1980's, A, pleuropneumoniae 
has been reported to have a toxic effect for porcine 
phagocytic cells. Both viable whole cells and culture 
supernatants were found to possess toxicity against 
alveolar and peritoneal macrophages, polymorphonuclear 
leukocytes (PMN) and peripheral blood monocytes 
(Bendixen et al., 1981; Kume & Nakai, 1986; Kume et al., 
1986b; Pijoan, 1986; Udeze & Kadis, 1988; Rosendal et 
al,, 1988; van Leengoed et al., 1989). Likely candidates 
as causes of this damage were the secreted extracellular 
haemolytic and cytotoxic activities of A, 
pleuropneumoniae (Udeze & Kadis, 1988; Rosendal et al,, 
1988; van Leengoed et al,, 1989; Frey & Nicolet, 1990). 
The mechanism by which these toxins damage phagocytic 
cells is unknown; however, it has been shown that one 
haemolysin of serotype 1 strain, 4074, forms pores in 
phospholipid membranes (Lalonde et al,, 1989).
At the start of this work, phagocytosis of A, 
pleuropneumoniae had been documented using porcine PMN 
and alveolar macrophages (Inzana et al,, 1988; Udeze & 
Kadis, 1988). There had also been reports of damage to 
alveolar macrophages by culture supernatants of the same 
A, pleuropneumoniae strains (Pijoan, 1986). These 
contradictory reports of damage to the phagocytic cells, 
and also to their ability to phagocytose adequately, 
left the situation unclear as to the actual extent of 
damage caused by A. pleuropneumoniae to the phagocytic 
cells•
Those phagocytosis studies used strains of A. 
pleuropneumoniae that produced both haemolytic and 
cytotoxic activity in their culture supernatant (Udeze & 
Kadis, 1988). These toxic activities have since been
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named haemolysin I and II (Hly I and Hly II). Hly I is a 
105 kDa protein and has been found to be both strongly 
haemolytic and cytotoxic and Hly II, a 103 kDa protein, 
possesses only weakly haemolytic and cytotoxic activity 
(Kamp et al., 1991). Similar results had also been
obtained with certain strains of A. pleuropneumoniae in 
this laboratory. They produced extracellular haemolytic 
and cytotoxic activities that appeared to be associated 
with 109 (haemolysin II, Hly II) and 120 kDa 
(pleurotoxin, PTX) proteins respectively (Fig. 6.1a) 
(Rycroft et al., 1991).
Phagocytosis of A. pleuropneumoniae had therefore been 
studied only in strains that produce both haemolysins I 
and II (Inzana et al., 1988; Udeze & Kadis, 1988). We 
had previously found that a serotype 2 strain, HK 361, 
produces a potent cytotoxin associated with a 120 kDa 
protein (Ptx) which was active against alveolar 
macrophages (Rycroft & Cullen, 1990b; Rycroft et al., 
1991). However, it was not known whether macrophages 
were able to phagocytose prior to being killed. The aim 
of this study was firstly therefore to evaluate whether 
phagocytosis by alveolar macrophages occurred in the 
presence of both Hly II and Ptx, and secondly, whether 
phagocytosis was occurring in the absence of Hly II and 
Ptx, using mutants deficient in either Hly II alone or 
both Hly II and Ptx (Fig. 6.1a).
6.2 MATERIALS & METHODS
6.2.1 Bacterial strains
HK 361 serotype 2 mutants were used in the work 
described in this chapter and have been described in 
detail in Chapter 2. HK 361 mutant e possesses cytotoxic 
activity only, associated with a 120 kDa protein 
(Pleurotoxin) , and mutant h is deficient in both Hly II 
(haemolysin type II, 109 kDa protein) and pleurotoxin.
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Fig. 6.1a Comparison of the presence of the toxic 109 
and 120 kDa polypeptides in bacteria-free 
culture supernatant from HK 361 and its 
mutants, e and h determined by Western 
blotting and probing with immune pig serum.
1) Parent strain HK 361 produces both 109 and 120 kDa 
proteins associated with haemolytic and cytotoxic 
activity respectively
2) Mutant e only produces the 120 kDa cytotoxic protein
3) Mutant h produces neither the 109 or 120 toxic 
proteins
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6.2.2 Bacterial preparation for phagocytosis studies
Bacteria were grown as previously described for serum 
bactericidal assays (3.2.1). The bacterial cultures were 
centrifuged at 11,300 x g for 1 minute, washed once with
o
gel-HBSS and resuspended in the same buffer 1 x 10° 
cells/ml (2pg NAD/ml added for A. pleuropneumoniae
strains).
6.2.3 Sera
The normal pig serum, immune pig serum and hyperimmune 
rabbit serum have been previously described in Chapter 
2.
6.2.4 Trypan blue exclusion test
The vital stain trypan blue is taken up only by dead 
cells, staining their nuclei blue. Viable macrophage
counts were determined by diluting cells in an equal 
volume of 0 .2 % (w/v) trypan blue solution and assessing 
those cells which had not taken up the vital dye using a 
haemocytometer.
6.2.5 Pig alveolar macrophages
Lungs were obtained from high health status pigs which 
were killed with barbiturates and used immediately. Lung 
lavage was performed using Hanks balanced salt solution 
(HBSS, Gibco, Scotland), which was placed in the trachea 
by means of a filter funnel (Fig. 6.1). The lungs were 
inflated to maximum capacity with HBSS and gently 
massaged. The HBSS was then emptied into a sterile
container held on ice and the procedure repeated using
fresh HBSS. The suspension collected in this way was 
then centrifuged at 110 x g for 4 minutes and the pellet 
washed twice with ice-cold gel-HBSS at 4°C (Leijh et 
al.f 1986, Rycroft et al., 1991). Gelatin was added to
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Fig. 6 1 In vitro lung lavage of porcine lungs via the 
trachea.
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Fig. 6.1
protect the bacteria in the phagocytosis assay, since 
HBSS alone is bactericidal (Roberts, 1967). Remaining 
red cells were lysed by the addition of 0.87% (w/v)
NH4CI for 10 minutes. Following centrifugation, the cell 
pellet was resuspended in gel-HBSS and the viability of 
the cell suspension determined by the trypan-blue
exclusion test. The cell suspension was adjusted to 1 x
7 ■ •10 viable cells/ml and Giemsa-stained cell preparations
were examined for cell type by light microscopy.
6.2.6 Cytospin preparation
Cytospins were prepared using ethanol precleaned 
standard microscope slides and cytospin filter cards 
(Shandon). 200^1 containing 4.5 x 10^ cells were loaded 
into the sample chamber and centrifuged for 5 minutes at 
55 x g in a cytocentrifuge (Shandon). Slides were 
allowed to air dry before being fixed with methanol and 
Giemsa stained.
6.2.7 Preopsonisation of bacteria
Bacteria were grown and washed as previously described 
in 6.2.1. Bacterial pellets were resuspended in gel-HBSS
n
(5 x 10 cells/ml) containing 10% serum and incubated at 
37°C under slow rotation (4rpm) for 30 minutes. 
Preopsonised bacteria were centrifuged at 11,300 x g for 
1 minute and washed once in gel-HBSS.
6.2.8 Inactivation of bacteria
Bacteria were grown as previously described and treated 
either for 2 minutes at 100°C, or with 0.5% v/v formalin 
overnight to inactivate the bacteria.
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6.2.9 Phagocytosis assay
The method used was based upon that of Leijh et al., 
(1986). Bacteria, grown or treated as previously 
described, were washed once in gel-HBSS and resupended 
in the same buffer to 5 x 10^ cells/ml. A portion 
(0.5ml) of bacterial suspension was incubated with 0.5ml 
of macrophages (1 x 10  ^ cells/ml) and 0 .1ml of serum in 
non-adherent tubes (Leijh et al., 1986) at 37°C with
slow rotation (4 rpm) . Samples were taken at 0, 1 and 2 
hours. Viable bacterial counts and preparations for
cytospins and electron microscopy were carried out by 
the methods described below.
Bacteriological determination of undigested, unattached 
viable bacteria was carried out as follows; lOOpl
samples were transferred to 300pl of ice-cold gel-HBSS 
to stop phagocytosis and centrifuged at 110 x g for 4 
minutes at 4°C. Supernatants were carefully aspirated 
and stored. Pellets were washed twice more using 300pl 
of gel-HBSS each time, giving a total of 1ml of 
washings. A portion (lOpl) of this supernatant was
diluted 10~^ and 10”  ^ in gel-HBSS. Samples (lOOpl) of 
each dilution were assessed for bacterial viability by 
the pour plate method. The pellets were then used to 
prepare both cytospin smears and sections for
examination by electron microscopy. Pellets were
resuspended in 400pl of gel-HBSS.
For cytospins, a portion (200pl) (4.5 x 10^ cells) of
each sample was centrifuged for 5 minutes at 55 x g in a 
cytocentrifuge (Shandon). Slides were air dried, fixed 
with methanol and stained with Giemsa solution. The
remaining 200jil samples were used for electron
microscopy. Samples were fixed with 1.3% 
paraformaldehyde and 1 .6% gluteraldehyde in 0 .1M sodium 
cacodylate. The samples were postfixed with osmium 
tetroxide, sectioned and stained with 2 0% uranyl acetate
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and lead citrate and examined with a transmission 
electron microscope (Zeiss 109). Electron microscopy 
sample preparation and photography was performed by the 
Electron Microscopy Unit in this department.
A. pleuropneumoniae strains HK 361 (Hly II+, Ptx+ ) , 
mutant e (Hly 11“, Ptx+) and mutant h (Hly II", Ptx,“) 
were assessed for phagocytosis by pig alveolar 
macrophages along with an E, coli control strain, CIO.
6.2.10 Different serum conditions
Heat-treated serum was prepared as previously described 
in Chapter 2. Heated and normal pig serum were used to 
assess the effects of the absence of complement and 
specific antibody, and the presence of complement but no 
specific antibody respectively. Heated and hyperimmune 
rabbit serum for -complement/+specific antibody and 
+complement/+specific antibody assessment respectively. 
The immune pig serum was used as a source of both 
homologous and heterologous pig antibody. Serum-free 
controls were included to assess the effects of the 
absence of both heated or normal serum.
6.2.11 Intracellular survival of A . pleuropneumoniae
Bacteria (5 x 10^ cells/ml) preopsonised with immune pig 
serum were incubated with 1 x 10^/ml macrophages for 30 
minutes under slow rotation (4rpm). Extracellular 
bacteria were removed by differential centrifugation (4 
minutes at 110 x g) and two washes with gel-HBSS. A 
portion (0.5ml) of gel-HBSS containing lOjig of 
gentamicin was added to the macrophages and left at room 
temperature for 5 minutes. Macrophages were centrifuged 
(4 minutes at 110 x g) and washed twice with gel-HBSS to 
remove the gentamicin. The cells were resuspended in 1ml 
of RPMI medium containing 10% heat-inactivated (56°C/30 
minutes) foetal calf serum (FCS) (Gibco). Samples
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(lOOpl) were taken from time 0 to 17 hours (time zero 
equal to initial preopsonisation stage) and washed as 
described for the phagocytosis assay. Pellets were 
resuspended in 400jil of gel-HBSS. Samples (200pl) were 
lysed either by the detergent Triton X-100 (0.001-1%) or 
3 freeze/thaw cycles using liquid nitrogen and a 37°C 
water bath in the presence of bovine serum albumin (1%). 
Viability of bacteria released from the macrophages was 
assessed using the pour plate method with iso-sensitest 
agar.
Samples for each assay were taken in duplicate or 
triplicate and each experiment was carried out between 3 
and 5 times.
6.3 RESULTS
6.3.1 Phagocytosis of A, pleuropneumoniae strain HK 361
A. pleuropneumoniae HK 361, which produces both Hly II 
and Ptx, was assessed for phagocytosis by alveolar 
macrophages following incubation with alveolar 
macrophages in the presence of normal pig serum.
Lung lavage samples were almost entirely composed of
alveolar macrophages. Following exposure of the 
macrophages to A. pleuropneumoniae HK 361, in the 
presence of normal pig serum, the majority of cells 
observed in the cytospin preparations had already 
undergone a degree of degeneration compared to the 
control in the time 0 sample, which was collected
immediately after the addition of the bacteria to the 
macrophage and serum mixture (Fig. 6.2a,b). In the 
presence or absence of normal pig serum, similar
macrophage degeneration occurred. In the presence of 
serum, bacteria were seen to adhere to the macrophage 
surface and occasional bacteria were present within
phagolysosomes. No bacteria were seen to be either
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Fig. 6.2 Giemsa stained cytospin preparations of HK 361 
incubated with porcine alveolar macrophages in 
the presence of normal pig serum over time.
a) Control macrophages incubated in the absence of 
bacteria.
b) HK 361 incubated with normal pig serum and alveolar 
macrophages at time 0 .
c) HK 361 incubated with normal pig serum and alveolar 
macrophages at time 2 hours.
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Fig. 6.2
phagocytosed or adhering to the macrophages in the 
absence of serum. After further incubation for 1 and 2 
hours, all macrophages displayed extensive damage both 
in the presence and absence of serum (Fig. 6.2c). 
Bacteria appeared to be located both around and within 
the dead macrophages, again only in the presence of 
serum. The numbers of bacteria observed in the cytospin 
preparations increased greatly with continued incubation 
(Fig. 6.2c).
Control macrophage samples, incubated either in the 
absence of bacteria (Fig. 6.2a), or with E . coli RY22 
(Fig. 6.3), showed no signs of damage at any stage of 
incubation. Large numbers of E . coli were seen to be 
phagocytosed after 1 and 2 hours incubation in the 
presence of serum (Fig. 6.3c,d).
6.3.2 Phagocytosis of A. pleuropneumoniae haemolysin and 
cytotoxin negative mutants
A . pleuropneumoniae HK 361 mutants e and h were 
evaluated for phagocytosis in the presence of normal pig 
serum.
The haemolysin deficient mutant, HK 361e, which 
possessed only the cytotoxin (Ptx), was found to behave 
in an identical fashion to the parent strain HK 361 
(Fig. 6.4). Incubation of this strain with the 
macrophages resulted in the rapid death of macrophages 
both in the presence and absence of serum. The increase 
in bacterial numbers over time, seen associated with the 
degenerating macrophages in the presence but not the 
absence of normal pig serum in the cytospin 
preparations, appeared to be similar to the parent 
strain, HK 361 (Fig.6 .4c).
Incubation of macrophages with the cytotoxin and 
haemolysin negative mutant h, resulted in a large
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Fig. 6.3 Giemsa stained cytospin preparations of
control E . coli incubated with porcine alveolar 
macrophages in the presence of heated normal pig 
serum over time.
Time samples taken at:
a) 0 hours
b ) 1 hour
c) 2 hours
d) 3 hours
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Fig. 6.3
Fig. 6.4 Giemsa stained cytospin preparations of HK 361 
mutant e incubated with porcine alveolar 
macrophages in the presence of normal pig serum 
over time.
a) Control macrophages incubated in the absence of 
bacteria.
b) HK 361 mutant e incubated with normal pig serum and 
alveolar macrophages at time 0 .
c) HK 361 mutant e incubated with normal pig serum and 
alveolar macrophages at time 2 hours.
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proportion of the macrophages remaining alive in the 
time 0 sample (Fig. 6.5b) Bacteria were observed both 
adhering to, and within, the macrophages in the presence 
of serum (Fig. 6.5b). After 1 and 2 hours incubation a 
proportion of macrophages still appeared healthy 
however, a similar number showed signs of degeneration 
(Fig. 6.5c). Phagocytosed bacteria could still be seen, 
although numbers did not appear to increase with 
prolonged incubation (Fig. 6.5c).
6.3.3 Effects of immune sera on macrophage survival and 
ability to phagocytose
Phagocytosis assays were also carried out in the 
presence of immune sera, which contained antibodies 
against Hly II and Ptx. This was to assess firstly, any 
increase in survival of macrophages incubated with A. 
pleuropneumoniae due to the presence of neutralising 
antibodies against the Hly II and Ptx and secondly, any 
increase in the number of phagocytosed A . 
pleuropneumoniae when incubated with immune sera. HK 361 
and mutants e and h were assessed for phagocytosis by 
alveolar macrophages incubated with both convalescent 
pig serum and hyperimmune rabbit serum.
No difference in the degree of damage caused to the 
macrophages incubated with HK 361 and mutant e was seen 
when incubated with either of the immune sera. 
Macrophages incubated with HK 361 and mutant e continued 
to sustain extensive damage. Preopsonisation of HK 361 
bacteria for 30 minutes at 37°C prior to incubation with 
the macrophages, did not reduce the level of damage to 
macrophages.
Incubation of mutant h with immune sera resulted in the 
macrophages initially appearing healthy. Continued 
incubation in the presence of hyperimmune rabbit serum 
resulted in the killing of a proportion of macrophages
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Fig. 6.5 Giemsa stained cytospin preparations of HK 
mutant h incubated with porcine alveolar 
macrophages in the presence of normal pig 
serum over time.
a) Control macrophages incubated in the absence 
bacteria.
b) HK 361 mutant e incubated with normal pig serum 
alveolar macrophages at time 0 .
c) HK 361 mutant e incubated with normal pig serum 
alveolar macrophages at time 2 hours.
361
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comparable to that seen with normal pig serum (Fig. 
6.5c). The presence of convalescent pig serum however 
did appear to reduce damage to the macrophages, 
resulting in most of the cells remaining healthy 
following continued incubation (Fig. 6 .6 ). Bacteria
could be clearly seen adhering to macrophages, and 
within phagolysosomes (Fig. 6 .6b,c,d). The numbers of 
phagocytosed bacteria also appeared to increase with 
prolonged incubation (Fig. 6.6 c,d). Phagocytosis of
mutant h was confirmed following electron microscopy. 
Bacteria could be seen within phagolysosomes (Fig. 
6.7a). A double membrane could be clearly seen 
surrounding several of the bacteria (Fig. 6.7b).
In control samples where mutant h was incubated with 
macrophages in the absence of serum, a slight reduction 
in the level of toxicity was observed after 1 hours 
incubation compared to all other serum conditions
excluding the convalescent serum. This difference could 
only be seen in the 1 hour sample. After 2 hours 
incubation the macrophages were at similar levels of 
degeneration in all the other serum conditions except
the convalescent serum. Controls of macrophages 
incubated in the presence and absence of E . coli 
bacteria, showed no signs of damage as previously
described (Fig. 6.2a, 6.3).
6.3.4 Phagocytosis of inactivated A. pleuropneumoniae
Both toxins produced by HK 361 are heat-labile (Rycroft 
et al., 1991). Other researchers have documented a heat 
stable toxin(s) that possesses both haemolytic and 
cytotoxic properties, and was polysaccharide in nature 
from a different serotype 2 strain (Kume et al., 1986). 
To assess whether the damage seen to macrophages
incubated with mutant h in the presence of normal pig 
serum was related to such a factor, bacteria,
inactivated by heat or formaldehyde, were assessed for
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Fig. 6.6 Giemsa stained cytospin preparations of HK 361 
mutant h incubated with porcine alveolar 
macrophages in the presence of immune pig 
serum over time.
Time samples taken at:
a) 0 hours
b) 1 hour
c) 2 hours
d) 3 hours
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Fig. 6.6
Fig. 6.7 Electron micrographs of HK 361 mutant h
incubated in the presence of immune pig serum 
within phagolysosomes of porcine alveolar 
macrophages.
a) Time 3 hour sample x 14f000 magnification
b) Time 3 hour sample x 24,000 magnification
Bar represents Ijml.
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Fig. 6.7
phagocytosis. Killed HK 361 and mutant h appeared to be 
readily phagocytosed by the macrophages in the presence 
of each serum used, independent of the method used to 
inactivate them. In the time 1 samples, mutant h 
bacteria could already be clearly seen inside the 
macrophages (Fig. 6 .8 ). After incubation for 2 hours the 
number of phagocytosed bacteria had increased 
substantially compared to the first sample (Fig. 6 .8c). 
No damage to the macrophages was apparent in any of the 
later samples (Fig. 6 .8d). No difference in the degree 
of phagocytosis of A. pleuropneumoniae was detected when 
incubated in the presence of either normal or immune pig 
serum. All macrophage controls were as previously 
described.
6.3.5 Determination of extracellular viable bacterial 
counts
Reproducible extracellular bacterial counts could not be 
determined for A . pleuropneumoniae HK 361 or mutants e 
and h. The ability of A. pleuropneumoniae to form chains 
and the adherence of large numbers of bacteria to the 
degenerate macrophages, even after 3 slow speed washes 
to remove extracellular bacteria, may contribute to the 
observed irregularities. Reproducible extracellular 
bacterial counts were obtained for the E . coli controls. 
Bacterial counts decreased with increased incubation 
time in the presence of both macrophages and serum. 
Increases in extracellular bacterial counts over time 
were observed for the serum free control, and also in 
the macrophage free control both in the presence and 
absence of serum. The increase in bacterial counts was 
very similar for the above three latter controls.
6.3.6 Intracellular survival
Attempts to assess the viability of phagocytosed mutant 
h were inconclusive. The use of the detergent Triton X-
161
Fig. 6.8 Giemsa stained cytospin preparations of killed 
HK 361 mutant h incubated with porcine 
alveolar macrophages in the presence of normal 
pig serum over time.
Time samples taken at
a) 0 hours
b) 1 hour
c) 2 hours
d) 3 hours
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Fig. 6.8
100 at a concentration which lysed the macrophages 
(0.1%), was found to be toxic for the bacteria. Lower 
concentrations found to be non-toxic for A,
va cfc v,
pleuropneumoniae r did not lyse the bae-betffla. Freeze,
thawing techniques using liquid nitrogen and a 37°C 
water-bath, in the presence of bovine serum albumin,
also killed the bacteria.
6.4 DISCUSSION
The results obtained to date regarding phagocytosis of 
A , pleuropneumoniae strains have been documented with 
strains that produce both the Hly I and Hly II (Inzana 
et al., 1988; Udeze & Kadis, 1988; Thwaits & Kadis,
1991; Udeze & Kadis, 1992). Serotypes 2,3,4,6 and 8 also 
produce a 120 kDa protein (Chapter 7, Cullen & Rycroft, 
1992a; MacDonald & Rycroft, 1992), which is associated 
with cytotoxicity (Rycroft et al,, 1991). The aim of
this work was to assess whether a serotype type 2 strain 
of A, pleuropneumoniae is phagocytosed by alveolar 
macrophages in the presence or the absence of toxic 
activities, Hly II and Ptx.
Phagocytosis of HK 361 or mutant e could not be assessed
due to the rapid toxic effect of these organisms on the 
macrophages (Fig. 6.2, 6.4). The addition of immune
serum, with or without preopsonisation for 30 minutes at 
37°C, did not remove this toxic effect. The difference 
observed in the neutralising ability of the immune serum 
compared to that previously assessed (Rycroft et al,, 
1991) may be related to the continual production of 
toxic activity by the growing bacteria during the 
phagocytic assay and the fixed amount of toxin which 
would have been present in the culture supernatant used 
in the previous study. This continued production of 
toxin may allow it to overcome the neutralising ability 
of serum antibody. The lack of toxin neutralisation also
did not appear to be related to the heterologous nature
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of the immune serum, since incubation of a serotype 3 
strain, which also produces both Hly II and Ptx (Rycroft 
et al., 1991), with its corresponding homologous immune 
serum, did not neutralise the toxic activities, 
resulting in damaged macrophages.
The absence of Hly II in mutant e appeared not to reduce 
the level of macrophage damage suggesting it was not an 
important cause of the observed toxicity. This is in 
agreement with work of others, who have found the Hly II 
to be weakly haemolytic and the least cytotoxic of the 3 
known cytotoxins (haemolysin I & II and pleurotoxin 
respectively) (Frey & Nicolet, 1990; Rycroft et al., 
1991, Smits et al,, 1991; Kamp et al,, 1991).
The limited macrophage damage observed after 1 and 2 
hours incubation with mutant h and normal pig serum may 
be due to the retention by this mutant of a level of 
toxic activity (Fig. 6.5). Culture supernatant from 
mutant h has previously been found to be non-toxic for 
alveolar macrophages, and neither Hly II nor Ptx were 
detected in the culture supernatant by immunoblotting 
(Rycroft et al,, 1991). This is in contrast to both HK 
361 and mutant e supernatant, which is extremely 
cytocidal for these cells (Rycroft et al., 1991). It may 
be speculated that the reduced toxic activity observed 
in A. pleuropneumoniae mutant h represents a cell- 
associated toxic component.
Only in the presence of convalescent pig serum was the 
toxicity of mutant h for macrophages neutralised (Fig. 
6 .6 ). The lack of neutralisation of toxic activity by 
the hyperimmune rabbit serum, which contained cross­
reacting but not neutralising antibodies against both 
haemolysin II and pleurotoxin (personal observations), 
may also imply the involvement of toxic activities in 
the macrophage damage by mutant h. The increase in 
phagocytosed mutant h following prolonged incubation in
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the presence of the immune pig serum suggests the toxin 
neutralising abilities of the convalescent pig serum are 
required to enhance the phagocytosis of this organism 
(Fig. 6 .6 ). Whether this is a result of the neutralising 
abilities of the immune serum alone, or in combination 
with the presence of specific antibodies, which have 
been reported to enhance opsonisation of A. 
pleuropneumoniae, is not known (Thwaits and Kadis, 
1991) .
The rapid phagocytosis of the killed bacteria and the 
lack of damage to the alveolar macrophages incubated in 
normal pig serum suggest that A . pleuropneumoniae is 
phagocytosed in the absence of any heat or formaldehyde 
sensitive extracellular toxins (Fig. 6 .8 ). The 
phagocytosis of killed mutant h also suggests that the 
toxic activity of mutant h is heat labile and therefore 
not LPS-associated or the heat stable toxin described by 
Kume et al •, (1986b). The similar numbers of
phagocytosed killed mutant h in normal pig serum 
compared to viable mutant h in immune pig serum, 
suggested the presence of specific antibody may not be 
necessary for phagocytosis of A. pleuropneumoniae by 
alveolar macrophages.
Attempts were made to assess whether phagocytosed mutant 
h was killed by macrophages. However, the use of the 
detergent Triton X at a concentration which lysed the 
macrophages (0 .1%), was found to be toxic for the 
bacteria. Freeze thawing techniques using liquid 
nitrogen and a 37°C water-bath, in the presence of 
bovine serum albumin, also killed the bacteria. It is of 
interest in Fig. 6.7, as detailed by an arrow, the 
bacterium within the phagolysosome appears to have 
undergone a degree of degeneration. Whether this 
demonstrates killing of mutant h within alveolar 
macrophages, or is merely an artifact of the electron 
microscopy, requires further investigation.
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A . pleuropneumoniae HK 361 and its mutants were found to 
remain attached to both the viable and the degenerate 
macrophages after washing to remove extracellular 
bacteria. This occurred only in the presence of serum 
irrespective of whether it had been heated or contained 
specific antibodies. Both Thwaits and Kadis (1991) and 
Inzana et al. (1988) recovered high percentages of total 
bacteria in the supernatant following 3 slow speed 
washes to remove extracellular bacteria in a procedure 
identical to that used here. Both these researchers used 
PMN and perhaps the differences can be attributed to 
this factor. This problem of adherence was not detected 
using the E. coli control.
Phagocytosis of live A. pleuropneumoniae by PMN has been 
described for strains 4074 (serotype 1) and K17 
(serotype 5a) that produced Hly I and II (Inzana et al., 
1988; Thwaits & Kadis, 1991). Hly I is reported to 
possess strong cytocidal activity and Hly II a weaker 
activity (Kamp et al., 1991). However, toxicity of 
alveolar macrophages has also been caused by the same 
strains (Pijoan, 1986). These differences may have been 
related to these 2 strains being toxic for porcine 
alveolar macrophages but not for PMN. A third study used 
porcine alveolar macrophages to study phagocytosis of 
serotype 1 strain, 4074 (Udeze and Kadis, 1988). They 
did report toxicity of the purified haemolysin for 
alveolar macrophages and PMN alike, however there was no 
discussion on whether toxicity was observed in the 
phagocytosis assays with whole bacteria. Recent studies 
with the same strain, 4074, have since found that this 
strain was in fact toxic for PMN (Udeze & Kadis, 1992). 
These researchers found that substantial phagocytosis 
could only be achieved when the assay was carried out in 
the presence of serum containing antibodies to the 
haemolysins I and II. It would therefore appear that 
strains producing Hly I and II are toxic for both PMN
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and macrophages alike, however the presence of immune 
serum neutralises the toxic effect of the bacteria and 
phagocytosis can therefore be assessed. The above 
explanation would therefore explain why there have been 
contradictory reports of damage to phagocytic cells by 
both culture supernatant and live bacteria, which were 
assessed in the absence of immune serum, and 
phagocytosis of the same strains which were assessed in 
the presence of immune serum. In the case of viable 
strains producing the Ptx, it would appear that even the 
presence of immune serum is not sufficient to neutralise 
all the toxic effects of Ptx for pig alveolar 
macrophages.
The delayed death of the macrophages in the serum-free 
control incubated with mutant h, compared to all other 
serum conditions excluding convalescent serum, may 
suggest that attachment of the organism to the 
macrophages enhances the action of the toxic components. 
It has been suggested that the toxin operates by 
diffusion mechanism (Udeze & Kadis, 1988), which would 
be in agreement with the observed results. It is of 
interest that A . pleuropneumoniae activates complement 
component C3 (Chapter 4, Cullen & Rycroft, 1990; Udeze 
and Kadis, 1992), and has been found to possess C3b on 
its surface (Udeze & Kadis, 1992) although it is 
resistant to immune pig serum (Chapter 3, Rycroft & 
Cullen, 1990a). C3b acts as an opsonin to attract 
macrophages to phagocytose organisms coated with C3b. It 
is possible that A . pleuropneumoniae has become adapted 
using opsonisation to increase the speed of macrophage 
attraction resulting in enhanced toxic activity of the 
organisms against these host defence cells.
In summary the results of this chapter suggest that 
phagocytosis of A . pleuropneumoniae serotype 2 strain by 
alveolar macrophages can only occur in the absence of 
both Ptx and Hly II and in the presence of immune serum.
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When Ptx is present either alone (mutant e) or in 
combination with Hly II (HK 361), phagocytosis cannot be 
assessed. This is due to the extremely toxic activity of 
the Ptx, which cannot be entirely neutralised by immune 
serum when live bacteria are used. The absence of the 
Hly II was not found to reduce the toxicity of the 
serotype 2 strain in the presence of Ptx. Therefore, it 
could be suggested that the Ptx of this serotype is both 
a potent cytotoxic and an anti-phagocytic factor. It is 
therefore suggested that A. pleuropneumoniae would be 
phagocytosed except for the fact it produces toxins 
active against phagocytic cells.
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CHAPTER 7
IMMUNOLOGICAL ASSESSMENT OF THE HAEMOLYTIC AND CYTOTOXIC 
PROTEINS OF A. PLEUROPNEUMONIAE
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7.1 INTRODUCTION
Over the last decade one of the major virulence factors 
of A. pleuropneumoniae to emerge has been the haemolytic 
and cytotoxic activities of both viable bacteria and 
their secreted products for a range of porcine cells 
including alveolar macrophages, neutrophils, PMN and 
erthrocytes (Bendixen et al., 1981; Pijoan, 1986; Udeze 
& Kadis, 1988; Rosendal et al., 1988; van Leengoed et
al., 1989).
The haemolysin of A, pleuropneumoniae was first 
partially characterised from a serotype 1 strain, as a 
protein of 105 kDa (Frey & Nicolet, 1988a). Further 
studies demonstrated a requirement for Ca++ as an 
inductor for biosynthesis of haemolysin. However, Ca++ 
was found not to be required for the biological activity 
of the haemolysin (Frey et al., 1988; Frey & Nicolet, 
1988b). The opposite result was found with the 
haemolysin of a serotype 2 strain. This haemolysin was 
not induced by the addition of Ca++ to the growth 
medium, however Ca++ was found to be required for 
biological activity in erthrocyte lysis. This discovery 
led these researchers to propose that the haemolysin of 
serotype 2 and its regulation was different from that 
produced by serotype 1. The haemolysin of serotype 1 was 
designated haemolysin type I (Hly I) and the haemolysin 
of serotype 2, haemolysin type 2 (Hly II) (Frey & 
Nicolet, 1988b).
All 12 serotype reference strains were then assayed for 
haemolytic activity both in the presence and absence of 
Ca++ in both the growth medium and assay titration 
buffer. Four distinct haemolytic patterns were found, 
serotypes 3 and 6 showed very weak haemolytic activity 
which could not be further quantified, serotype 1 
required Ca++ for the biosynthesis of haemolytic 
activity but not for its activity, serotypes 2, 4, 7 and
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8 possessed weak haemolytic activity that required Ca++ 
for activity but not for biosynthesis, and lastly 
serotypes 5a, 5b, 9, 10, 11 and 12 showed both
haemolysins, one requiring Ca++ for biosynthesis and 
another for activity (Frey & Nicolet, 1990). This 
information suggested that A. pleuropneumoniae strains 
possessed at least 2 different haemolysins.
Other researchers studying the same serotype 1 strain 
found that the haemolysin possessed both haemolytic and 
cytotoxic activities associated with a 130 kDa band and 
3 protein bands of smaller molecular weight (Udeze & 
Kadis, 1988). The purified haemolysin was found to be 
toxic for porcine alveolar macrophages, PMN and 
neutrophils.
Attempts were made to isolate these toxic activities in 
order to purify and characterise them. However it was 
found that the cytotoxic and haemolytic activities 
produced in the bacterial culture supernatant of 
serotype 1 co-purified (Udeze & Kadis 1988) and a 
substantial loss of activity was experienced both on 
purification and in the crude form (Frey & Nicolet, 
1988a; Devenish & Rosendal, 1989). Further examination 
of representative strains from the 12 serotypes revealed 
the presence of a 104 kDa protein in all strains that 
reacted with a polyclonal antiserum raised against a 
serotype 1 strain (Devenish et al., 1989). In addition, 
this serum also detected proteins of a similar size in 
related pathogens Pasteurella haemolytica, Escherichia 
coli and Actinobacillus suis. The haemolytic activity of 
the serotype 1 strain was neutralised by some, but not 
all, of the sera raised against the strains from the 12 
serotypes of A. pleuropneumoniae. This led these 
researchers to propose that a similar, but not 
identical, 104 kDa protein was produced by all the 
serotypes of A. pleuropneumoniae, and suggested it may 
be related to the cytolysins produced by other Gram-
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negative bacteria (Bhakdi et al,, 1986; Lo et al,, 
1985) . Examination of culture supernatants of the 12 
serotypes reference strains for haemolytic and cytotoxic 
activity by another research group also revealed both 
similarities and differences in the activities reported 
(Kamp & van Leengoed, 1989). They found the haemolytic 
activity in all serotypes were serologically 
homogeneous, but that 4 distinct cytotoxic activities 
could be detected.
The situation was therefore very confusing regarding 
whether the haemolytic activities were the same or 
related, or if the haemolytic and cytotoxic activities, 
observed in some but not all of the serotypes, was in 
fact the Hly I or II or indeed another protein. The
similarity in molecular weights between Hly I and II 
also added to the confusion.
Several serotype 2 and 3 strains under study in this
laboratory were found to secrete both cytotoxic and
haemolytic activities into their culture supernatant and 
initially a protein of 109 kDa was identified in the 
culture supernatants of these strains. This activity was 
found to require Ca++ for the expression of haemolytic 
but not cytotoxic activity (denoted haemolysin II, Hly
II). In order to study these proteins in greater detail, 
Mabs were developed against the 109 kDa protein, found 
in serotype 2 and 3 strains under investigation within 
this laboratory, that appeared to have both cytotoxic
and haemolytic properties associated with a 109 kDa 
protein and which required Ca++ for the activity of the 
haemolytic but not for the cytotoxic activity.
Further analysis of culture supernatant from these 
serotype 2 and 3 strains revealed the presence of 
another secreted polypeptide that was shown to be a 120 
kDa protein. Mutant strains had also been produced 
within this laboratory from a serotype 2 strain HK 361
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minutes at 200V) . Standard and mini gels were fixed and 
stained in 40% (v/v) methanol, 10% (v/v) glacial acetic 
acid and 0.25% (w/v) Coomassie Brilliant Blue R250 for 
30 and 15 minutes respectively. Gels were destained in a 
mixture of 40% (v/v) methanol and 10% (v/v) glacial
acetic acid overnight.
7.2.2 Bacterial culture supernatant
Bacteria were grown to logarithmic phase as previously 
described (2.3). Subcultures were then made (1 in 25) 
into fresh TSB/NAD and grown for a further for 5 hours. 
Bacteria were removed by centrifugation for 10 minutes 
at 10,000 x g and culture supernatants stored at -20°C.
7.2.3 Isolation and purification of the pleurotoxin of
A. pleuropneumoniae (120 kDa protein)
A. pleuropneumoniae Hly 11“ mutant e, which secretes 
only the pleurotoxin (120 kDa protein), was used to 
prepare the immunising antigen sample for Mab production 
against the 120 kDa cytotoxic protein of serotype 2 
strain HK 361. Bacteria-free culture supernatants of 
mutant e were freshly prepared and used without prior 
freezing. The culture supernatants (30ml) were held in 
an ice-cold container and ethanol added to give a final 
concentration of 23% (v/v) . The supernatant was held on 
ice for 60 minutes and centrifuged at 12,000 x g for 15 
minutes at 4°C. The resultant pellet was gently 
redissolved in 3ml of saline. 1.5ml was retained and 
Triton X-100 added to the other 1.5ml to make a final 
concentration of 0.2% (v/v) Triton X-100. Triton X-100 
treated supernatant was processed through a Sephacryl S- 
300 column (Pharmacia) column which had been previously 
washed through with Tris-Triton X-100 buffer. 1ml 
fractions were collected and refrigerated until tested. 
Eluate fractions were tested for 120 kDa protein content 
by SDS-PAGE• 30jil of each sample was assessed and those
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fraction(s) containing the maximum amount of 120 kDa 
protein were saved.
7.2.4 Protein A preparation
Staphylococcus aureus Cowan strain was used to prepare 
protein A and was obtained from Dr. Rick Randell, St 
Andrews University, Scotland. 3g of dry weight S. aureus 
was resuspended in 30ml of phosphate buffered saline 
(PBS) containing azide (0.1%). The bacteria were 
centrifuged at 8,000 x g for 10 minutes and washed twice 
in the same buffer. The pellet was resuspended in 10% 
w/v PBS/azide and 1.5% formalin and stirred at room 
temprerature for 90 minutes. Following the 
centrifugation and washing procedure as described 
before, the pellet was resuspended in 1 0% w/v of 
PBS/azide in a flask, keeping the depth of liquid below 
2.5cm. This was heated to 80°C for 5 minutes shaking 
occasionally and then cooled in an ice-bath. The 
solution was centrifuged at 8,000 x g for 10 minutes and 
washed twice in PBS/azide (pH 7.2). The pellet was 
dried, reweighed and resuspended at 10% w/v in 
PBS/azide. S. aureus protein A was aliquoted and stored 
frozen at -70°C.
7.2.5 Preparation and isolation of 109 kDa protein 
(haemolysin II)
A Mab had been previously produced against the culture 
supernatant of serotype 2 strain HK 353, which contained 
only haemolysin II (109 kDa protein). This Mab did not 
produce a strong reaction when tested against culture 
supernatant from HK 353 by both ELISA and 
immunoblotting. It was decided to use this Mab as part 
of an immunising complex and conjugate it to protein A, 
which would act as a carrier, and also to the 109 kDa 
protein. This immunising complex would hopefully elicit
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a stronger response to the 109 kDa protein due to its 
attached carrier protein A.
200jil of protein A was centrifuged 8,000 x g for 10 
minutes and the supernatant discarded. The protein A 
pellet was resuspended in 200jil of tissue culture 
supernatant containing Mab against the 109 kDa protein 
and incubated overnight at 4°C with rotation. The 
mixture was centrifuged at 8,000 x g for 10 minutes and 
washed 4 times with PBS.
The protein A-antibody complex was incubated with 0. 5ml 
culture supernatant from HK 361 containing 109 kDa 
protein overnight at 4°C with rotation. This allowed the 
Mab to bind with the 109 kDa haemolysin protein to 
complete the complex. The mixture was centrifuged at
8.000 x g for 10 minutes and the pellet resuspended in 
immunoprecipitate buffer. Following centrifugation at
8.000 x g for 10 minutes, the pellet was washed a 
further three times in immunoprecipitation buffer and 
once in PBS. The mixture was resuspended in sterile PBS 
to lOx the original volume of antibody solution (final 
volume 2ml) and stored at -70°C.
7.2.6 Immunisation protocol
7.2.6.1 120 kDa protein
150fil of the purified 120 kDa protein was diluted with 
PBS to QOOpil and thoroughly emulsified with 800^ /1 of 
Freund's complete adjuvant. 0.2ml of the immunising 
mixture was injected i.p. into 6 week old female Balb C 
mice. Further immunisations were given using Freund's 
incomplete adjuvant at day 21. The third and fourth 
immunisations were administered at a minimum of 4 weeks 
between each injection. All injections were given i.p. 
except the final, which was i.v.
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7.2.6.2 Protein A-Ab-Ag
0. 2ml of the protein A-Ab-Ag immunising antigen was 
administered i.p. for all immunisations. No adjuvant was 
used in any of the immunisations.
Blood samples were taken around 10 days after an 
injection from the mouse tail vein. Blood was allowed to 
clot and serum recovered as previously described 
(2.4.1).
7.2.7 Enzyme linked immunosorbent assay (ELISA)
A double antibody indirect ELISA was constructed to 
screen Mabs for reactivity against the immunising 
antigens of either haemolysin II (109 kDa) or 
pleurotoxin (120 kDa).
7.2.7.1 Materials used and their preparation
Normal mouse serum and serum recovered from the fusion 
mouse were used as negative and positive controls 
respectively and was obtained as described in 7.2.6. 
Hyperimmune rabbit serum raised against a serotype 2 
strain (HK 353) and immune pig serum from a pig infected 
with a serotype 3 strain (see Chapter 2) were also used 
as positive controls. Test samples consisted of 
hybridoma fluid taken from each well containing growing 
cells.
Bacteria-free culture supernatant from either serotype 2 
strain HK 361 or its mutant, e, was used as the 
antigenic material bound to the ELISA plates and was 
prepared as described in 7.2.2.
Conjugated antiserum used included goat anti-mouse IgG 
and goat anti-rabbit IgG alkaline phosphatase conjugates 
(Bio-rad) and rabbit anti-pig HRP (Sigma Ltd.). All
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conjugates were raised against both the heavy and light 
chain IgG.
Substrates used were alkaline phosphatase substrate kit 
(Bio-rad). The reaction was stopped by adding 100^1/well 
of 0.4M NaOH and OD were read at 405nm. TMB peroxidase 
EIA substrate (Bio-rad) kit was used to develop HRP
colour reaction. The reaction was stopped with 
100jil/well of IN H2SO4 and the OD read at 655nm.
ELISA Maxisorp plates (Nunc) were used with an ELISA 
reader (Micro-ELISA Autoreader MR 580, Dynatech 
Laboratories Inc., Virginia, USA).
7.2.7.2 Construction and standardisation of ELISA
Optimum working dilution of antigens, control serum and 
conjugated antiserum was determined by chequerboard 
titration. Firstly the relative dilution of conjugate 
was assessed. A fixed concentration of antigen was
coated on the plates and fixed dilution of positive and
negative mouse serum was added to wells and then double 
dilutions were made across horizontal rows. Conjugate 
was then double diluted down vertical columns. Substrate 
was added for the manufacture's recommended time and 
once the reaction was stopped, the plates were read at 
405nm. The well with the maximum readable absorbance, 
the lowest concentration of conjugate and the highest 
concentration of serum was assessed from the ELISA
reader printout. This dilution of conjugate was regarded 
as the relative dilution and was used until the optimum 
dilution was calculated. Chequerboard titrations were 
repeated for each antigen and antiserum used. Next the 
relative antibody dilution was found by using a fixed 
relative conjugate dilution and titrating both the 
antigen and serum to detect the well that produced the 
maximim readable absorbance with the lowest 
concentration of serum and the highest concentration of
178
antigen. Once the relative dilutions for the control 
| serum and conjugate were found, the ELISA was repeated 
! under different temperature conditions and incubation 
periods for each step in the ELISA (Burrells & Dawson, 
1982). Once the optimum conditions had- been assessed, 
the ELISA was repeated by titrating each of the reagents 
to assess the optimum working dilution. The optimum 
working dilution for each reagent was taken to be the 
concentration that gave the maximum readable absorbance 
at the end of the plateau of the curve. Following 
completion of standardisation, the ELISA was carried out 
as described below.
1. Optimum concentrations of bacterial culture 
supernatant from HK 361 and mutant e were found to have 
batch to batch variations and ranged from 1/2 to 1/8 
dilutions. Samples (50jil) of antigen were mixed with 
coating buffer (50pil) to give the final optimum 
dilution. 100/jI were added to each well of the 96 well 
plate and incubated overnight at 4°C. During all 
incubations the plates were covered with cling film to 
prevent loss of liquid and drying of the wells.
2. Plates were washed 3 times with washing buffer and 
blocked for 1 hour at 37°C with 200pl/well of blocking 
solution.
3. Following incubation, plates were washed twice and 
lOOpl of the appropriate serum (test serum or hybridoma 
supernatant) was added and incubated for 2 hour at 37°C. 
Initial concentrations of control positive and negative 
serum used were 1/100 and double diluted down.
4. Plates were washed 3 times and lOOpl of the 
appropriate conjugated second antibody added to each
| well and incubated at 37°C for 1 hour. All conjugates 
were used at a working dilution of 1/500.
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5. Wells were washed a final 4 times and 100^1 of the 
relevant substrate was added to each well. For the 
alkaline phosphate substrate, the reaction was allowed 
to continue for 30 minutes at room temprerature. The 
reaction was stopped by adding lOOjil/well of 0.4M NaOH 
and the OD read at 405nm. TMB peroxidase EIA substrate 
kit was added and the reaction was continued until a 
dark blue product colour had developed. The reaction was 
stopped with 100^1/well of IN H2SO4 and the OD read at 
655nm.
7.2.7.3 ELISA controls
Positive and negative controls included the use of 
positive mouse serum recovered from the fusion mouse and 
preimmune serum taken from the same mouse was used as 
the negative mouse serum. Rabbit serum raised against a 
serotype 2 bacteria-free culture supernatant and immune 
pig serum were also used as positive controls for the 
detection of 109 and 120 kDa proteins. Hybridoma fluid 
from unrelated clones was also used as a negative 
control to assess the possible interference of bovine 
serum used as a growth supplement. Intra-assay controls 
included wells containing all reagents except one to 
assess possible background from each reagent.
The lower cut off point was determined to be 1.5 times 
the background from a well containing the known negative 
sample of preimmune mouse serum. The end point for the 
assay was chosen to be 0.2 OD units above the 
background.
7.2.8 Myeloma fusion partner cells (NSO)
Myeloma fusion partner cells, NSO (Galfre & Milstein, 
1982) were recovered from liquid nitrogen stocks 
approximately 1 week prior to the fusion. The NSO were 
grown in RPMI++ containing 10% FCS. NSO cells were re­
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fed daily to ensure the cells were growing rapidly in a 
logarithmic fashion until the day of the fusion. Cells 
were recovered using a cell scraper and collected in 
RPMI+++. NSO cells were then centrifuged at 900 x g for 
5 minutes and resuspended in 20ml RPMI+++.
7.2.9 Splenocyte feeder cultures
Splenocyte feeder cultures were prepared from the spleen
of a sacrificed female Balb C mouse. The spleen was
removed aseptically and transferred to a tissue culture
dish containing RPMI. Excess tissue was trimmed off and
the spleen transferred to fresh medium and teased apart
to release the splenocytes. Cell clumps were disrupted
by pipetting and the cells and medium were transferred
to a container. The cell suspension was held for 5
minutes to allow large cell clumps to settle to the
bottom. Following this, the cell suspension was
transferred to a centrifuge tube taking care to avoid
the sediment. Cells were centrifuged at 900 x g for 5
minutes and resuspended in 2ml RPMI+++. The cell
suspension was irradiated for 9 minutes at 3000 RADS 
fi 0(DUCobalt). The suspension was washed a further twice in 
RPMI+++ and finally resuspended in 60ml of RPMI+++HAT. 
lOOpl of splenocyte suspension was added to each well in 
the 96 well tissue culture plates (Microtest III,
Falcon). Plates were wrapped in a plastic bag and 
incubated at 37°C in a 5% humid CO2 incubator for 1 day 
prior to use.
7.2.10 Mouse fusion
3 days after the final immunisation, the mouse was 
sacrificed, the spleen removed aseptically and
transferred to a tissue culture dish containing 
prewarmed RPMI. Excess tissue was trimmed off and the 
spleen transferred to fresh medium where it was teased 
apart to release the splenocytes. Cells clumps were
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disrupted by pipetting and the cells and medium were 
transferred to a universal bottle. The cell suspension 
was allowed to sit for 5 minutes to allow any large cell 
clumps to settle to the bottom. The cell suspension was 
then transferred to another centrifuge tube taking care 
to avoid the sediment. The cells were centrifuged at 900 
x g for 5 minutes and resuspended 5ml of RPMI+++. Spleen 
cells were underlayed in ficoll-paque (Pharmacia) and 
centrifuged at 900 x g for 10 minutes. The interphase, 
which contains the B and T lymphocytes, was removed 
carefully, resuspended in 20ml RPMI+++ and centrifuged 
for 5 minutes at 900 x g. The cell pellet was 
resuspended in 20ml of RPMI+++. Both NSO and spleen 
cells were counted using a haemocytometer and adjusted 
to a concentration containing 3 spleens 1 NSO. The cell 
mixture was centrifuged, the supernatant discarded and 
the pellet tapped to break up the cells. 0.5ml of 
prewarmed PEG-1500 (Boehringer) was slowly added 
dropwise to the cells with continual shaking of the 
cells to ensure constant mixing. The cells were 
incubated at 37°C for 2-3 minutes and 20ml of RPMI added 
very slowly, gently swirling the cells to ensure 
continual mixing. Following centrifugation at 900 x g 
for 5 minutes, the cells were resuspended in 60ml of 
RMPI+++HAT. lOOjil of the cell suspension was pipetted 
into each well which already contained IOOjjI of 
irradiated spleen cells prepared 24 hours previously. 
Plates were wrapped in individual plastic bags to 
minimise contamination and incubated in a 5% humid CO2 
incubator.
Mouse fusions were carried out using mice immunised with 
either the 120 kDa protein or the protein A complex 
containing the 109 kDa protein.
182
7.2.11 Hybridoma screening
Plates were screened 10-14 days after each fusion for 
developing clones. Clones were tested for antibody 
secretion at a size just visible to the naked eye. At 
this stage sufficient antibody should have been produced 
by the cells to give a positive reaction by ELISA. lOOpl 
of culture supernatant was carefully removed and tested 
by ELISA.
7.2.12 Hybridoma cell cloning by limiting dilution
Clones deemed positive by ELISA were selected and 
dilution cloned using the method below to give 0.3, 1
and 3 cells per well. This procedure will select 
individual cell secreters from which "all positive" 
clones can be selected.
Cells were diluted to 1 x 10^ cells/ml. The following 
dilutions were made:-
1 . IOjjI of 1 x 105 cells/ml added to 1ml medium (1 x 1 0 3 
cells/ml)
2. 150^1 of 1 x 103 cells/ml added to 5ml of medium (3 x 
1 0  ^cells/ml)
3. 2ml of 3 x 10^ celsl/ml added to 4ml of medium (1 x 
1 0* cells/ml)
4. 2ml of 1 x 101 cells/ml added to 4ml of medium (3.3 x 
10® cells/ ml)
100jil of the above dilutions were added to wells already 
containing 100/j1 of irradiated splenocytes. Plates were 
wrapped in plastic bags and incubated in a humid 5% CO2 
37°C incubator for 10-14 days.
7.2.13 Expanding positive clones
Clones secreting antibody against the immunising 
antigen, determined by a positive reaction of their
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supernatants by ELISA, were transferred to a 24 well 
tissue culture plate (Cluster^, Costar) supplemented 
with splenocyte feeders and RPMI+++ HAT and incubated at 
37°C in a 5% CO2 humid incubator until growth became 
dense. The cells were then transferred into 5ml of 
RPMI+++HAT in a 50ml tissue culture flask (Nunclon, 
Nunc) and a further 5ml of RPMI+++HAT added when cell 
concentration reached around 10^ cells/ml. Drug 
selection was removed at this stage by switching from 
RPMI+++HAT to RPMI+++HT and then decreasing the 
concentration of HT by half each time the cells were 
fed. Cells were transferred to 260ml and then to 600ml 
flasks following their increase in numbers. At this 
stage a maximum of 300ml of hybridoma culture 
supernatant can be obtained from each 600ml flask. The 
positive clones were continued to be screened at each 
growth phase to verify the continued secretion of 
positive antibody. Only those clones which continued to 
secret positive antibody were further grown and 
purified.
7.2.14 Freezing positive clones
Cells were frozen in a solution of 90% FCS plus 10% 
dimethylsulfoxide (DMSO) (Sigma Ltd.) at various stages 
of growth. Cells were centrifuged at 900 x g for 5 
minutes and the supernatant discarded. The cells were 
suspended in cold freezing solution and transferred to 
freezing tubes (Cryotubes, Nunc). Cells were stored 
overnight at -70°C and transferred to liquid nitrogen 
the following day.
7.2.15 Purification of monoclonal antibodies
Cells were grown up to 100ml in 600ml flasks. Further 
additions of medium were added to a volume of 300ml 
using RPMI++ containing decreasing concentrations of FCS 
to give a final concentration of 2% FCS in 300ml. Cells
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were allowed to overgrow the medium and die. Increased 
amount of antibody are produced as clones die. Culture 
supernatant was centrifuged for 10 minutes at 12,000 x 
g. Supernatants were filter through a 500ml bottle 
filter (0.2pm) (Costar) under pressure. IgG antibody was 
purified from the culture supernatant using a Protein G 
Sepharose 4 fast flow column (MAbTrap G, Pharmacia LKB). 
Purified IgG antibodies were precipitated overnight in 
an equal volume of 50% saturated ammonium sulphate in 
the cold. The precipitation mixture was centrifuged at
12,000 x g for 10 minutes, the supernatant discarded and 
the pellet carefully resuspended in 3ml saline. The 
amount of purified antibody present in the sample was 
evaluated by calculating the total amount of protein. 
This was determined by measuring the absorbance at 280nm 
using a spectrophotometer. An OD2 8O equivalent to 1.0 is 
approximately equal to 0.75 mg/ml of purified 
immunoglobulin. Purified Mabs were stored at -70°C in a 
standard phosphate buffered solution.
7.2.16 Isotyping monoclonal antibodies
A commercial kit was used to determine the isotype of 
the mouse Mabs (Inno-Lia Mouse Mab Isotyping 
(Innogenetics N.V., Antwerp, Belgium). The kit is based 
on a line immunoassay and consists of strips coated with 
rat anti-mouse Mabs against the different mouse antibody 
isotypes. Following incubation with test hybridoma 
supernatant, the strip was developed and compared to a 
control strip. The isotype was determined by comparing 
the test line to the known control lines.
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7•2.17 Screening reactivity of monoclonal antibodies 
raised against the 109 and 120 kDa protein by Western 
blotting
A panel of Mabs deemed positive by ELISA were screened 
to assess their specificity against the immunising 
antigen visually by Western blotting.
Due to the work involved in dilution cloning and after 
care only a handful of possible clones were assessed at 
any one time. All remaining clones were held frozen for 
future assessment. A panel of 6 positive clones that 
remained stable following cloning, were chosen to be 
examined. Hybridoma fluid from the 6 clones was assessed 
for the possession of antibody against the immunising 
antigens of the haemolysin II (109 kDa) and pleurotoxin 
(120 kDa). Bacteria-free culture supernatant from HK 361 
and mutant e were used as the screening antigens, which 
possessed both the 109 and 120 kDa proteins and only the 
120 kDa protein respectively.
The Mabs were next screened against all the serotype 
reference strains of A. pleuropneumoniae, together with 
related pathogens, to assess the presence of similar 
proteins that may cross-react with the Mabs raised 
against the haemolysin II (109 kDa) and pleurotoxin (120 
kDa) of the serotype 2 strain HK 361. HK 361 and mutant 
e together with the A. pleuropneumoniae reference 
serotype strains and related pathogens including E • 
coli, A. suis, A. equuli, and P. haemolytica were grown 
with the addition of lOmM CaCl2 , and culture supernatant 
obtained as described in 7.2.2. The culture supernatants 
(5ml) were held in an ice-cold container and ethanol 
added to give a final concentration of 23% (v/v) . The
supernatant was held on ice for 60 minutes and 
centrifuged at 12,000 x g for 15 minutes at 4°C. The 
resultant pellet was gently redissolved in 60jil ro^O 
and 30^1 of x3 sample buffer. 90^1 of each sample was
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added to each well and electrophoresed using SDS-PAGE. 
Gels were then Western blotted.
7.2.18 Western blotting
Both standard and mini Trans-Blot Cell systems were used 
(Bio-rad)• Prior to blotting gels were washed in NT 
buffer for 30 minutes. Proteins were electrophoretically 
transferred onto nitrocellulose membrane filters (Bio­
rad) using both the standard (overnight blotting) and 
the mini (1 hour) Trans-Blot systems in the above 
buffer. Membranes were incubated overnight in TNT 
blocking solution. Proteins were then probed overnight 
with the appropriate antiserum diluted in 5% (w/v)
skimmed milk in TNT. Antibody-antigen complexes were 
probed with HRP conjugated antibody for 1 hour and 
developed with HRP substrate. Samples were probed with 
Mabs against both the pleurotoxin (120 kDa protein) and 
the haemolysin II (109 kDa protein) and immune pig serum 
from a pig recovering from infection with a A. 
pleuropneumoniae serotype 3 strain, 6664.
7.2.19 Neutralisation assays
Mabs were tested with active pleurotoxin (120 kDa 
protein) and haemolysin II (109 kDa protein) to assess 
their neutralising capabilities against these toxic 
activities.
7.2.19.1 Haemolysin determination and neutralisation
Production and measurement of A. pleuropneumoniae 
culture supernatant containing haemolytic activity has 
been described in 5.1.4 and 5.1.5. Haemolysin- 
neutralising activity of the Mabs was determined 
(Rycroft et al., 1991). A sample (lOpl) of hybridoma
fluid or diluted hybridoma fluid was incubated with 90pl 
of haemolytically active cell-free culture supernatant
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at 0°C for 60 minutes. Samples were then assayed for 
haemolytic activity as described in 5.2.5 and compared 
to controls treated identically with immune or preimmune 
pig serum. The neutralising titre was expressed as the 
reciprocal of the dilution of serum required to achieve 
at least 50% reduction in haemolytic activity of a 
standard fresh haemolysin preparation.
7.2.19.2 Cytotoxin preparation and neutralisation
Cytotoxin was prepared by growing the A . 
pleuropneumoniae as previously described in 7.2.2. 
Subcultures were then made (1 in 25) into fresh TSB/NAD 
and grown for a further 4 hours. Bacteria were removed 
by centrifugation for 10 minutes at 10,000 x g at 4°C. 
Culture supernatants were filtered (0.22pm), held on ice 
and used immediately.
Pig alveolar macrophages (6.2.4) were recovered from 
liquid nitrogen and diluted in Minimum Essential Medium 
(MEM) (Gibco, BRL) with 10% foetal calf serum to 10^/ml 
cells. A sample (lOOpl) was added to each well in a 96 
well culture plate (Nunc) and incubated for a few hours 
at 37°C in a 5% CO2 humid incubator. The supernatant was 
replaced with fresh medium after 2 hours.
Cytotoxic-neutralising activity of the Mabs was 
determined (Rycroft et al., 1991). 50pl of the cytotoxic 
culture supernatant was mixed with an equal volume of
hybridoma fluid or diluted hybridoma fluid at 0°C for 60
minutes. The medium from the macrophages was removed and 
a sample (lOpl) of the previously incubated cytotoxic
culture supernatant and hybridoma fluid was added to
90pl MEM in a well containing alveolar macrophages and 
incubated at 37°C for 1 hour. The wells were examined 
microscopically following the addition of the vital 
stain, Trypan blue, and macrophage viability was 
determined. The neutralisation titre was the reciprocal
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dilution of hybridoma fluid or control immune or 
preimmune pig serum required to prevent completely the 
cytotoxic effect of the test sample.
7.3 RESULTS
7.3.1 120 kDa cytotoxin protein purification
Analysis of the SDS gel demonstrated that well 3 
contained the largest amount of 120 kDa protein (Fig.
7.1). The remaining sample from the corresponding eluate 
fraction was used as the immunising antigen.
7.3.2 ELISA
The number of wells containing hybridoma cells which 
secreted antibody reactive against the immunising 
antigen of 120 kDa pleurotoxin were determined by 
screening against mutant e culture supernatant which 
only possessed the 120 kDa protein. 68 wells from a
total of 6 x 96 well plates were positive for reacting 
antibody. Of those wells, the hybridoma fluid obtained 
from 7 wells gave readings over 3.0 OD units, 42 wells 
gave OD readings of between 2.0 and 3.0 and 19 wells
readings of between 1.0 and 2.0 OD. Due to the large
number of wells containing positive secreting cells, 
those wells with an OD below 1.0 were not further 
assessed. The contents of all other wells with an OD 
above 1.0 were either further grown or stored in liquid 
nitrogen for future assessment.
The number of wells secreting positive antibody against 
the srtaph A-Mab-109 kDa immunising antigen were screened/ 
against HK 361 culture supernatant which contained both 
the 109 and 120 kDa proteins. Only 2 wells were deemed 
positive from a total of 6 x 96 well plates. The cut off 
point for this assay was the normal background plus an 
OD of 0.2 units.
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Fig. 7.1 Detection of 120 kDa pleurotoxin in column
eluates by SDS-PAGE followed by Comassie blue 
staining.
120kDa
Fig.7.1
The final 6 Mabs, 5 of which were from the mouse fusion 
immunised with 120 kDa pleurotoxin (GJMC-1 to 5) and 1 
from 109 kDa complex (GJMC-6 ), were selected due to 
their continued secretion of specific antibody as 
determined by ELISA.
Following the observation that the Mabs raised against 
the 120 kDa pleurotoxin were also cross-reacting with 
the 109 kDa, all ELISAs employed HK 361 culture 
supernatant as the screening antigen.
7.3.3 Isotyping monoclonal antibodies
The final selection of 6 Mabs (GJMC-1 to 6 ) were 
assessed for isotype. Mabs raised against the 120 kDa 
protein were found to be of both isotype IgG2a and IgG2b 
(Fig. 7.2). The 1 Mab raised against the 109 kDa protein 
was isotype IgGl (Fig. 7.2). The faint reaction seen 
with GJMC-5 was correlated with a decrease in antibody 
levels produced by these clones as detected by ELISA. 
This clone was frozen down in order to be recloned and 
assessed at a later stage.
7.3.4 Reactivity of monoclonal antibodies by Western 
blotting
Reactivity of Mabs raised against the 120 kDa protein 
(GJMC-1 to 5) was assessed by screening against antigen 
containing both the 109 kDa and 120 kDa proteins 
obtained from HK 361 culture supernatant. The Mabs 
raised against the 120 kDa protein reacted with the 120 
kDa protein in the concentrated culture supernatant of 
the parent strain HK 361 (Fig. 7.3). The Mabs also 
reacted with a protein present in the culture 
supernatant of the parent strain, HK 361, corresponding 
to around 109 kDa, a similar size to the haemolysin II 
protein (Fig. 7.3). It had been determined within this 
laboratory that cloned pleurotoxin (120 kDa) produced
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Fig. 7.2 Isotypes of monoclonal antibodies raised
against either the 109 or 120 kDa polypeptides 
secreted by A. pleuropneumoniae.
Mabs raised against 120 kDa protein:
1) Mab GJMC-1, isotype IgG2b
2) Mab GJMC-2 f isotype IgG2b
3) Mab GJMC-3, isotype IgG2b
4) Mab GJMC-4, isotype IgGl
5) Mab GJMC-5, isotype IgG2b
Mab raised against 109 kDa protein:
6 ) Mab GJMC-6 , isotype IgG2a
7) Control illustrating all isotype locations
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Fig, 7.3 Western blot reactions of Mabs raised against 
the 120 kDa protein probed against HK 361 bacteria- 
free supernatant antigen preparation.
1) Mab GJMC-1 hybridoma supernatant (neat)
2) Mab GJMC-2
3) Mab GJMC-3
4) Mab GJMC-4
5) Mab GJMC-5
6 ) Positive control immune pig serum (1/200)
7) Negative control preimmune pig serum (1/200)
Fig. 7.4 Western blot reactions of Mabs raised against 
the 120 kDa protein probed against HK 361 and 
mutant e bacteria-free supernatant antigen 
preparation.
1) Mab GJMC-1 reacted with HK 361 antigen
2) Mab GJMC-1 reacted with mutant e antigen
3) Mab GJMC-2 reacted with HK 361 antigen
4) Mab GJMC-2 reacted with mutant e antigen
5) Mab GJMC-3 reacted with HK 361 antigen
6 ) Mab GJMC-3 reacted with mutant e antigen
7) Mab GJMC-4 reacted with HK 361 antigen
8 ) Mab GJMC-4 reacted with mutant e antigen
9) Mab GJMC-5 reacted with HK 361 antigen
10) Mab GJMC-5 reacted with mutant e antigen
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breakdown products, one of which was of a similar 
molecular weight to the 109 kDa haemolysin II.
The Mabs were then rescreened against bacteria-free 
culture supernatants from mutant e which only produced 
the 120 kDa protein. It was hoped to compare any 
breakdown product that was in a similar size position to 
that seen in the HK 361 antigen preparation previously.
All 5 Mabs reacted in a similar fashion. The Mabs 
reacted strongly with the 120 kDa protein present in 
both mutant e and HK 361 antigen preparations (Fig. 
7.4). The Mabs also reacted with several protein bands 
of various molecular weights, however none of these 
appeared to be the same size (109 kDa) as that seen with 
the HK 361 antigen.
To assess whether indeed the Mabs raised against the 120 
kDa pleurotoxin were also cross-reacting with the 
haemolysin II (109 kDa), the Mabs were screened against 
antigen material from an E . coli strain in which the 
haemolysin II had been cloned (available within the 
laboratory). All 5 Mabs (GJMC-1 to 5) were found to 
react with the cloned 109 kDa haemolysin II (Fig. 7.5). 
The negative controls, which consisted of the E . coli 
antigen which did not possess the cloned Hly II, did not 
show a reaction when screened against one of the GJMC-1 
to 5 Mabs raised against the 120 kDa pleurotoxin. Other 
controls included screening both the cloned Hly II and 
the host E. coli antigen with immune pig serum which 
resulted in a positive and negative reaction 
respectively.
The Mab (GJMC-6 ) raised against the 109 kDa haemolysin 
II protein was tested in the same way with cloned 109 
kDa Hly II and was found to react with it (Fig. 7.5). 
The Mab GJMC-6 was then tested against bacteria-free 
culture supernatant from both HK 361 and mutant e to
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Fig. 7.5 Western blot reactions of Mabs with cloned 109 
kDa haemolytic protein.
E . coli host producing cloned 109 kDa haemolytic protein 
from A. pleuropneumoniaei
1) Mab GJMC-1
2) Mab GJMC-2
3) Mab GJMC-3
4) Mab GJMC-4
5) Mab GJMC-5
6 ) Mab GJMC-6
7) Positive control immune pig serum (1/200)
8 ) Negative control preimmune pig serum (1/200)
E . coli host antigen, negative control
9) Mab GJMC-2
10) Mab GJMC-6
11) Positive control immune pig serum (1/200)
12) Negative control preimmune pig serum (1/200)
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assess any cross reactivity of GJMC-6 with the 120 kDa 
pleurotoxin present in both these antigen preparations. 
Culture supernatant from mutant h was used as a negative 
control. This Mab raised against the 109 kDa haemolytic 
protein was also found to cross-react with a protein of 
120 kDa molecular weight present in both HK 361 and 
mutant e antigen preparations (Fig. 7.6).
The 120 kDa pleurotoxin protein had also been 
sucessfully cloned within this laboratory (available 
within the laboratory) and this was used to screen for 
conclusive reactivity of the GJMC-6 Mab (Hly II) against 
120 kDa pleurotoxin. The GJMC-6 Mab was found also to 
react with the cloned 120 kDa pleurotoxin (Fig. 7.7).
Mabs raised against both the 109 kDa haemolysin II 
protein, (GJMC-1, GJMC-2, GJMC-3, GJMC-4 and GJMC-5), 
and the 120 kDa pleurotoxin (GJMC-6 ), were used to 
screen for the possible presence of similar cross­
reacting haemolytic and cytotoxic activities in culture 
supernatant from the 12 reference serotypes together 
with related pathogens from which toxic activities had 
been reported.
The Mab GJMC-2, raised against the 120 kDa pleurotoxin, 
cross-reacted with proteins of a similar size in 
serotypes 2,3,4,6 and 8 (Fig. 7.8). This Mab also 
reacted with protein in the 109 kDa size range in all 
serotypes except 2 (Fig. 7.8). In serotype 1, 5 and 9 
there was a thick band around the 109 kDa location in 
certain blots which appeared to demonstrate 2 closely 
related bands. Cross-reacting proteins were also 
detected in related pathogens E. coli, A. suis, A. 
equuli and P. haemolytica but not H . parasuis. Mab GJMC- 
2 reacted with proteins in the molecular weight range of 
102 (P. haemolytica) to 107-109 kDa (E . coli, A. suis
and A. equuli).
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Fig. 7.6 Western blot analysis of the cross-reactions
of Mabs GJMC-2 to GJMC-6 with HK 361, mutant e
and mutant h antigens.
Mab GJMC-2 (raised against 120 kDa protein):
1) HK 361 antigen
2) Mutant e antigen
3) Mutant h antigen
Mab GJMC-6 (raised against 109 kDa protein);
4) HK 361 antigen
5) Mutant e antigen
6 ) Mutant h antigen
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Fig. 7.7 Western blot reaction of Mab GJMC-6 (raised 
against 109 kDa protein) with cloned 109 and 
120 kDa proteins.
1) Mab GJMC-6 reaction with cloned 120 kDa cytotoxic 
protein from A. pleuropneumoniae
2) Mab GJMC-6 reaction with cloned 109 kDa haemolytic 
protein from A. pleuropneumoniae
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Fig. 7.8 Western blot assessment of proteins present in 
the bacteria-free culture supernatants of A. 
pleuropneumoniae reference serotype strains 
and related pathogens reacting with a Mab 
GJMC-2 raised against the 120 kDa cytotoxic 
protein from A . pleuropneumoniae serotype 2 
strain HK 361.
Numbers 1-12 represent the serotype reference stains of 
A. pleuropneumoniae. Related pathogens are denoted by 
their name. The control was HK 361.
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Similarly Mab GJMC-6 , raised against the 109 kDa
haemolysin II protein, reacted with proteins of the same 
molecular weight in all serotype except 2 (Fig, 7,9), As 
with Mab GJMC-2, Mab GJMC-6 also detected what appeared 
to be 2 bands closely related in serotypes 1, 5 and 9. 
It also reacted with proteins in the 120 kDa weight
range in serotypes 2,3,4,6 and 8 (Fig. 7.9).
Mab GJMC-6 also reacted with proteins in the molecular 
weight range of 102-109 kDa in related pathogens E • 
coli, A. suis, A. equuli and P. haemolytica (Fig. 7.9).
To ensure that the Mabs were reacting with all the 109 
and 120 kDa protein present, the bacterial culture
supernatant of the 12 serotype reference strains and 
related pathogens were assessed by both the silver stain 
method for detection of total protein and Western blot 
assessment followed by probing with immune pig serum 
(against serotype 3 strain, 6664). Both the silver 
staining and screening via immune pig serum gave 
identical results for the presence of 109 and 120 kDa 
protein bands. The reactions of immune pig serum was 
comparable to that with Mabs GJMC-2 and GJMC-6 in that 
proteins in the 109 kDa range were present in all 
serotype except 2 and 120 kDa protein was present in
serotype 2,3,4,6 and 8 (Fig. 7.10). The reaction of 
immune pig serum with all the proteins present in the 
silver stain gel demonstrated cross-reactivity of the 
immune pig serum with all the the haemolytic and 
cytotoxic proteins present in the A. pleuropneumoniae 
serotype specific strains. Cross reaction was also seen 
in the 102-109 kDa range with all the related pathogens 
except H. parasuis (Fig. 7.10). The presence of similar 
cross-reacting proteins in the 12 serotype reference 
strains is summarised in Table 7.1.
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Fig. 7.9 Western blot assessment of proteins present in 
the bacteria-free culture supernatants of A. 
pleuropneumoniae reference serotype strains 
and related pathogens reacting with a Mab 
GJMC-6 raised against the 109 kDa haemolytic 
protein from A. pleuropneumoniae serotype 2 
strain HK 361.
Numbers 1-12 represent the serotype reference stains of 
A. pleuropneumoniae• Related pathogens are denoted by 
their name. The control was HK 361.
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Fig. 7.10 Western blot assessment of proteins present in 
the bacteria-free culture supernatants of A. 
pleuropneumoniae reference serotype strains 
and related pathogens reacting with immune pig 
serum from A. pleuropneumoniae serotype 3 
strain 6664.
Numbers 1-12 represent the serotype reference stains of 
A. pleuropneumoniae. Related pathogens are denoted by 
their name. The control was HK 361.
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7.3.5 Toxin neutralisation tests
All 6 Mabs were found not to neutralise either the 
haemolytic or cytotoxic activity even when neat 
hybridoma supernatant was used (Table 7.2). This was in 
contrast to immune pig serum which was found to possess 
strong neutralising activity against both haemolytic and 
cytotoxic activities (Table. 7.2).
7.4 DISCUSSION
In the 3 year period between the beginning and end of 
the experimental work described in this thesis, there 
had been an enormous amount of literature reported on 
the haemolytic and cytotoxic activities of A.
pleuropneumoniae. The information available at the
beginning of the work described here was that a protein 
of 105 kDa had been identified as the haemolysin of A. 
pleuropneumoniae. On the basis of different requirement 
for Ca++, 2 different haemolysins were designated, Hly I 
and Hly II (Frey & Nicolet, 1990). These 2 haemolysins
were shown to be immunologically related but possessed
distinct activities following the observation that 
polyclonal rabbit serum raised against Hly I from a
serotype 1 strain cross-reacted with the Hly II from a
serotype 2 strain as shown by Western blotting. However, 
the Hly II activity could not be neutralised by
polyclonal rabbit serum raised against Hly I, but could 
be neutralised by convalscent pig serum from a serotype 
1 strain. In contrast immune pig serum from a serotype 2 
infection however could not neutralise the Hly I 
activity.
Other studies using the same serotype 1 strain reported 
both haemolytic and cytotoxic activity for a range of 
pig cells that appeared to be associated with a 130 kDa 
protein along with several smaller molecular weight 
proteins (Udeze & Kadis, 1988). Haemolytic activities
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Pig Serum Anti-haemolytic
activity
Anti-cytotoxic
activity
Convalescent 256 128
Normal 8 8
Monoclonal
Antibody
GJMC-1 <2 <2
G JM C -2 <2 <2
G JM C -3 <2 <2
G JM C -4 <2 <2
G JM C -5 <2 <2
G JM C -6 <2 <2
Table 7.2 -  Reciprocal dilution of antibody source 
required for neutralisation of 
haemolytic and cytotoxic activity.
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were found in strains from 12 serotypes associated with 
a 104 kDa protein and were showed to be immunologically 
related but possessed differences in activity (Devenish 
et al,, 1989). In this laboratory both 109 and 120 kDa 
proteins were identified in strains from serotype 2,3 
and 4 that were associated with both haemolytic and 
cytotoxic activity. The isolation of a serotype 2 mutant 
that secreted the 120 kDa protein only, and possessed 
cytotoxic but not haemolytic activity, and a mutant, h, 
which was negative in both the 109 and 120 kDa proteins 
and did not secrete cytotoxic or haemolytic activity, 
suggested the cytotoxin of this strain was associated 
with a 120 kDa protein. This together with the 
observation that polyclonal serum raised against the 120 
kDa protein neutralised cytotoxic but not haemolytic 
activity, suggested that the cytotoxic activity, 
associated with the 120 kDa protein, was distinct from 
the haemolysin in these strains.
Although similar proteins to the 109 kDa haemolysin had 
been reported by other researchers (104 and 105 kDa; 
Devenish et al., 1989; Frey & Nicolet, 1990), the
appearance of the non-haemolytic 120 kDa cytotoxic 
protein had not.
The cross-reactivity of the Mabs produced individually 
against the 109 kDa Hly II and the 120 kDa Pleurotoxin 
with both the 109 and 120 kDa proteins demonstrated that 
in fact these 2 proteins appeared to be immunologically 
related (Fig.7.6). The intensity of reaction of each Mab 
was stronger for the immunising antigen than for the 
cross-reacting antigen (Fig. 7.6). This was in contrast 
to that seen with the polyclonal rabbit serum described 
by co-workers who did not detect cross-reaction with the 
109 kDa protein. However the concentration of antigen 
described in this chapter was much greater that that 
used in the previous study, and further assessment of 
the polyclonal serum used in that study (Rycroft et al.,
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1991) with the antigen preparation used here, 
demonstrated that in fact the polyclonal rabbit serum 
raised against the 120 kDa protein did cross-react with 
the 109 kDa protein. This suggested that although the 2 
proteins appeared to be distinct in activity, they were 
immunologically related. Similarly the previous reaction 
seen with the original Mab produced against the 109 kDa 
protein, which was used as part of the immunising 
complex in an attempt to elicit a stronger reaction, 
also appeared to react only with the 109 kDa protein. 
However this reaction was weak and in hindsight the 
antigen concentration used in those previous 
examinations would not have been high enough to detect 
any possible cross reaction.
Around this time other researchers had also noted the 
presence of a 120 kDa protein in the culture supernatant 
from a different strain of serotype 2 of A .
pleuropneumoniae. They proposed that the 120 kDa protein 
was the cytotoxin and that the 105 kDa was its inactive 
form (Kamp et al., 1990). Following the successful 
cloning of both the 109 and 120 kDa proteins within this 
laboratory by co-workers, it was conclusively shown that 
the the 109 kDa protein was not a breakdown product of 
the 120 kDa, and that, in fact, they were 2 distinct 
proteins. They did however share some degree of 
immunological relatedness as demonstrated by the cross­
reactivity of the Mab raised against the 109 Hly II
protein, GJMC-6 , to both the cloned 109 and 120 kDa 
proteins, and similarly the cross reaction of Mab GJMC- 
1-5 raised against the 120 kDa pleurotoxin, to both the
cloned Hly II and Ptx (Fig. 7.5, 7.7).
The presence of a 120 kDa protein had been previously 
reported within this laboratory in serotypes 2, 3, and 
4. Following the analysis of all the serotypes by Mabs, 
immmune pig serum and silver staining, the 120 kDa 
protein was found in serotypes 2, 3, 4, together with 6
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and 8 (Figs. 7.8, 7.9, 7.10). Other groups also had
recently reported the presence of a 120 kDa protein in 
serotypes 2, 3, 4 and 8 but not 6 (Kamp et al., 1991). 
The presence of a 120 kDa protein in these serotypes, 
including 6 , was confirmed by DNA hybridisation 
experiments within this laboratory that showed the gene 
encoding for this protein to be in serotypes 2 ,3,4,6 and 
8 . The presence of a potent cytotoxin in serotype 6 was 
unexpected because it had been found to produce little 
or no cytotoxic activity in vitro (Pijoan, 1986; Kamp & 
van Leengoed, 1989). This highlighted the differences 
that were being experienced by all researchers in this 
field who found a varying range of activities from the 
same strains. The method of culture appeared to be 
important in the expression of both haemolytic and 
cytotoxic proteins due to their fast biodegradability 
once secreted by the organism.
The Mabs and immune pig serum detected the presence of a 
109 kDa protein in all serotypes (Fig. 7.8, 7.9, 7.10). 
This had previously been reported by others who found 
the corresponding 104 or 105 kDa protein in all
serotypes (Devenish et al., 1989, Frey & Nicolet, 1990). 
It had also been previously reported that Hly I and Hly 
II were immunologically related and therefore following 
the detection of Hly II 109 kDa protein, in all
serotypes that possessed either Hly I or Hly II or both, 
it was shown that the Mabs against Hly II also cross­
reacted with Hly I.
Other researchers had also raised Mabs against the
culture supernatant from a serotype 2 strain and also 
against a serotype 9 strain (Kamp et al., 1991). They 
found the presence of 3 different proteins in the 12 
serotypes. A 103, 105 and 120 kDa protein. The 103 kDa 
protein was proposed to be Hly II, the 105 kDa to be Hly 
I and the 120 kDa protein, to be the equivalent of the 
pleurotoxin reported here. These researchers found the
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Hly I (105 kDa) to be present in serotypes 1, 5, 9, 10 
and 11, Hly II (103 kDa) in all serotypes except 10 and 
the equivalent of Ptx (120 kDa) in serotypes 2,3,4 and 
8 . The location of the closely related 103 and 105 kDa 
proteins in serotypes 1,5,9 and 11 correlates at least 
in part to the thick band that appeared in certain blots 
to be two closely related proteins in serotypes 1,5 and 
9 (Fig. 7.10). The closeness of these bands explains why 
it is very difficult to distinguish them.
The panel of Mabs from the study by Kamp et al. (1991) 
reacted with either the Hly I, or Hly II or the Ptx. 
Only one Mab reacted with both the Hly I and Hly II. 
This suggested that only Hly I and II possessed cross 
reactive epitopes. However here it has been shown that 
all 3 protein possess similar cross reactive epitopes. 
The Mabs in that study were found to possess 
neutralising abilities against the reacting antigen. The 
Mabs described in this chapter did not possess any 
neutralising abilities and therefore it would appear 
that these Mabs have been raised against a common, but 
not neutralising, epitope.
The cross-reaction of both Mabs with related pathogens 
confirm the relatedness of the toxins of A. 
pleuropneumoniae with other Gram-negative bacteria. DNA 
studies have also confirmed this recently and found the 
toxins of A . pleuropneumoniae (Hly I and II) to be 
members of the RTX (repeat in structural toxin) toxin 
family (Chang et al., 1989; Frey et al., 1991) along 
with alpha-haemolytic E. coli, A. suis, A. equuli and P. 
haemolytica. H. parasuis has not been reported to be a 
member of the RTX secreters and non-detection of any 
cross-reactive proteins is therefore in agreement with 
this (Fig. 7.8, 7.9, 7.10).
The reduction in the antibody levels of Mab GJMC-5 was 
perhaps due to non-secreting cells overgrowing the
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secreting cells. This appearance of non-secreting clones 
can be due to these clones having a genetic
rearrangement and the vital genetic material for 
specific antibody production being thrown out. The 
solution to this is to continually test clones and to 
perform dilution cloning to detect any non-secreting 
sub-groups.
In summary the results reported here are in agreement 
with those reported by others with a few minor
differences. Kamp et al. (1991) reported the presence of 
a weak 103 kDa protein together with a 120 kDa protein 
in the serotype 2 reference strain. The haemolytic 
activity of the strain has previously been found to be 
very weak (Frey & Nicolet, 1990). The presence of a
strong 109 kDa (equivalent to 103 kDa) band has been
found in other serotype 2 strains at lesser
concentrations of antigen within this laboratory and 
therefore the difference between these strains and the 
serotype 2 reference strain may be due to the quantity 
produced by individual strains. The presence of a 120 
kDa protein in serotype 6 also contrasted with the 
results reported here and those of Kamp et al, (1991). 
However it was confirmed by DNA hybridisation
experiments within this laboratory (MacDonald & Rycroft, 
1992). It therefore appears that each serotype of A. 
pleuropneumoniae possesses at least 1 of the 3 toxic 
proteins. The activities of the 3 toxins have been
further analysed by Kamp et al, (1991). The Hly I (105 
kDa) is strongly haemolytic and cytotoxic, the Hly II 
(103 kDa, 109 kDa in this laboratory) is weakly 
haemolytic with moderate cytotoxic activity, and the 
equivalent of the 120 kDa Ptx reported here, was
strongly cytotoxic with no haemolytic activity. The 
presence of these toxins in all serotypes of A, 
pleuropneumoniae helps to explain why the 12 serotypes 
are all capable of producing the same pattern of disease 
(Nielsen, 1986a; Rosendal et al., 1985; Sebunya and
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Saunders, 1983). The differences in virulence between 
the serotypes may be due to the differences in the type 
and/or amount of toxin produced.
The cross-reactivity of the Mabs described here for 
related pathogens is similar to that seen by others 
using a polyclonal serum against the haemolysin of 
serotype 1 (Devenish et al., 1989). The lack of 
specificity of these Mabs for A. pleuropneumoniae, rules 
out the potential use of these Mabs to screen 
specifically for A. pleuropneumoniae infection.
2 11
IGENERAL DISCUSSION
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The specific aims of this study were to examine the 
interaction of the pig's host defences against A • 
pleuropneumoniae. Clinical signs can occur within 4 
hours post infection. The rapid onset of clinical signs, 
together with the severity of the disease, suggest that 
the natural defences of the non-immune pig have little 
or no effect against A . pleuropneumoniae. Two of the 
major host defences available to fight against infection 
are the complement and phagocytic systems. The role of 
these 2 host defence systems in the control of A. 
pleuropneumoniae was therefore assessed. The first aim 
was to examine the effect of the complement system 
against A, pleuropneumoniae, which had been previously 
unexplored.
The results in Chapter 3 describe how A . 
pleuropneumoniae was found to be resistant to both 
normal and immune pig serum. This suggested the presence 
of specific antibody did not sensitise A . 
pleuropneumoniae to the bactericidal effects of 
complement. During this period other researchers also 
found different strains of A. pleuropneumoniae to be 
resistant to immune pig serum (Inzana et al., 1988; 
Udeze & Kadis, 1992). One of the reasons proposed for 
the serum resistance of A . pleuropneumoniae was the 
possession of a capsule (Inzana et al., 1988). Capsules
have been described to aid the resistance of bacteria to 
complement by inhibiting complement activation (Kasper, 
1966) .
The results presented in this chapter also suggest that 
the outer membrane may be important in the resistance of 
A. pleuropneumoniae to complement bactericidal activity 
since A. pleuropneumoniae could not be sensitised to 
complement following treatment with a membrane 
disorganising chemical, polymyxin B. It therefore 
appears that both the capsule and the outer membrane are 
perhaps involved in the serum resistance.
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The work described in Chapters 4 and 5 describes 
attempts to define the exact mechanism used, by which A . 
pleuropneumoniae avoids complement bactericidal 
activity. Bacteria employ a range of mechanisms to avoid 
the detrimental activities of complement (Joiner, 1988). 
One of these methods includes non-activation of 
complement. The results presented in Chapter 4 suggest 
that this is not the case with A. pleuropneumoniae. High 
percentages of complement activity were consumed via 
both the classical and the alternative pathways by all 
strains of A. pleuropneumoniae tested. This is in 
agreement with other researchers who have since found
that different strains of A. pleuropneumoniae also 
consume complement activity (Udeze & Kadis, 1992). The 
possession of a capsule by A. pleuropneumoniae therefore 
did not appear to prevent complement activation. It has 
been shown in other bacteria that possession of a 
capsule does not always block subcapsular activation by 
LPS (van Dijk et al., 1979). Udeze and Kadis (1992)
found that the amount of complement activity consumed 
increased when increased amounts of immune pig serum
were added to pig serum previously absorbed with A.
pleuropneumoniae. Up to 100% complement consumption was 
seen in the presence of 2.5% immune serum. Normal pig 
serum was also found to increase the amount of 
complement consumed but to a lesser extent than immune 
serum. This suggested both specific and non-specific 
antibodies function to increase complement consumption. 
It is reported in this thesis that high complement 
consumption rates occurred in the presence of normal pig 
serum which did not contain any detectable specific 
antibodies to A. pleuropneumoniae. This may suggest the 
presence of specific antibody against A. 
pleuropneumoniae is not a prerequisite for high 
complement consumption.
Consumption of complement activity does not always 
result in activation of complement as described in
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Chapter 4. However it was shown that complement 
component C3 was in fact activated. This demonstrated 
that both consumption and activation of complement was 
occurring at least up to the C3 stage. Other researchers 
have demonstrated bound C3 on the surface of a serotype 
1 strain 4074 suggesting that C3 was also activated 
(Udeze & Kadis, 1992).
Knowing that the lack of complement activation was not 
the mechanism used by A. pleuropneumoniae to avoid 
complement-mediated activity, other mechanisms were 
investigated. Serum resistant bacteria can also avoid 
complement damage by releasing molecules that can
activate, deplete or destroy complement components
(Joiner, 1988). These mechanisms may or may not depend 
on bacterial viability. In Chapter 5 the ability of 
viable and non-viable bacteria to consume complement was 
assessed and only viable bacteria were found to consume 
complement activity. This suggests the factor(s) 
responsible for consumption of complement was produced 
only by viable A, pleuropneumoniae. The secreted 
products of metabolism, which include toxins produced by 
A . pleuropneumoniae, were next assessed for consumption 
of complement activity. However, it was found that 
bacteria-free culture supernatant, which possessed
haemolytic activity, did not consume complement 
activity. At that time only the haemolytic activity 
associated with a 109 kDa protein (haemolysin II) had 
been identified from these strains. Later, a potent 
cytotoxin (pleurotoxin, Ptx), that possessed no 
haemolytic activity, was also found to be secreted by 
these same serotypes used in Chapter 5. The preparations 
used in Chapter 5 would have also contained cytotoxic 
activity as determined by later experiments using 
identical growth conditions. It can therefore be 
concluded that Hly II and Ptx, are not responsible for 
the consumption of complement activity.
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There are numerous other ways in which complement
bactericidal activity can be avoided and these include 
incorrect formation or insertion of the complement
membrane attack complex (MAC)• Alternatively, both 
completion of the complement cascade and correct
formation of the MAC may occur, but are prevented from 
causing lethal damage by perhaps the capsule or outer 
membrane of A . pleuropneumoniae. These other options of 
complement resistance can only be studied when 
sufficient pig complement components have been purified 
and antisera raised in order to study the complement
cascade in detail.
Although the specific mechanisms utilised by A. 
pleuropneumoniae to avoid complement damage are still 
not known, it has been shown by this study that the lack 
of complement damage is not due to non-activation of 
complement activity at least to component C3. It has 
also been demonstrated that a component(s) of viable A. 
pleuropneumoniae is required to consume complement 
activity and the component(s) responsible is not one of 
the secreted toxins of A. pleuropneumoniae.
Other researchers have proposed that the mechanism of 
complement resistance in A. pleuropneumoniae involves 
non-specific antibody present in both non-immune and 
immune pig serum (Udeze & Kadis, 1992). This has been 
suggested to block the bactericidal activity of 
complement. In agreement with the results shown here, it 
was found that A. pleuropneumoniae was resistant to both 
normal and immune pig serum and consumed up to 1 0 0% of 
the complement activity. They also found that non-immune 
pig serum absorbed with A. pleuropneumoniae was lethal 
for A. pleuropneumoniae when purified specific antibody 
was added into the system. The non-immune serum used in 
that study reacted with almost all of the proteins found 
in A. pleuropneumoniae as determined by Western 
blotting. In contrast the pre-immune serum described in
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this thesis did not possess any reactive antibody 
against A. pleuropneumoniae and did not kill A • 
pleuropneumoniae. Although the preimmune serum described 
in this thesis did not possess reacting antibody against 
A. pleuropneumoniae, and therefore so called "blocking 
antibody" would not be present, the presence of purified 
specific antibody against A . pleuropneumoniae is perhaps 
required to detect killing. Only one serotype strain was 
studied by Udeze and Kadis (1992) and until more 
serotypes are analysed, and the strains used in this 
study are assessed by the same method, this mechanism of 
serum resistance for the strains used here cannot be 
confirmed.
The second aim of the work was to define the role of 
phagocytic cells in the presence of toxins produced by 
A. pleuropneumoniae. Chapter 6 detailed the effect of 
the secreted toxins of A. pleuropneumoniae on the 
ability of pig alveolar macrophages to phagocytose. Only 
mutant h, which was deficient in both Hly II and Ptx, 
was found not to cause damage to alveolar macrophages 
and to be phagocytosed in large numbers, but only in the 
presence of immune pig serum. Heat or formaldehyde- 
treated mutant h was phagocytosed readily in the 
presence of normal pig serum demonstrating that specific 
antibody was not required for the phagocytosis of A. 
pleuropneumoniae as previously thought (Udeze & Kadis, 
1988; Thwaits & Kadis, 1991). Immune serum was required 
however to neutralise the toxic activity to allow the 
survival of the phagocytic cells and to enable them to 
phagocytose. The results reported in the thesis 
therefore demonstrate the mechanism used by A. 
pleuropneumoniae to avoid phagocytosis is by secreting 
toxins which kill alveolar macrophages.
The final chapter investigated the relationship between 
the 2 toxic activities associated with a serotype 2 
strain (Hly II and Ptx) and to assess the presence of
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similar proteins in the serotype reference strains of A . 
pleuropneumoniae. The presence of 1 or more cross­
reactive proteins in all 12 serotypes demonstrated a 
common property of A. pleuropneumoniae strains. 
Reactivity of Mabs with proteins that were later found 
to correspond to Hly 1, Hly II and Ptx, demonstrated all 
toxins were in fact immunologically related. This result 
appears to differ from those of other researchers who 
found that the majority of Mabs reacted only with either 
the Hly I or Hly II or Ptx and only 1 Mab reacted with 
both Hly I and Hly II (Kamp et al., 1991). A more recent 
report using Mabs raised against either the haemolysin 
from serotype 1 or serotype 2 , found that they reacted 
with only one of the 3 toxins produced by A. 
pleuropneumoniae (Frey et al., 1992). Polyclonal rabbit 
serum also reacted only with the haemolysins used as the 
immunising antigen. The Mabs described in Chapter 7 do 
not neutralise haemolytic or cytotoxic activity in 
contrast to those reported by Kamp et al. (1991) and 
perhaps this could explain the differences in cross 
reaction. However, Mabs produced by Frey et al., (1992) 
also did not neutralise any toxic activity and did not 
cross-react with the other 2 toxins.
The results presented here show that all 3 toxins do 
possess cross-reactive epitopes and the reasons for the 
lack of detection by others may be due to either the 
Mabs being raised against different epitopes or the 
concentration of antigen preparation used in Western 
blotting, which may not have been sufficient to allow a 
positive reaction. It has also been shown in this thesis 
that immune serum raised against a serotype 3 infection 
cross-reacts with all 3 toxins. This serum was raised 
against a strain producing both Hly II and Ptx and 
therefore suggests that these antibodies are also able 
to cross-react with the third toxin not produced by that 
strain. A degree of relatedness between the 3 distinct 
toxin patterns has been confirmed by DNA sequencing and
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hybridisation studies. These results have recently been 
summarised by Frey et al., (1993). The 3 toxins have now 
been characterised in terms of their activities and the 
serotypes which possess them. Due to several groups 
working simultaneously on the characterisation, several 
different designations were used, however this has now 
been standardised (Frey et al,, 1993). The presence of 
the 120 kDa protein in serotype 6 described in this 
thesis has now been documented by others (Jansen et al,,
1992). The most recent published consensus of the 
distribution of the 3 RTX toxins in the 12 serotypes of 
A. pleuropneumoniae is summarised in Table 8.1.
The 3 toxins produced by A, pleuropneumoniae all belong 
to the RTX toxin family (Frey et al,, 1993). The 
haemolysins I, II and pleurotoxin described in this 
thesis are now designated Apx I, II and III 
respectively. Apx I is a 105 kDa protein and possesses 
strong haemolytic and cytotoxic activity and requires 
Ca++ for induction but not the expression of these 
activities; Apx II (103 kDa) is weakly haemolytic with 
moderate cytotoxicity and requires Ca++ for expression 
but not induction of activity; Apx III (120 kDa) is a 
strongly cytotoxic protein and possesses no haemolytic 
activity (Frey et al., 1993).
Although the toxins are likely to be important factors 
in pathogenicity and have been shown to be important
immunogens (Devenish et al., 1990a,b; Ma & Inzana, 1990; 
Frey & Nicolet, 1991; Rycroft et al., 1991), other
virulence factor are also likely to be involved since 
vaccination with these toxins alone does not always
prevent lung pathology, although they do prevent death 
and reduce the severity of the disease (Devenish et al., 
1990a; van den Bosch et al., 1992).
Recent vaccine studies using a combination of an outer 
membrane protein of 42 kDa, which was not further
219
Ta
bl
e 
8.1
 
Di
st
rib
ut
io
n 
of 
RT
X 
to
xi
ns
, 
Ap
x 
I, 
Ap
x 
II 
an
d
CVJ
r- *
T“
* *
o
T—
♦
0 )
* *
00 * *
*
CD * *
10 * *
* *
00 * *
CM * *
T- * *
co
o
a
>*W"0
O
Urn
o
CO A
px Xa
<
X
a
<
220
characterised, and both Hly I (Apx I) and Ptx (Apx III), 
was found to prevent death (van den Bosch et al., 1992). 
In certain studies no lung lesions developed, however 
when a different challenge serotype was used, small lung 
lesions were detected. It seems that a multi-component 
vaccine may be the way forward, providing it possesses 
all the important immunogens.
It has been demonstrated that specific antibody is 
sufficient to allow full protection against disease. 
This has been shown in pigs receiving colostrum from 
infected sows or pigs passively receiving immune sera, 
being protected until the decline of the antibody. This 
suggests stimulation of antibody is sufficient to 
provide full cross protection. One way to assess which 
components of the bacteria are important in stimulating 
a protective immune response is to screen all antibodies 
produced following infection to determine their antigen 
specificity.
Certain antigens have been shown to be produced only 
under conditions that mimic those in vivo. These include 
those directed against iron repressible proteins (Deneer 
& Potter, 1989a; Niven et al., 1989; Gonzalez et al., 
1990; Ricard et al., 1991; personal observations). If
antibody detection systems used to determine the 
reacting antigen following infection do not contain
antigens that are only produced in vivo, then 
potentially important immunogens will not be assessed. 
It has been found that all 12 serotypes of A.
pleuropneumoniae produce iron repressible outer membrane 
proteins, many of which are of similar molecular weight 
(personal observations). Iron is one of the essential 
requirements of growing bacteria and many have developed 
systems to sequester iron from the host. A vaccine
containing a common iron repressible protein may 
therefore prevent the continued growth of bacteria. Pigs 
can also become carriers of A. pleuropneumoniae although
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they do not appear to suffer from the disease. These 
bacteria are able to remain in contact with the tonsils 
of healthy carrier pigs. Certain strains of A. 
pleuropneumoniae are reported to possess pili (Utrera & 
Pijoan, 1990). Another important immunogen may also 
contain pili which may block attachment of A. 
pleuropneumoniae. Stress and changes in climate, among 
other things, have been shown to promote outbreaks of 
disease perhaps originating from the carrier pigs. 
Isolation of carrier from the non-carrier pigs would 
also promote reduction in disease.
The prevention of disease due to A. pleuropneumoniae 
could therefore be angled in 2 ways. Firstly an 
effective screening system which can be used in the 
field prior to introdution of new pig stock into a clean X 
herd. The test would ideally be fast and simple to use 
and be able to screen against all serotypes of A. 
pleuropneumoniae without cross-reaction from related 
organisms. Secondly, an effective vaccine might include 
a mixture of the 3 toxins and a common iron repressible 
protein together with an adhesion factor. This would 
hopefully neutralise toxic activity, prevent any 
significant growth and reduce colonisation by the 
bacteria.
In summary the results presented in this thesis 
demonstrate that A. pleuropneumoniae is capable of 
avoiding the anti-bacterial effects of 2 major non­
specific humoral defences, the complement and phagocytic 
systems. This may help to explain why the disease can 
occur so quickly and violently in naive animals.
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APPENDIX
Chapter 3 buffers and solutions
Calcium chloride (30mM)
6 .573g CaCl2 .6H20
to 1L reverse osmosis (ro) H20. Filter sterilise and 
store at 4°C.
Magnesium chloride (lOOmM)
20.330g MgCl2 .6H20
to 1L roH20. Filter sterilise and store at 4°C.
Gelatin solution (10%)
lg gelatin
to 10ml roH20. Heat to 56°C to dissolve and filter 
sterilise. Store at 4°C.
Buffer M
8g NaCl 
0.2g KCL
2.9g Na2HPO4 .12H2 0 
0.2g KH2P04
to 900ml roH20 and heat sterilise. Once cool add in:
10ml gelatin 
5ml 30mM CaCl2 
lml lOOmM MgCl2
to 1L roH20 r pH7.4. Store at 4°C.
Chapter 4 buffers and solutions
Reagents were kept cold unless otherwise stated. All 
experiments were performed using glassware except for 
centrifugation procedures.
Functional haemolvtic complement assay stock solutions
Veronal-buffered saline x5 (VBS)
Solution A
85.Og NaCl
3.75g NaCQHiiN203
to 1L ro H20
Solution B
5•75g CqHi2N203
to 600ml roH20 by vigorous stirring on a heated plate. 
Mix solutions A and B and adjust to 2L roH20. pH 7.4- 
7.6. Store at 4°C for 1 month.
Isotonic EDTA (86mM/l)
Solution A
89.338g Na2H2 EDTA
to 1.5L roH20, then to 2L. pH 4.5.
Solution B 
24g NaOH
to 1.5L roH20, then to 2L. Add solution A to B until pH 
between 7.2-7.6 .
Calculate final molarity of the EDTA by:
starting volume EDTA divided by starting volume EDTA 
plus volume NaOH and this figure multiplied by 0.12. 
Store at 4°C for 1 month.
EGTA (lOOmM)
38•04g EDTA
to 500ml roH^O. pH 7.4 with 10M/L until EDTA dissolved. 
Adjust to 1L roH20. Store at 4°C for 1 month.
10% Gelatin
lOg gelatin
to 100ml roH20 on heated plate. Store at 4°C. Redissolve 
in boiling water.
Calcium chloride (30mM/L)
3.286g CaCl2.6H20
to 500ml roH20. Store at 4°C.
Magnesium chloride (lOOmM/L)
10.165g MgCl2.6H20
to 500ml roH20. Store at 4°C.
Isotonic veronal-buffered saline containing gelatin and 
cations (GVB^+)
200ml 5 x VBS 
10ml MgCL2 (100mM/1)
5ml CaCl2 (30mM/l)
10ml 10% gelatin
Add gelatin to 100ml roH20 at room temprerature. Add 
other reagents and roH20 to 1L. Store at 4°C, prepare 
fresh twice weekly.
Isotonic veronal-bufjered saline containing gelatin but 
without cations (GVB“).
200ml 5 x VBS 
10ml 10% gelatin
Melt gelatin in boiling water and add to 100ml roH20 
prior to adding to 5 x VBS. Make to 1L. Store at 4°C, 
prepare fresh twice weekly.
VBS-EGTA
20ml 5 x VBS 
10ml EGTA (lOOmM/L)
7ml MgCl2 (100 mM/L)
to 100ml roH20. pH 7.4-7.6. Store at 4°C, prepare fresh 
daily.
Isotonic dextrose without cations (D5W~)
50g D-glucose
to 1L roH20. Store at
4°C, prepare twice weekly.
Mg-EGTA
10ml EGTA (lOOmM/L)
7ml MgCl2_(100mM/L)
83ml DGVB“ (3 parts D5W” :1 part GVB“)
pH 7.4-7.6. Store at 4°C, prepare fresh daily.
EDTA (10mM/l) GVB=)
58ml 0.086 M/L EDTA 
442ml GVB”
Store 2-4°C, prepare twice weekly.
Alsever's solution
41g D-glucose 
16g Na3C6H507•2H20 
8.4g NaCl
0.8g citric acid (anhydrous)
to 1L roH20. pH 6.0-6.5. Store at 4°C for several weeks. 
Immunoelectrophoresis stock solutions
Tank buffer
17.Og NaC8H n N 203 
23.5ml HCL (1M)
to 1L roH20, pH 8.4. Dilute 1:2 with roH20 before use.
Slide buffer 
4.5g NaCgHnN203 
11.65ml EDTA (86mM)
32.5ml NaOH (lOOmM) 
to 500ml roH20, pH 8.4.
Agar solution
A 1.2% agar (High EEO, Sigma) solution was prepared by 
dissolving 1.2g of agar in 100ml of slide buffer. The 
solution was heated in a microwave until molten.
Chapter 5 buffers and solutions
Haemolysin assay buffer
6g tris/HCL 
8.8g NaCl 
2.5g CaCl2
To 1L roH20. pH 7.2.
150mM NaCl 
8.8g NaCl 
To 1L roH20.
Chapter 6 buffers and solutions
10% Gelatin
lOg gelatin
to 100ml roH20. Warm until dissolved. Filter (0.2pm) 
sterilise, aliquot and store refridgerated. Heat to melt 
before use.
0.5% Gel-HBSS
25ml Gelatin (10%)
500ml HBSS
pH to 7.3 with 7.5% sterile Na2C0 3 . Store 4°C.
Chapter 7 buffers and solutions
1M CaCl2
11.lg CaCl2
to lOOmls roH20. Dilute 1/100 to achieve lOmM solution.
SDS-PAGE Stock solutions
1.5M Tris-HCL 
27.23 g tris
to 80ml roH20. Adjust to pH 8.8 with IN HCL. Make to
150ml roH20 and store at 4°C.
0.5M Tris-HCL
6g tris
to 60ml roH20. Adjust to pH 6.8 with IN HCL. Make to
100ml with roH20 and store at 4°C.
20% SDS
20g SDS
to 100ml roH20. Heat gently to dissolve.
Sample buffer
1.8ml 1M tris-HCL pH 6.8
3ml 20% SDS
3ml glycerol
1•5ml mercaptoethanol
0.2ml 0.05% Bromophenol blue
to 10ml roH20. Store at 4°C.
Electrode running buffer x5 
9.0g tris 
43.2g glycine 
3.0g SDS
to 600ml roH20. Store at 4°C. Dilute 1:5 with roH20 
before use.
Mini-Protean II Cell system
Acrylamide/PDA (30% T, 4% C)
87.6g acrylamide
2.4g piperazine di-acrylamide
to 300ml roH20. Filter (0.44pm) and store at 4°C in the 
dark for a maximum of 1 month.
Stacking gel - 4%
2.5ml 0.5M tris-HCL, pH6.8 
lOOpl 10% SDS
1.3ml acrylamide/PDA solution 
6.1ml roH20
Mix and degas under vacuum in a desiccator for 15 
minutes. Immediately before pouring add 50pl 10% (w/v)
ammonium persulfate (fresh daily) and lOpl N,N,N','N'- 
Tetramethylethylene-diamine (TEMED).
Separating gel - 10%
2.5ml 1.5M tris-HCL 
lOOpl 10% SDS
3.3ml acrylamide/PDA solution 
4.1ml roH20.
Mix and degas under vacuum in a desiccator for 15 
minutes. Immediately before pouring add 50pl 10% 
ammonium persulfate and 5pl TEMED.
10% SDS
lOg SDS
to 100ml roH20. Heat gently to dissolve.
Standard Gel System
Separating gel
18ml acrylamide/PDA solution 
16.8ml 1M tris-HCL, pH 8.7 
225pl 20% SDS 
10ml roH20
Mix and degas under vacuum in a desiccator for 15
minutes. Immediately before pouring add 150pl 10%
ammonium persulfate and 38pl TEMED.
Stacking gel
2.4ml aerylamide/PDA solution 
1.25ml tris-HCL, pH 6.8 
50pl 20% SDS 
6.35ml roH20
Mix and degas under vacuum in a desiccator for 15
minutes. Immediately before pouring add 50pl 10%
ammonium persulfate and 15pl TEMED.
ELISA Stock solutions
Coating buffer
1•59g Na2C03 
2.93g NaHC03 
to 1L roH20, pH 9.6.
Tris buffered saline xlO
42.075g NaCl 
15.14g tris/HCL 
0.475g MgCl2 
to 500ml roH20, pH 8.0.
Wash buffer
Tris buffered saline x 1 plus 0.1% Tween 20.
Blocking solution
Wash buffer plus 2% marvel dried skimmed milk. Store at 
4°C, keep for 1 day.
Western blotting, Stock solutions
NT
1.21g tris/HCL 
8.7g NaCl
to 1L dH20, pH 8.0.
TNT
Nt plus 0.5ml tween 20 
TNT Blocking solution
TNT plus 10% skimmed milk. Store at 4°C, keep for 1 day.
Horseradish peroxidase substrate 
Solution A
30mg 4-chloro-l-napthol 
20ml cold methanol
Prepare fresh daily, store on ice protected from light.
Solution B
30pl cold H202
50ml NT (TNT-Tween 20)
Prepare immediately before use at room temprerature. Mix 
solution A and B and use immediately.
Antiserum
Goat anti-rabbit (Bio-rad) 1:3000 
Rabbit anti-pig (Sigma Ltd.) 1:3000 
Sheep anti-mouse (Sapu) 1:50
Monoclonal antibody production stock solutions
Tris-Triton X-100 buffer
2.4g tris
8.2g NaCl
0.2% triton X-100
To 1L roH20.
Immunoprecipitation buffer
18.99g NaCl 
1.436g tris 
0.186g EDTA 
2.5ml NP40[check ]
0.5g azide 
0.5g SDS 
to 500ml roH20.
Phosphate buffered saline
8.Og NaCl
0.2g KC1
1•15g Na2HP04
0.2g KH2P04
to 1L dH20, pH7•3.
White blood cell fluid
50ml glacial acetic acid 
2 0ml absolute alcohol 
to 1L dH20.
Aminopterin x 1000
0.016g aminopterin (Sigma Ltd.)
to 50ml roH20. Heat 4 5°C and add 0. 1M NaOH to dissolve. 
Make to 100ml roH20. Filter sterilise (0.2pm) and store 
at -20°C.
HAT x 50
0.34 0g hypoxanthine (Sigma Ltd.)
0.097g thymidine (Sigma Ltd.)
25ml aminopterin (X1000)
to 500ml PBS. Filter sterilise (0.2pm) and store at - 
20°C.
HT x 50
0.340g hypoxanthine 
0 .0 97g thymidine
to 500ml PBS. Filter sterilise(0.2pm) and store at -20°C
Penicillin/Streptomycin solution
10,000 U penicillin (Gibco) 
lOmg streptomycin (Gibco)
to 100ml roH20. Aliquot and store at -20°C.
L-Glutamine solution
30ml L-glutamine (Gibco)
to 100ml roH20. Aliquot and store at -20°C.
RPMI++
5ml penicillin/streptomycin solution 
5ml L-glutamine solution 
490ml RPMI 1640 (Gibco)
Incubate 37°C for 24-48 hours prior to use to ensure 
contamination free. Store at 37°C for a maximum of 2 
weeks.
RPMI+++
5ml penicillin/streptomycin solution 
5ml L-glutamine solution 
100ml foetal calf serum 
390ml RPMI 1640 
Store as above.
RPMI+++HAT
2ml HAT X50
to 100ml of RPMI+++. Store as above.
RPMI+++HT
2ml of HT X50
to 100ml RPMI+++. Store as above.
APPENDIX 2
Fig. 4.1a Immunoelectrophoretic patterns of human serum 
incubated in the absence of bacteria over time 
and developed with anti-human factor B.
Factor B activation fragments are denoted by Ba and Bb.
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Factor B depleted serum
Serum was incubated at 50°C in a water bath for 20 
minutes. The serum was cooled in ice, aliquoted and 
stored at -70°C until used.
Classical pathway depleted serum
Serum was incubated at 37°C for 15 minutes in an equal 
volume of Mg-EGTA buffer. EGTA chelates Ca2+ ions which 
are required for Cl activation of the CCP. The Mg2+ ions 
provided by the buffer allow activation by the ACP.
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